

US EPA ARCHIVE DOCUMENT

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

UNITED STATES

ENVIRONMENTAL PROTECTION AGENCY

PESTICIDE PROGRAM DIALOGUE

COMMITTEE MEETING

DAY ONE - OCTOBER 21, 2015

Conference Center - Lobby Level

2777 Crystal Drive

One Potomac Yard South

Arlington, VA 22202

P R O C E E D I N G S

- - - - -

MR. HOUSENGER: Good morning, and welcome to PPDC. I'm Jack Housenger. I'm the director of the Office of Pesticide Programs. As you look around, you'll see that membership has declined by five. We have brand new PPDC membership, including 15 new members, 12 representative members and 3 regular government employees. So, it's a little different. We'll hopefully get some different perspectives than we have in the past.

I appreciate everybody coming today, taking the time. I know it's not an easy thing to take off a couple days to attend these, but I think it's important for us to hear different views on what we're doing. It's probably important for you to hear what we're doing.

Along those lines, we try to give enough notice that people can plan around these meetings. We had a lot of members or nominations for these seats. So, for those of you who are new, please take that seriously and try to be present for these meetings. We're going to announce upcoming meetings for 2016 that will occur in May and November. So, we give enough notice, and we just ask

1 that you hold those dates and attend in person for these.

2 I just wanted to go over the agenda a little
3 bit before we get started. It reflects what we heard at
4 the end of last May's meeting with respect to some of the
5 topics. Some of the topics we've added that we think you
6 should be hearing. It also includes more time for
7 discussion. Last time, we heard that members thought
8 that we maybe rushed through some topics, and there
9 wasn't an opportunity to discuss. So, today's agenda
10 allows for enough time.

11 Because we have a lot of new members, we're
12 going to go over the rules of the Advisory Committee Act.
13 Jim McCleary from ODACMO, which stands for something, I
14 have no idea what it stands for, I'm sure he'll tell you,
15 is here to give us some important information. We were
16 going to do this in a webinar, but there was trouble
17 getting everybody at the same time. We thought it would
18 be good for existing members to hear the rules once more.

19 Then we're going to talk a little bit about the
20 workgroups. We've broken it up into two chunks, one
21 today and one tomorrow, about these workgroups, the
22 original charge, what they've accomplished, and then we

1 want to hear about if there's a continuing need for these
2 same workgroups or have they accomplished what they've
3 set out to do.

4 The first group up is the pollinator workgroup.
5 Pollinators are always a big topic. It's led by Rick
6 Keigwin, followed by the comparative safety statements
7 that is led by Marty Monell, and then 21st century tox
8 led by Jennifer McLain. Then that gets us to lunch,
9 believe it or not.

10 Following lunch, we're going to talk about the
11 WPS. That was a big rule that we've been working on for
12 a number of years, a 20-year-old rule that was signed off
13 by the administrator on September 28th. We're going to
14 need a lot of assistance in getting the word out, the
15 outreach, the implementation as we go through the next
16 year and ramp up for when it finally kicks in in about a
17 year. So, we're going to hear about assistance and
18 collaboration that you people may help us in implementing
19 this rule.

20 So, after that, we're going to talk about
21 certification and training rule. So, it's kind of a
22 worker safety afternoon. Kevin Keaney is going to talk

1 about that and Michelle Arling. This rule is currently
2 out as a proposal, but it gives the rules/training for
3 people handling the most restricted pesticides that we
4 have registered. We'd like to hear your thoughts on it.

5 After a short break, no PPDC would be complete
6 unless we talked about ESA. So, we're going to talk a
7 little bit about biological opinions and biological
8 evaluations and the work that's being done. Gina Shultz
9 from Fish and Wildlife is here, and Anita Pease of our
10 office will be talking about that.

11 Then, for the last topic of the day, Dana Vogel
12 will talk about OPP's risk assessments, human health risk
13 assessments for the organophosphates. At the end of the
14 day, we'll have an opportunity for public comment. So,
15 if you want to make a public comment, anybody in the
16 audience, please sign up at the registration desk at the
17 outside of this room.

18 Then, when we reconvene in the morning
19 tomorrow, Jim Jones, who couldn't be with us today, will
20 be here. Jim is the assistant administrator for our
21 office. I'm sure he'll give some inspiring words that
22 will resonate anyway.

1 Following Jim, we're going to go back to the
2 workgroups. We'll have school IPM led by Bob McNally,
3 public health led by Susan Lewis, and then Jackie Mosby
4 will give you a quick update on our newest workgroup,
5 pesticide incidents. Certainly, this is something that's
6 been in the news lately with methyl bromide
7 and sulfuryl fluoride incidents that have
8 happened. So, I'm sure there will be a lot of interest
9 in that workgroup.

10 Then, our final topic will be endocrine
11 disruption screening program that David Dix will come
12 over and talk about, what progress we've made in terms of
13 that program. Like I said, we're going to talk about the
14 dates for the next year, 2016. PPDC is currently
15 scheduled for May 11th and 12th for our spring session
16 and then November 2nd and 3rd for our fall session, and
17 also the topics for the next PPDC.

18 I look forward to a productive meeting.
19 Welcome. It would be good to go around the room and
20 introduce ourselves. So, please, Gina, why don't you
21 start. These are new microphones. I think you have to
22 turn them on and then after you're done, turn them back

1 off.

2 MS. MONELL: Slide the button towards you to
3 turn it on, and push it away from you to turn it off.

4 MR. HOUSENGER: Marty used to be a stewardess.

5 MS. SCHULTZ: Good morning, everybody. I'm
6 Gina Shultz. I'm deputy assistant director for
7 Ecological Services at US Fish and Wildlife Service.

8 DR. CALVERT: I'm Geoff Calvert, and I'm with
9 the Centers for Disease Control and Prevention.

10 MS. CODE: I'm Aimee Code with the Xerces
11 Society for Invertebrate Conservation. I'm the pesticide
12 program director.

13 MS. SELVAGGIO: Hi, I'm Sharon Selvaggio with
14 the Northwest Center for Alternatives to Pesticides. I'm
15 the healthy wildlife and water program director.

16 MR. KUNKEL: Good morning. I'm Dan Kunkel with
17 the IR4 Program.

18 MR. JAKAI: Louis Jakai, North Carolina A&T
19 State University, one of the few ag schools in North
20 Carolina which addresses mostly small farmer problems.

21 MS. GILDEN: Good morning, Robyn Gilden,
22 University of Maryland School of Nursing.

1 MS. LUDWIG: Good morning, Gabriele Ludwig,
2 Almond Board of California, and I'm also on the Minor
3 Crops Farmer Alliance.

4 MR. COY: I'm Steve Coy. I'm a commercial
5 beekeeper and queen breeder. I represent the American
6 Honey Producers Association.

7 MR. GUPTON: I'm Richard Gupton for the
8 Agricultural Retailers Association sitting in for Donald
9 Taylor.

10 MS. LAW: Good morning, I'm Beth Law with the
11 Consumer Specialty Product Association.

12 MR. JAIN: Good morning, Komal Jain, Assistant
13 General Counsel for American Chemistry Council. I serve
14 as counsel for the biocides panel.

15 MR. FORTH: Good morning, Chris Forth
16 representing the National Association of Landscape
17 Professionals. I'm here subbing for Tom Delaney.

18 MR. HANKS: I'm Douglas Hanks, National Potato
19 Council.

20 MS. CLEVELAND: Cheryl Cleveland, BASF. I'm in
21 the global consumer safety portion.

22 MR. McALLISTER: Ray McAllister of CropLife

1 America. Thank you for the new name tag.

2 MR. WHITTINGTON: Andy Whittington with the
3 Mississippi Farm Bureau Federation.

4 MS. RAY: Liz Ray with SIPCAM,
5 representing BPIA, sitting in for Nina Wilson.

6 MR. BAREFOOT: Al Barefoot, DuPont Crop
7 Protection. I'm a scientist in the environmental fate
8 and modeling area. I'm sitting in for Jake Vukich today.

9 MS. MONELL: When you get close to the
10 microphone, make sure you push it on and push it off
11 after you're done. Thank you.

12 MS. LIEBMAN: Good morning, my name is Amy
13 Liebman. I'm the director of Environmental and
14 Occupational Health for the Migrant Clinicians Network.

15 MR. LAME: Hello, I'm Marc Lame with Indiana
16 University's School of Public and Environmental Affairs.
17 I'm representing the National Environmental Health
18 Association.

19 MR. McLAURIN: Good morning, my name is Allen
20 McLaurin, and I'm a cotton producer in North
21 Carolina. I'm representing the National Cotton Council.

22 MS. BISHOP: Good morning, I'm Pat Bishop. I'm

1 with the Regulatory Testing Division of People for the
2 Ethical Treatment of Animals.

3 MS. HARRIOTT: Good morning, I'm Nichelle
4 Harriott with Beyond Pesticides.

5 MR. WHITE: Mike White, Council of Producers
6 and Distributors of Agrotechnology.

7 MR. PECKHAM: John Peckham, Minnesota
8 Department of Ag. I'm representing AAPCO.

9 MS. PALMER: I'm Cynthia Palmer. I'm Director
10 of Pesticides Science and Regulation for the American
11 Bird Conservancy.

12 MR. BUHLER: I'm Wayne Buhler, enthusiastic
13 entomologist from the eastern US, representing North
14 Carolina State University and the American Association of
15 Pesticide Safety Educators.

16 MS. GOUGE: Dawn Gouge, overly enthusiastic
17 entomologist from the western US. I'm here today
18 representing the National Environmental Health
19 Association.

20 MR. STELL: I'm Fred Stell from the Armed
21 Forces Pest Management Board.

22 MS. KUNICKIS: I'm Sheryl Kunickis. I'm the

1 director in the USDA Office of Pest Management Policy,
2 and I'm married to an entomologist.

3 MS. MONELL: Marty Monell, Deputy Director of
4 OPP.

5 MS. VOGEL: Hi, I'm Dana Vogel. I'm the
6 Director of the Health Effects Division in OPP.

7 MR. KEIGWIN: I'm Rick Keigwin. I'm the
8 Director of the Pesticide Reevaluation Division in OPP.

9 STEVE: Steve Knizner. I'm the Director of
10 the Antimicrobials Division in OPP.

11 MS. MOSBY: Hi, I'm Jackie Mosby, the Director
12 of the Field and External Affairs Division in OPP.

13 MR. HOUSENGER: All right. It's kind of
14 disappointing that none of our people are enthusiastic.
15 Let's go to the first presentation which is by James
16 McCleary, attorney, Office of Diversity Advisory
17 Committee, Management and Outreach. That's the ODACMO.

18 MS. ZIMMERMAN: I'm hoping Jim is here. Jim
19 doesn't appear to be here.

20 MR. HOUSENGER: Jim missed my talk about
21 showing up, I guess.

22 MS. MONELL: At least the on time part.

1 RICHARD: Can Mr. Gragg introduce himself?

2 MR. HOUSENGER: He was here and he left.

3 RICHARD: Hello, good morning.

4 MS. MONELL: Wait a minute, somebody is on the
5 phone.

6 MR. HOUSENGER: Jim?

7 RICHARD: No, Richard Gragg, the enthusiastic
8 Professor of Environmental Science and Policy,
9 representing Florida A&M University School of the
10 Environment.

11 MR. HOUSENGER: That's right, we have people on
12 the phone. I forgot the phone. Thank you. It takes an
13 enthusiastic entomologist again to --

14 RICHARD: No, toxicology, toxicology.

15 MR. HOUSENGER: Oh, all right.

16 MS. ZIMMERMAN: There may be a couple of other
17 PPDC members on the phone. If you're a PPDC member and
18 you're on the line, can you hit pound 6 to unmute your
19 phone. Please introduce yourself.

20 (No response.)

21 MS. ZIMMERMAN: Okay, we've globally unmuted a
22 line for a moment. So, if there are other PPDC members

1 who are on the phone, can you please introduce yourself?

2 (No response.)

3 MR. HOUSENGER: Is there anybody else on the
4 phone?

5 (No response.)

6 MS. ZIMMERMAN: I will put the global mute back
7 on.

8 MR. HOUSENGER: All right, well, we can go to
9 the pollinator workgroup. Rick Keigwin is going to lead
10 this discussion.

11 MR. KEIGWIN: So, unfortunately, Mary Clock-Rust
12 was here, and she is enthusiastic. She was here earlier.

13 So, what we wanted to do today, Don Brady is
14 the co-chair of this workgroup. He's on vacation this
15 week. We wanted to provide you all with an overview of
16 what the pollinator workgroup's initial mission was and
17 what the group has accomplished to date. Then, I think
18 this will fit in with the discussion that Jack will be
19 leading later on about where you all would like to take
20 each of these workgroups. So, we'll kick things off
21 there.

1 Mary Clock-Rust has really been our leader and
2 coraller and making sure that we get everything done.
3 So, I'm going to turn things over to Mary to lead us
4 through the presentation.

5 MARY: Good morning. The pollinator protection
6 workgroup was begun in 2011. This group of full PPDC
7 decided to start a workgroup to focus on pollinator
8 protection. On the board here, you can see that these
9 are the initial 2011 objectives for the workgroup. At
10 that time, if you all recall, we were developing the
11 science, we are still working very hard to improve our
12 science. We wanted a workgroup to focus on so-called low
13 hanging fruit and things that could be changed
14 immediately and quicker.

15 So, back in 2011, these are the objectives that
16 the group identified, exploring initial science-based
17 risk management approaches, including appropriate label
18 restrictions and training; develop information on State
19 approaches and different authorities; transfer lessons
20 learned by various stakeholders in order to improve
21 existing management practices; continue international
22 communication; and any other issues that came up.

1 So, as I said, this was five years ago now,
2 four years ago, four-and-a-half years ago. The group met
3 frequently. The group was huge. I mean, it is huge. At
4 one point it had almost 80 people, a lot of people on the
5 phone. It made it really cumbersome and difficult for
6 anything to get done, actually. We had a lot of diverse
7 people on the phone. We have beekeepers, we have
8 growers, we have registrants, we have academics, anybody
9 who was interested. The most important, probably, is the
10 agriculture extension agents and the people that actually
11 meet with people on the ground.

12 As we go through here, I'll identify each of
13 these objectives and how we put them into action, and the
14 things that the group worked on. The first one is the
15 workgroup recommended, somewhat confusingly, that we should
16 replace visiting and actively visiting on pesticide
17 labels with the word foraging, not actively foraging,
18 just foraging. So, this has been implemented somewhat on
19 a case-by-case basis. As you probably know, it's
20 difficult to change pesticide labels after they've
21 already gone out and they're already on products and
22 things.

1 So, this is being implemented now. I'm pretty
2 sure our registration division here is working hard to
3 get rid of the visiting and actively visiting. The only
4 opportunity to do that kind of thing is when there's a
5 label amendment or new use proposed for that pesticide.
6 So, it's going slowly, but this is a change that's being
7 implemented.

8 Next, the workgroup recommended that labels be
9 harmonized and protective language should be made
10 clearer. This topic was so difficult. We got a lot of
11 people chiming in and talking about all of their opinions
12 and experiences on the phone. It was, for sure, a
13 difficult topic for the workgroup to handle. As you're
14 probably aware, the president's initiative has kind of
15 usurped this and the media and everything that's
16 happening with pollinators in the last four or five years
17 has really taken a life of its own.

18 As you can see, EPA has been responding to that
19 with a number of national level actions that have to do
20 with this. Nonetheless, we allowed the group to discuss
21 and talk about the neonicotinoid language that was
22 proposed back in June 2014 and then again in the fall of

1 2014. Then, this year we've had some changes. As you
2 know, there's proposals for mitigation. They were out
3 there for comment, extended three times our comment
4 period. I think we have over 100,000 comments. So, this
5 topic has been taking on a life of its own. I'm not sure
6 the workgroup itself is very effective in working on it.

7 Next, the workgroup recommended that the RT25
8 data would be a useful tool to make available for
9 pesticides. So, this information is on our website now.
10 Also, some labels have RT25 on them. Response to this
11 workgroup advice, the EPA just put all of the RT25 data
12 that we have, made it available pretty much just
13 instantly as soon as it was something that needed to get
14 done. So, that was something that took place. I have a
15 link to it if you wanted to get that.

16 Next, the workgroup recommended that more
17 research on BMPs, best management practices, be done and
18 have them posted in a centralized location. For this, I
19 really have to look at Wayne Buhler and say thank you to
20 him because he made his website available,
21 pesticidestewardship.org. If you go to that website and
22 click on the pollinator protection link, you will find so

1 much information, including the best management practices
2 for beekeepers, best management practices for
3 applicators, and a whole bunch of other information.

4 So, EPA's website links to Wayne's website, as
5 well as the IPM Center's website also links to his
6 website on this. So, there's a number of ways that
7 people that want this information can get it now. So, we
8 made that available.

9 Also, the next topic is the workgroup
10 identified many kinds of pesticide applicator training
11 information around the country that has included
12 pollinator awareness information. Again, Wayne's website
13 links to ours for this information. Also, a lot of this
14 information has been compiled and is easily accessible
15 now on our website, as well as the
16 pesticidestewardship.org website.

17 Finally, the workgroup recommended that there
18 be more uniform and transparent bee kill investigations.
19 Responding to this, Region 5 developed enforcement
20 guidance for state inspectors and inspectors that go to
21 bee kill investigations. We found that there was a real
22 knowledge gap there, and that they could really use this

1 information. So, we made that available. It's been done
2 and it's finished now. So, that guidance is available.

3 MR. KEIGWIN: So, that's a quick overview of
4 where the workgroup has been and what the workgroup has
5 accomplished. I think from EPA's standpoint, the group
6 has really accomplished the initial mission that it had
7 been charged with. We'd like to, I think at this point,
8 get feedback from you all. And then, if there are areas
9 where you all think that the workgroup should go next,
10 we'd like to hear that.

11 MR. HOUSENGER: Mark.

12 MARK: Yes. It's a good report and was an
13 important topic. I think the workgroup has really made
14 great strides and has accomplished a lot. As with a lot
15 of things, we're kind of just at the beginning of things.
16 Of course, it was mentioned that the president has an
17 initiative. While the administration might have a
18 workgroup, or whatever, task force, I don't know what
19 they're calling themselves, I'm sure they're a group of
20 (inaudible) people but not as enthusiastic entomologists
21 like us.

22 But I think it behooves the agency to maintain

1 a presence of advisors and workgroup members to basically
2 look and see how this beginning gets going, whether it
3 really gets on its feet and is moving in a measured
4 direction of improvement. That would be my concern.

5 MR. HOUSENGER: Nichelle.

6 NICHELLE: Thank you for the report. So, a lot
7 of work on pollinator protection these days has now
8 shifted to states and their development of their state plans for
9 pollinator protection. Do you think that this workgroup
10 would have any type of role to play in sort of helping to
11 guide these states since EPA ultimately has that
12 responsibility as well to guide states into developing
13 robust pollinator plans?

14 MR. KEIGWIN: I think that's one of the things
15 that we'd like to hear from this wider group, is what
16 other areas that you all as advisors to us think that we
17 should be taking on. So, we have been working with
18 states as they develop guidance for how these state and
19 tribal pollinator plans should be developed.

20 We've identified some common criteria that we
21 think are important in the development of those plans,
22 specifically focused on that there's a mechanism for

1 communication, that there's a mechanism for monitoring
2 the effectiveness of the plan that's developed, and that
3 the plan is developed in an open and transparent way so
4 that all stakeholders can participate.

5 But each state and each tribe are approaching
6 these plans in different ways. SFIREG, the state FIFRA
7 issues, research, and evaluation group, which is largely
8 the state regulators responsible for pesticides has
9 developed a very detailed guidance document that is being
10 used.

11 Now, I think there are approximately 40 states
12 that are in the process of developing these plans. I
13 think there are only about five, though, that are all the
14 way completed. So, that could possibly -- Nichelle,
15 getting back to your suggestion -- be one of the areas
16 that this group could play.

17 MR. HOUSENGER: One of the things that you're
18 going to hear as we go through the workgroups is we're
19 not interested in just having workgroups for the sake of
20 having workgroups. We want to get meaningful input into
21 critical issues that we need advice on. So, any
22 workgroup that is done, we would like to close it up and

1 move on. We can give updates about topics here at the
2 PPDC, but we're looking for issues to receive advice on.

3 UNIDENTIFIED FEMALE: One area that the
4 pollinator workgroup discussed was looking into our
5 native bees, because while there's a lot of overlap with
6 managed bees and native bees, they aren't exactly the
7 same beast. There are issues that need to be faced.
8 That's really only just started to talk about. That
9 would be an area I'd love to see more focus on.

10 One other area is I feel like it's so much
11 easier to respond to incidents and look at that short
12 term immediate concern. It makes sense that we need to
13 address those immediate concerns first. But, with the
14 increasing use of systemic long lived neonicotinoids, we are
15 trying to think of how do we respond to the effects over
16 time.

17 Just very quickly looking at trees, we're
18 seeing -- and woody plants, we're looking at exposure or
19 at least residues in pollen years after applications.
20 So, how do we better understand what that concern may or
21 may not be, and then respond to it.

22 MR. HOUSENGER: Ray?

1 RAY: A couple of questions. I sympathize with
2 the task that the agency has of responding to more than
3 100,000 comments.

4 MS. MONELL: We can't really hear you too well,
5 Ray. Get closer and speak up.

6 RAY: I sympathize with the agency's task of
7 responding to more than 100,000 comments on the recent
8 proposal regarding the compounds that are toxic to bees.
9 What's the time line for responding? We're still waiting
10 to see the comments that have posted on the website.
11 What's your time line for getting those posted, for
12 formulating a response, for announcing next steps?

13 MR. KEIGWIN: So, as many of you may know, that
14 website regulations.gov is not an EPA website. So, we
15 don't have much control on how quickly the comments that
16 are submitted actually get posted for public viewing. I
17 think to date there are only about 500 comments that have
18 been made available to the public. I will say there's
19 only about 500 comments that have been made available to
20 EPA staff to begin to be able to do the evaluation.

21 What we are told is that the vast majority of
22 the comments were a single comment that was replicated

1 multiple times as part of a petition type of campaign.
2 So, we're reasonably confident that the 500 or so that
3 are publicly available are the most substantive of the
4 comments. Not that people voting with their e-mail isn't
5 important, because it is, but we think from a substantive
6 directional standpoint, we have the vast majority of
7 them. So, you all have those as well.

8 We're trying to build that time line now. I
9 will say from the preliminary review that we've done,
10 there have been some very robust and thoughtful and
11 substantive ideas that have been brought forward. So, I
12 think over the next couple of months, once we've digested
13 those a little bit more, we'll be in a better position to
14 be able to provide a time line for moving forward on that
15 action.

16 RAY: A couple of follow-up questions. You
17 mentioned earlier the incident investigation guidance
18 which is provided. Does the agency have any feedback
19 from states on how useful that has been in practice and
20 to what extent it has been used?

21 MR. PECKHAM: The states in Region 5 have
22 adopted it, and I think it's been very, very useful.

1 Each state has its own authorities and abilities to do
2 things certain ways. I know in Minnesota we've adopted
3 it. Actually, it's kind of prompted us to do additional
4 training for both colony health as well as pesticide
5 incidents. So, all of our staff are trained, and they're
6 all trained in the guidance. We have a couple little
7 different things that we do that other states maybe are
8 not doing because we have entomologists on staff that can
9 actually go out on our bee kills.

10 RAY: And I'm sure those
11 entomologists are enthusiastic.

12 MR. PECKHAM: You know what, they're kind
13 of laid back.

14 RAY: Well, the guidance itself and its use has
15 a direct impact on how the agency should handle the
16 comments, because there was a significant emphasis in
17 that proposal regarding reports of incidents had been
18 received. We're very interested in the extent to which
19 those incidents listed by the agency as a justification
20 for their proposal have been investigated or
21 investigations will continue. It's important that these
22 reports of incidents be verified, validated, and their

1 true significance with respect to regulatory decisions is
2 determined and made public.

3 One last question. In the present strategy on
4 pollinator protection, they rolled in the monarch
5 butterfly issue into the same document. The agency, a
6 few months ago, put out its own proposal regarding some
7 strategy regarding the monarch protection.

8 Is this an appropriate topic for the pollinator
9 protection workgroup to handle, or will you bring it up
10 in another different PPDC workgroup?

11 MR. KEIGWIN: So, thanks, Ray. On the risk
12 management framework that we put out for public comment,
13 for that one we received about 46,000 comments. I think,
14 though, about 30,000 of them were really a letter writing
15 campaign through one organization. About another 10,000
16 or so were a letter writing campaign sponsored through
17 another organization.

18 But similar to the acute risk mitigation
19 proposal that we put forward in May, a number of very
20 thoughtful comments on what types of information, what
21 types of data the agency should be taking into account
22 when we're looking at making regulatory decisions for

1 pesticides and what impacts, if any, those regulatory
2 decisions might have, particularly on milkweed habitat
3 for monarch butterflies.

4 I think that one from a time line standpoint,
5 we're in a very similar time line situation to be able to
6 digest the comments and formulate a response. I don't
7 know at this point that we've decided how we would
8 specifically roll that out, but it is an important part
9 of EPA's contribution to the national strategy.

10 MR. HOUSENGER: Okay.

11 CYNTHIA: Can I just clarify real quick?
12 The guidance you asked about, Ray, it wasn't the
13 MP3; it was the incident reporting guidance. I just got
14 confused there.

15 MR. HOUSENGER: Okay, Richard?

16 RICHARD: Thank you. One, I want to thank the
17 PPDC's working group. It's an important thing to
18 pollinators, so it's a priority trying to get consensus
19 on how to address this issue.

20 We're actively involved in the honeybee health
21 coalition. EPA and USDA is involved in that. We think
22 that has a broad diverse group of participants that can

1 hopefully have some programs in place and
2 recommendations. I think it's in alignment with the
3 president's task force for the most part. So, we look
4 forward to working with you.

5 I did have some questions as far as the
6 workgroup and things that are of concern. From the
7 applicator's standpoint, and this goes back, I guess, to
8 Monday, the USDA had given a report as far as bee kills,
9 bee deaths. Part of that was pesticides, but a big
10 portion of that were the pesticides related to verroa mites
11 for home brews. So, maybe misuse or not
12 following the labels of some of the products or off use
13 of label of products.

14 So, when you talk about training and
15 enforcement on pesticide product use, is that just the
16 applicator you're focusing on or others that are using it
17 that are impacting bee kills as well?

18 The other thing, from an applicator's
19 standpoint, if you don't know where the bee hives are and
20 you're not part of the contract between the farmer and
21 the beekeeper, it may be a farm adjacent to it, it makes
22 it very difficult. So, I was just wondering what EPA is

1 doing to encourage -- and this is really a state and
2 local issue to resolve these issues.

3 What is EPA doing to encourage some of these
4 state plans for reporting of where these bee locations
5 are from the applicator's standpoint? Again, if they
6 don't know where the hives are, it makes it very
7 challenging for the applicator if they're not aware of
8 them.

9 MR. KEIGWIN: Thanks, Richard. On the training
10 piece, the website that Wayne developed through NC State
11 not only has best management practices for applicators,
12 but it also has best management practices for beekeepers.
13 I think the honeybee health coalition, one of their
14 subgroups has substantive discussions on hive management,
15 which again I think is developing best management
16 practices for beekeepers on the appropriate use of
17 pesticides and training opportunities there. EPA is
18 contributing to that group separate. We think that's an
19 important piece of work that the honeybee health
20 coalition is doing.

21 In terms of the concern that applicators might
22 have about where beehives might be located, what we have

1 been encouraging as part of the development of the state
2 and tribal managed pollinator protection plan is that
3 applicators and growers and beekeepers at a local level
4 reach agreement on what is the best way to facilitate
5 that identification and communication of where hives
6 might be located in relationship to agricultural fields.

7 How states and tribes and stakeholders within
8 those communities reach agreement on how to do that, we
9 have said to this point that that's a state and tribal
10 decision, but there has to be agreement amongst all of
11 the parties in the development of the plan or how they
12 best want to do that.

13 Some states are taking advantage of some
14 commercial software that's available through Field Watch.
15 Other states either have or are considering the
16 establishment of apiary registration programs. But at
17 this point, EPA has not said which way is the best way to
18 do it. We've just been encouraging that there be
19 communication channels established that all the
20 interested parties agree to.

21 MR. HOUSENGER: Cynthia?

22 CYNTHIA: So, in terms of new directions or

1 priorities for us, two things. The elephant in the room
2 seems to be the use of coated seeds and impact on water
3 quality and biodiversity. Maybe there could be some
4 guidance from the workgroup in terms of whether use of
5 coated seeds is out of sync with integrated pest
6 management.

7 Secondly, we would like to suggest looking at
8 pollinators beyond managed bee populations echoing what
9 Aimee mentioned earlier, looking at native invertebrate
10 species and also, of course, at birds, bats, butterflies,
11 and other wildlife. Thank you.

12 MR. HOUSENGER: Gabriele?

13 GABRIELE: A couple of thoughts and also
14 response to what I've just heard, a suggestion. I think
15 the main one, what I'm seeing, is that EPA is in the
16 midst of registration review. That's your process for
17 trying to get additional information to help you make
18 good assessments of where are the potential impacts and
19 where they're not.

20 Again, I'm not the risk assessor here, but I
21 don't think there's a lot of clarity about what data is
22 needed, what the methods are for those data. I mean,

1 just yesterday, I had someone call me up, I'm not a risk
2 assessor, for advice on what studies they needed for bees
3 because the kinds of questions they'd been getting from
4 the agency just weren't making sense.

5 I know that registrants for post-harvest
6 fumigants have been asked for bee studies. You're kind
7 of going, it's a post-harvest fumigant, why are you
8 asking for a bee study.

9 Then, if I looked at what was in the proposal
10 for acute toxicity and the state plans, there was
11 discussion about needs for additional tests, whether it
12 was for insect growth regulators and so forth. So,
13 there's a lot of questions about what data is needed for
14 EPA to make good questions.

15 I will also say, looking around this room, you
16 have people in the room that want every bit of data.
17 That's unrealistic. So, the other balancing act here is
18 what data is realistic to get, what data is not realistic
19 to get. We have others in the room that would prefer not
20 to have any data because it's all additional money. So,
21 this is the balancing act. I don't think we've had a
22 good discussion about what are all the questions that are

1 coming up and so forth.

2 I am going to be editorial here. I will say
3 that the acute pesticide risk assessment showed that lack
4 of asking questions. That is one of the least thought
5 out proposals I've seen come out of EPA. Sorry, guys. I
6 think the comment flow that you've gotten reflects part
7 of that. It's like, wait a minute, you've not had the
8 dialogue, so it's not as well thought out as it could
9 have been.

10 So, I think that's one thing I would say. I
11 will say that I'm not interested in having the workgroup
12 start dealing with the state plans. There's enough other
13 groups and feedback going on in that arena. I don't
14 think it's something that's needed right now. Maybe if
15 we get further down the line, yes.

16 It's partly also because for those of us who
17 are engaged on bee issues, there's only so many meetings
18 we can handle. We're on a number of other groups. So,
19 I'm just trying to figure out how to make it effective.
20 So, to me, one thing that's really unique here is of the
21 whole range of things that could be asked, what makes
22 sense to really be asking, what are the criteria for when

1 something should be asked or not be asked on the risk
2 assessment side.

3 MR. HOUSENGER: The last PPDC meeting where we
4 went over the framework for conducting bee assessments,
5 which outline tier one data, tier two data, tier three
6 data. So, I'm a little confused.

7 GABRIELE: Yeah, but then there's questions
8 coming up about secondary effects. There's a question of
9 if you're looking at a developmental potential effect in
10 the honeybee hive, what exactly should you be looking at.
11 So, the big broad outline, sure.

12 But it's now getting into EPA and the
13 registrants are sitting down and negotiating what are the
14 data call-ins. That means you have to have a good idea
15 of what kind of data is relevant when. So, I'm asking
16 for a level deeper than the big broad -- you know, here
17 are the various tiers, because there are a lot of
18 questions coming up in that arena from a lot of different
19 voices in this room, is my sense. Again, it's a
20 difficult area because some people want every bit
21 possible.

22 MR. HOUSENGER: Right.

1 GABRIELE: That's not realistic. Some would
2 like as little as possible, and that's probably not
3 realistic either. So, just trying to find that balance.

4 MR. HOUSENGER: Yeah, I'm struggling with
5 trying to figure out if you're saying that the data that
6 we're requiring aren't adequate.

7 GABRIELE: I think in some cases that's a
8 question that's on the table. I think the flip side of
9 it is that questions are being asked that seem utterly
10 unreasonable. It's both. So, why for certain best
11 biopesticides do you suddenly need bee health effects?
12 There's just some questions. I'm just saying there
13 doesn't seem to be a balance there. Again, I'm not the
14 person sitting in those meetings; I'm just reflecting
15 what has come to me in the form of questions or comments.

16 I'm just saying, hey, there's a lot of
17 confusion at the moment when you are in the midst of
18 trying to move this process forward. Would having this
19 committee have some more feedback -- or may it's not this
20 committee and you do one of your day long meeting where
21 you really go through the risk assessments in some of
22 these questions. It's not an SAP level, not that deep.

1 I mean, I've gone to some of those and that's over my
2 head.

3 MR. HOUSENGER: I think when we issue our first
4 risk assessments for bees, which will be in December of
5 this year, for the neonics, or imidichloprid, we'll see
6 how the data that we require will fit in with our
7 assessment of bee health. Maybe that would be a good
8 place to start to see how the data that's required
9 actually allows us to do an assessment.

10 Steven.

11 STEVEN: Looks like these new microphones
12 revert to old technology.

13 MR. HOUSENGER: They are.

14 STEVEN: Just an observation. So, I was one of
15 the members of the workgroups that kept things
16 interesting at times. I do not want to go back through
17 all that again. It was a lot of head banging on my part.
18 Before I forget it, I do think that a better risk
19 assessment is needed for many of these products. You all
20 just discussed that, and a lot of that was over my head.

21 I'd like to go back and talk a little bit about
22 the Region 5 development and the workgroup

1 recommendations for bee kill investigations. I think
2 it's important to remember that bee kills is not a
3 violation of the label. It's a symptom of a label
4 violation. The beekeepers believe that the label is the
5 law.

6 Personally, I have some concerns that the goal
7 line is being moved as we approach it. So, I don't want
8 the label changed to meet what's currently happening out there
9 in the fields. I'm a little concerns that the MP3
10 programs are usurping the federal label with a less
11 restrictive label by the state. It may not be written
12 that way, but that's the way it's going to be happening.
13 That's what's going to happen on the ground.

14 Many of these plans put most, if not all, of
15 the risk mitigation on the backs of the beekeepers. I
16 don't know that any of those things are suitable for a
17 workgroup discussion, but those are all things that we
18 discussed in various aspects of our discussions over the
19 last several years. Those haven't been adequately
20 addressed.

21 MR. HOUSENGER: Cheryl?

22 CHERYL: So, I'm listening more to the broader

1 question that's been raised about all the workgroups. I
2 know we're going to speak about all of them. Have they
3 achieved their goals? Do they need to continue? I'm
4 seeing a lot of levels here. You have a lot of different
5 resources to get stakeholder input. You have the docket.
6 You have this broad PPDC forum.

7 Then you have the workgroups. The workgroups
8 are supposed to exist for a deeper drill. The best
9 outcome of a workgroup is if you can have that diverse
10 conversation and reach consensus. It's not always
11 possible.

12 The second outcome of a workgroup is that you
13 raise issues that then get discussed and discussed and
14 kind of brought back here. I was hoping that in this
15 presentation that we skipped on roles and
16 responsibilities, we might get a little bit more clarity
17 about what you want out of workgroups, not just what you
18 want out of the PPDC membership.

19 At times, we hear, okay, this was discussed at
20 PPDC. It was vetted at PPDC. You don't get consensus,
21 and yet you move forward. So, PPDC is kind of used as a
22 place to go. So, those are my questions. I'd like to

1 get a little bit more from you as we go through the whole
2 process of reevaluating all the workgroups. What do you
3 want from them?

4 Then, if I look at this particular workgroup
5 and I look at the top page and they say, what was the
6 charge in 2011, what was achieved, you did a good job of
7 explaining what had happened. I think you can check, a
8 lot of low hanging fruit kind of came out of here. It's
9 easier -- I'm not trying to say, Wayne, it was super
10 easy, but it's probably easier to gather best management
11 practices than it is to agree on some of these other
12 things. Yet, you have a group that's very large and very
13 interested.

14 So, I think I would be a little bit reticent to
15 just see this let go, but it should be refocused to say
16 where can you take advantage of the fact that there are
17 some things that are going to have diversity. You're not
18 going to reach consensus, but what can you do in that
19 workgroup to gather and still take advantage of this
20 broad forum? Thank you, Jack.

21 MR. HOUSENGER: Thank you, Cheryl. You know,
22 this is one thing that we've struggled with, too, is what

1 are the workgroups. Certainly, the workgroups have
2 served as an update for people, which is good. But what
3 we're looking for are the things that we aren't thinking
4 about. Like one of the workgroups, I guess one of the
5 things that was recommended that we made available was
6 the RT25. I think it's coming at it from a different
7 way. We're probably close enough to it that maybe
8 sometimes we just miss the finer points or really what's
9 on the minds of a diverse group like this. That's kind
10 of what we're looking for here.

11 I agree, I think the management plans, I think
12 we've got a good public process going. I'm not sure that
13 the workgroup, if the members haven't already commented
14 through the regular means, that it's a good use of the
15 time of the workgroup. But that's kind of what I'd like
16 to see out of the workgroups, advice on things that may
17 not be as evident to us sitting here.

18 Dan?

19 DAN: Thanks, Jack. I'd echo, I think the
20 workgroup has done a great job. I'd echo some of the
21 comments that were made here. But I still have one
22 comment that I'd like to add. That is, has there been

1 any retrospective analysis of the indications of how
2 these plans have actually helped in resolving the issue
3 with regard to bee health? If there has, then maybe that
4 could be communicated to the public in a broader sense.
5 Or, if it hasn't, then maybe that can be a further charge
6 of this working group.

7 MR. KEIGWIN: I think that's something we were
8 envisioning once more plans got developed. Many of the
9 plans that have been developed to date have really only
10 been in place for maybe one use season. So, I think it's
11 hard to say one way or the other, but that was one of the
12 reasons why when we did layouts and criteria for the
13 states and tribes, we said it would be important to have
14 a process in place to revisit those plans to see how well
15 they're working. So, if improvements are needed, they
16 can be made. So, that's a good point, thanks.

17 MR. HOUSENGER: I remember back when Jim Gray
18 brought the plan forward and talked about how much he
19 thought it helped in his state. We said, well, what if
20 that's expanded across the United States. So, I think
21 it's still an outstanding question about how these plans
22 are implemented by each state, whether they make a

1 difference or not.

2 Doug?

3 DOUG: I just have to echo. In the beginning,
4 you said that you had accomplished your purpose. I just
5 want to say that as you look at this, that all metrics
6 needs to be followed up on. The studies for bee
7 pollination and pollinators have begun, so we need to
8 monitor those still as a workgroup but not as a full
9 group, just a follow up group. Like you say, are you
10 monitoring that training at state and tribal levels to
11 follow up how well that's being done. That's all I have.

12 MR. HOUSENGER: Ray again.

13 RAY: Your mention of depending on PPDC for
14 bringing up topics that the EPA staff may not have
15 thought of brings to mind that we individually as members
16 of the PPDC represent larger constituencies also. This
17 particular workgroup on pollinators was a very large
18 group, well beyond the folks around this table. I'd
19 suggest you put the same questions to that larger group
20 and give a short but reasonable time for them to feedback
21 on what they see the value of the group is before you
22 make hard and fast decisions on its future.

1 MR. KEIGWIN: I think that's something that we
2 can explore, Ray. I will say I think we've tried that at
3 least once, but maybe since the national strategy has
4 come out, this would be a good time to revisit that
5 question with the workgroup.

6 MR. HOUSENGER: All right, seeing no cards
7 except Ray, who just put it down, I think we'll move on
8 to -- let's do the next workgroup and then think about a
9 break.

10 MS. MONELL: I guess that's me. So, the title
11 of our committee is a bit misleading. Comparative safety
12 statements is actually prohibited on a pesticide product
13 label.

14 But about five years ago, this group, or the
15 PPDC at that time, requested of the agency that we form a
16 workgroup to look at the issue of allowing some sort of
17 distinction on pesticide labels with respect to a
18 product's greenness. We can't say safety because we
19 address that in our regulatory process.

20 But consumers at the time, and actually to this
21 day, really are very interested in information about the
22 relative greenness of products across the board, and that

1 includes pesticide products. So, this group was formed
2 to look into that issue. We did a lot of research. We
3 interviewed several organizations that did sort of a
4 screening of components in both pesticide and non-
5 pesticide chemical products.

6 We decided upon partnering with our sister
7 organization, the Office of Pollution Prevention and
8 Toxics. At the time, they were running their DFE, Design
9 for the Environment program, which involves a screen of
10 all ingredients in a product by a third party screener.
11 If the product passes that screen, then it is eligible
12 for allowing that logo on a pesticide product label if it
13 meets certain criteria within the pesticide program.

14 So, we essentially focused on antimicrobial
15 products because those are the ones that lent themselves
16 to the ability to pass the DFE screen. Then, we
17 gradually included biopesticides. Although we don't have
18 any biopesticide active ingredients yet that have
19 actually pursued the screening process, we do have 7
20 antimicrobial active ingredients and 10 products that
21 have been approved to have the DFE logo on them.

22 Obviously, the registrant's interests are to

1 provide consumers with the marketing information that
2 they desire. It's the agency's position that our job is
3 to make sure that whatever is on that label is not false
4 or misleading. So, there's sort of a three-legged stool
5 approach to this process. While we do have the 7 AIs
6 approved and 10 products, I don't believe any states have
7 permitted the registrations.

8 The states are very concerned about this, about
9 the issue of allowing this logo. They believe that it
10 could be false or misleading. We have two opinions from
11 Office of General Counsel in this regard. The basic
12 underlying principles are that A, we are utilizing a
13 program that is run by a federal agency so there's a bit
14 of credence given to the rigor with which these chemicals
15 are reviewed. There is a third party certifier so there
16 is no vested interest in the process.

17 Of equal importance, when the DFE logo is
18 allowed on a pesticide product, there is a reference to
19 the website so that it is very clear that what the DFE
20 for pesticide products is intended to convey, there is
21 educational material on the website. It's actually
22 different than that message which the industrial chemical

1 DFE logo had historically conveyed.

2 As you know or may not know, but I will tell
3 you, the DFE program for industrial chemicals has now
4 evolved into a program called Safer Choice. This
5 decision followed a lot of market research, an extensive
6 amount of market research, and a desire by the agency to
7 encourage green purchasing across the board. This was a
8 way of enabling consumers to make choices in terms of the
9 products that they buy.

10 We, in the pesticide world, cannot, both by
11 statute and regulation, allow the use of the words safe
12 or safer on a pesticide label. So, that's a non-starter
13 for us. The workgroup agreed to extend the pilot for the
14 DFE logo use for another year, so we're still
15 aggressively pursuing with the states sort of clearing up
16 any misunderstandings or apprehensions that they have
17 about the use of the logo. I think that we're in a good
18 place there. They seem to be very interested in pursuing
19 better understanding and ultimately approving the use of
20 the logo on state labels, which is critical to achieving
21 any kind of success. So, that was one piece of our work.

22 The other piece was allowing certain factual

1 statements on pesticide labels. We started with the two
2 that are sort of the most straightforward, and that is
3 making statements about dye free or fragrance free. A
4 lot of consumers really need that information for allergy
5 reasons or just their desire to stay away from dyes and
6 fragrances.

7 So, we had a history in this program of sort of
8 allowing it. We memorialized that in terms of it being a
9 part of the factual statement pilot program. We also
10 allowed statements which essentially are a reference to a
11 website that a pesticide company might want to put on a
12 product label that references the website and their
13 corporate commitment to the environment, to public
14 health, recognizing that a reference to the website does
15 become part of the label. So, we have actually had a
16 fairly good amount of interest in that and have about 30
17 product labels that have been approved through this pilot
18 for the corporate commitment.

19 This is all over a period of five years, mind
20 you. So, we also allowed biodegradability, the status of
21 a product's biodegradability. So, we decided that there
22 were two situations where you could have this statement

1 on a label. One is if all of the ingredients in the
2 pesticide products are biodegradable, then you could put
3 that statement on your label.

4 If the surfactants in the product formulation
5 is biodegradable, we would allow that statement. Thus
6 far, we have no products that have been pursued to have
7 the complete biodegradability statement, but we did have
8 two products with surfactants that are biodegradable come
9 forward. They're allowed to put that on their label.

10 Then, the last and most recent was our sister
11 organization, USDA, has a program wherein a product can
12 achieve a bio-based mark. This is an effort to promote
13 sustainability in various product sectors. So, we agreed
14 that we would allow a bio-based mark once the product had
15 been certified by USDA through its program. We would
16 allow that mark to be on our label with a disclaimer that
17 it is in no way a statement as to the safety of the
18 product. So, we still don't have any products that have
19 been put forth for that particular mark.

20 All of these efforts are again designed to
21 provide consumers with information that we believe they
22 want. I think that's more true today probably than it

1 was five years ago. I think people want to know what's
2 in the products they're using, whether they're
3 pesticides, cleaning products, or anything like that.

4 In the past year, we had a request to revisit
5 our position on allowing statements on labels as to the
6 safety of a product for use on a particular surface. So,
7 this is a very specific claim. Apparently, years ago, we
8 used to allow statements that said safe for use on
9 porcelain, like toilets, or safe for use on counter tops,
10 formica, et cetera, et cetera.

11 There was a determination made that while it's
12 true that consumers probably would be interested in
13 having that information, that the opportunity for
14 consumers to be mislead by the use of the term safety
15 outweighed the utility of it to consumers.

16 So, a group of companies came forward and they
17 believed that consumers really would take advantage of
18 this information. In fact, if you knew that something
19 was specifically safe for use on a formica table top,
20 that you would only buy one product rather than six or
21 seven and keep trying them all until something worked.

22 Anyway, they constructed a survey, a consumer

1 survey which was really very, very rigorous in the
2 diversity of the consumers to whom it was made available.
3 It was a large number, over 2,500, I believe,
4 respondents. Usually, I guess, the norm is about 400 or
5 500, so this was above and beyond.

6 The agency had the opportunity to review the
7 survey. We couldn't tell them what to put in the survey
8 because that runs afoul of information collection rules.
9 But we did say, if you're trying to elicit X, Y, Z
10 information, you might want to ask questions about this.

11 So, the survey results came back. They were
12 presented to the workgroup on a couple of occasions, most
13 recently summarized again yesterday. The feeling is that
14 consumers, and the results support it, are not confused
15 by statements about the safety of a product for the
16 surface. They don't feel it's in any way confusing that
17 I can drink this or I can pour this on my child or
18 anything like that. There was absolutely no confusion
19 whatsoever.

20 So, the workgroup talked a lot about it. We
21 came down on the side of yes, let's allow the use again
22 of this statement as to the safety for the surface for

1 which it was planned to be applied and under the
2 construct of the factual statement pilot, so that we can
3 get a little bit of experience under our belts. The
4 companies obviously will be continuing with their market
5 surveys to assess whether or not this is helpful
6 information and whether consumers are confused by it.

7 So, that's the most recent discussion we've had
8 there. As you can see, there are various angles to this
9 whole desire to provide consumers with information. It
10 seems every year we get another proposal to look at. To
11 that end, we have brand new business that was brought
12 before our workgroup meeting yesterday. Actually, it was
13 a result of last May's PPDC meeting which had to do with
14 comparative efficacy statements.

15 So, my product is 10 percent more effective
16 than the leading brand, those kinds of statements. We
17 see it on advertising on television all the time. So,
18 clearly, this is something that's before us. It's in our
19 life. The issue is does the pesticide program, with our
20 scarce resources, do we become embroiled in the business
21 of approving these claims for pesticide product labels.
22 There's legal arguments why we may have to. There are

1 realistic constraints, policy issues as to why we need to
2 really be thoughtful about this.

3 So, that was the new business presented to our
4 workgroup yesterday. I think there is a lot of interest
5 in pursuing that, as you could imagine, pursuing the
6 discussion if not the implementation of such statements.
7 In any event, the workgroup feels we should continue on.
8 We started with about 40 non-EPA participants. We're
9 down to now about 15 regular participants. Twenty-three
10 are officially on the workgroup.

11 So, our recommendation back to this group is
12 that we continue on but that we open up membership that
13 we get some new members. I am particularly interested in
14 having consumers or NGO involvement in these discussions,
15 because if you have just trade associations and
16 companies, clearly, you're hearing one perspective on an
17 issue. The whole purpose of having the workgroups and
18 this meeting and this committee is to get a diverse
19 interest represented in all of our discussions.

20 So, any questions? Gabriele?

21 GABRIELE: Just to clarify, because I know
22 nothing about this. What is the concern about not on the

1 label, per se, but in the advertising part, which is what
2 I'm hearing became a new item?

3 MS. MONELL: Maybe I wasn't clear. The reality
4 is in the advertising world, there are comparative
5 statements made all of the time. What we're being asked
6 to do is take those comparative statements and put them
7 on pesticide product labels, allow them on pesticide
8 product labels. That's where the distinction is.

9 UNIDENTIFIED FEMALE: So, my question is back
10 to again trying to understand workgroups versus EPA
11 actions. You described a whole lot of things that
12 wouldn't have been in the workgroup. You kept using we.
13 So, sometimes it was we as the workgroup, sometimes it
14 was we as EPA. Can you articulate for us what the best
15 use of this workgroup is in this space? How are you
16 using this workgroup to move this program forward to meet
17 the needs that you just described?

18 MS. MONELL: Well, think somebody described it
19 earlier as a deeper dive into issues. This particular
20 diving has been around issues of information that we
21 allow on pesticide product labels to assist consumers in
22 understanding or selecting or whatever they're interested

1 in.

2 So, unlike this committee, which recommended
3 that this was an issue that was worthy of a deeper dive
4 -- that's what the workgroup is doing, is a deeper dive.
5 The results of our initial diving resulted in the agency
6 -- and we brought it back here, the recommendation back
7 here, but then the agency proceeded to develop the
8 criteria and allow the DFE logo on pesticide product
9 labels, factual statements, biobase, biodegradability.

10 So, it was just sort of evolving through the
11 discussions to recommendations to this group and then
12 carrying them forth. So, when I say we, I guess it's in
13 two different contexts, my workgroup context as well as
14 the EPA context, sorry.

15 UNIDENTIFIED FEMALE: I just think that "we" is
16 an important distinction as we go through trying to
17 understand if we cue up all these workgroups, what are
18 they doing? Do they need to refocus? The "we" is
19 important.

20 MS. MONELL: Got it.

21 Pat?

22 PAT: Marty, I think it was a year or so ago we

1 had talked about somehow if there was a way to include
2 animal testing information on these labels, particularly
3 in the light of EPA's new thrust into trying to replace a
4 lot of these toxicity tests with non-animal alternatives.
5 I'm wondering if that ever went anywhere or is that
6 something that might be able to be reopened for
7 discussion.

8 MS. MONELL: Absolutely. As you may or may not
9 recall, Kristie Sullivan, who used to be a member of the
10 PPDC and was an active member of this workgroup, did a
11 lot of work on that very issue and came up with various
12 options. I will have to say there was some concern
13 raised about emphasizing the fact that animal testing
14 occurred in the first place. So, to have statements
15 about well, animals were not tested in the development of
16 this product, could perhaps have an adverse impact.

17 So, the workgroup had some serious concerns
18 about proceeding without wrestling with that issue.
19 Then, Kristie left the PPDC and left the workgroup, so
20 it's just been languishing. We did talk about it
21 yesterday, though, and there is a desire by the workgroup
22 to work closer with OPP to talk about where we're at with

1 the reduction in the use of animal testing and any
2 encouragement that we could give through statements,
3 factual statements, to that effort.

4 So, we agreed we would have Jennifer McLain and
5 Anna Lowit come to our next workgroup meeting to talk
6 about where we're at with those efforts to reduce, if not
7 preclude, the need for animal testing in the pesticide
8 registration process. So, it languished for a bit, but
9 it's very much back on our agenda.

10 PAT: (Inaudible)

11 MS. MONELL: Thanks, Pat.

12 Aimee.

13 AIMEE: You actually touched on it. I was
14 curious to have access -- I don't know if there is access
15 to see the criteria you used for the DFE and these
16 statements of safety on different surfaces.

17 MS. MONELL: There is a website, PPDC
18 comparative safety statement website.

19 AIMEE: But is the comparative safety the
20 correct one for DFE?

21 MS. MONELL: Yes, yes. It's under this
22 umbrella.

1 Dawn?

2 DAWN: So, as an academic who has an extension
3 component to her job, I talk about efficacy of products
4 and approaches all the time. Terribly important stuff.
5 But given the dynamic reality to efficacy in both time
6 and space, I'm wondering how that could possibly be
7 constantly updated if it was placed on a label?

8 MS. MONELL: That is clearly one of the big
9 issues that we have to wrestle with.

10 Sharon?

11 SHARON: Just two questions. The first one, to
12 clarify, when you said that safe and safer are not words
13 that can be used on pesticide labels, did I understand
14 that correctly, so that the safer choice label is only
15 going to be for the non-pesticidal products?

16 MS. MONELL: At this point, yes. We have
17 regulations that specifically preclude comparative safety
18 statements. In those same regulations, there is an
19 example given of comparative language that is
20 prohibitive. Safe and safer are specifically enunciated.
21 We're looking, as an AAship towards the possibility of
22 amending our regulations because they are out of step,

1 some think, with the times.

2 SHARON: So, a follow up on that is that the
3 other aspects, it looked like they are going to be
4 included on pesticide labels, including the
5 biodegradability, fragrance types of information?

6 MS. MONELL: Yes, yes, that's correct. We
7 recommended that as a workgroup. We recommended that to
8 this group. The agency took the recommendation and is
9 moving forward.

10 Wayne?

11 WAYNE: This is an issue that may be outside of
12 what you discussed, Marty, so I'm sorry for targeting you
13 with this. What is the difference in the websites -- and
14 maybe this is an item for further discussion later. The
15 WW2 seems to be the new EPA website prefix, but I've
16 noticed that there are still some WWs. Are the WW2s
17 going to revert to WW or is the whole new complex of the
18 EPA's website remaining with this WW2 prefix? The reason
19 I ask that is that you have information on comparative
20 safety statements without the 2 in the prefix; whereas,
21 the others seem to have the 2. I guess I'd like to know
22 that in regards to changing links within my own program.

1 MS. MONELL: I cannot specifically answer that
2 question. Actually, Claire Gessalman, I
3 believe, made a big presentation on the changes to our
4 website at the last meeting. I didn't commit it to
5 memory, so I'm not the person to answer that question.

6 (Inaudible), Dea can you?

7 DEA: I didn't quite get the question, Wayne.

8 WAYNE: I was just asking, in terms of the new
9 EPA website, it's a prefix of WW2. But I still see a
10 number of sites, like the one that Marty has listed here
11 within comparative safety, for the WWW. I'm wondering if
12 we made changes to our own home pages and websites,
13 what's going to stick? Is it the WW2 or the WWW?

14 DEA: I'll get with Claire.
15 I'll send her an e-mail and see if she can help us answer
16 that question.

17 WAYNE: Okay.

18 MS. MONELL: Yeah, we'll have that
19 information for you before we leave tomorrow.

20 MS. MONELL: Cheryl?

21 CHERYL: On the possibility of comparative

1 either safety or efficacy, the criteria by which you make
2 that claim and that comparison, depending on how deep it
3 goes and what criteria you use, those comparisons could
4 change. To Dawn's point, there's also going to be market
5 and dynamics that change.

6 So, I guess I'm wondering, in the current label
7 approval process, which is very laborious and legally
8 binding, is that really the place for some of this
9 information, or could you take a page from the pollinator
10 group where they pulled off the RT25 and they posted it
11 on the website? So, it's easier to update and have more
12 information than a label.

13 MS. MONELL: That's definitely something that
14 we will be talking about as we go forward. As I say,
15 this whole issue really -- it was directed to our
16 workgroup. Yesterday was the first time that we actually
17 had a conversation about it and decided that yes, this is
18 an area that we should further discuss. But the
19 parameters and a framework for it, all of that is yet to
20 come. But that's good advice.

21 Beth?

22 BETH: I guess one thing, you sent an e-mail,

1 but there was an announcement I think about a week or
2 week and a half ago that EPA sent out regarding the
3 change of the new URL for the pesticides website. It did
4 say that you would need to change a lot of your links if
5 they didn't actually carry over. So, I just offer that.

6 I guess what we were talking about earlier, and
7 Cheryl, you might have raised the point initially, what
8 is the scope or the mission of these workgroups and what
9 do you want them to do. From having just compared what
10 the pollinator workgroup has done with what this
11 comparative statements workgroup has done, I would urge us
12 to not to try to come up with a monolistic solution. I
13 think what you want from those workgroups really does
14 depend on what subjects they are addressing.

15 With this comparative safety statements
16 workgroup, clearly what they're dealing with is a much
17 more defined universe of issues. My understanding of the
18 pollinator workgroup is that it has so many moving parts
19 and there's so many separate issues, I would think what
20 you'd need from that would be more like policy and
21 ranking. Whereas, compared to the safety workgroup,
22 you're dealing with should biodegradability be a label

1 statement. So, that would be my contribution to that
2 discussion.

3 MS. MONELL: Thank you, Beth.

4 Okay, thank you very much. I appreciate it.

5 MR. HOUSENGER: All right. Well, we're about
6 on time. Let's take a 15-minute break. When we come
7 back, we have one more workgroup. Jim McCleary is on his
8 way. So, 15-minute break, back here at 10 of.

9 (A brief recess was taken.)

10 MR. HOUSENGER: We're going to get started now.
11 Jim McCleary is here. He's going to talk about the FACA
12 rules. Jim?

13 MR. McCLEARY: Good morning, everyone. Thank
14 you, Jack. My name is Jim McCleary. I'm with the Office
15 of Diversity, Advisory Committee Management and Outreach,
16 an office within EPA. Our primary function and the roles
17 that involves you is that we manage the federal advisory
18 committees that provide advice and guidance to the
19 agency.

20 First of all, let me say welcome. Thank you
21 very much for serving. We do appreciate your efforts and
22 the time and attention it takes to be here today and to

1 work on this committee.

2 FACA, the Federal Advisory Committee Act, was
3 passed by congress in 1972, and it governs all aspects of
4 your work. One of the things that the government has to
5 be careful of is not invoking FACA unintentionally. So,
6 if we grabbed a group of people from the outside together
7 to provide consensus or group advice, FACA is usually
8 invoked. So, we have to go through the formal membership
9 process and chartering process to bring everyone on board
10 to make sure that we're doing it right and that we're not
11 in violation of FACA.

12 At EPA and elsewhere throughout the government,
13 members of the committee serve at the administrator's
14 discretion, at her pleasure, we call it. We try to
15 balance the committee to make sure it's balanced in
16 reference to the points of view to be represented and in
17 the functions to be performed.

18 FACA requires several things, including
19 openness and transparency. This is an open meeting
20 today. We have a visitor's gallery. We have noticed
21 this meeting in the Federal Register and in other places.
22 Opportunities are provided for the public to provide

1 comments.

2 We appoint members depending on whether the
3 member is being asked to represent a point of view of the
4 group, which is what you are, you are representative
5 members, or if you're representing your own expertise,
6 and that would be an SGE member. This committee has no
7 SGE members. Every single one of you here are asked to
8 provide the point of view of the group that you're
9 representing.

10 We also keep detailed meeting minutes, and
11 committee documents are available to the public. Our
12 minutes will be certified by your committee chair, Jack,
13 and the requirement applies to all of the meetings,
14 including teleconferences. If you invoke a forum, we
15 have to maintain these records.

16 You have a designated federal officer
17 representing the agency here today. That's Dea
18 Zimmerman. Dea is one of our best and finest DFOs.
19 You're very lucky to have her. The DFO manages the daily
20 operations of the committee, and the DFO has to be
21 present for every single committee meeting. If you're
22 having a meeting, whether in person or remotely, the DFO

1 has to be here. In the event Dea can't make it, the
2 agency can appoint someone else to be DFO, acting DFO,
3 for the purposes of running that meeting.

4 A couple of things we ask of you, to
5 participate. This is a dialogue committee, and it
6 doesn't work if you're not here to talk with each other
7 and express your points of view. We ask that you come
8 prepared to the meetings. Like we send our children to
9 school, you're supposed to send them to school prepared
10 to learn. We ask you to come here prepared to
11 participate. That means reviewing the materials in
12 advance. We ask that you engage in a cordial, polite,
13 and professional manner with each other.

14 We ask that you represent your interest group.
15 So, while your own personal views might be very important
16 and interesting, you're really here representing an
17 organization. We want to hear the points of view of that
18 organization or group.

19 We ask that you work towards consensus where
20 possible and where appropriate, and that you provide
21 feedback through your chair. The chair is the person
22 that provides the leadership for this committee. If you

1 have any issues or concern, please bring them to Jack's
2 attention.

3 We ask that you collaborate with each other to
4 achieve the committee's charge, and that you serve your
5 appointed term. Now, sometimes things come up. Life
6 gets in the way. For whatever reason you can't serve
7 your term, we ask that you please notify Jack as soon as
8 possible, because it may throw off the balance of the
9 committee. If the balance of the committee is not
10 appropriate, then we have to bring someone else on board
11 before the group can meet again.

12 We ask that you stay in close communication
13 with your DFO, Dea. Dea is really the point of contact
14 through the agency for this group.

15 There are travel and ethic considerations to
16 talk about. As invitational travelers, the government
17 pays for your travel here. Later on, I'm going to throw
18 it to Dea so she can introduce the person who manages
19 your travel. You're also entitled to a per diem for
20 every day that you're on government travel.

21 The next item is our plays well with other
22 item. We ask that you refrain from any language that may

1 be offensive to other members of the committee. We don't
2 expect that to be a problem with this committee, but
3 unfortunately, in the past, with one of our committees,
4 it has been a problem.

5 The next issue is that members may not lobby
6 congress in their capacity as advisory committee members.
7 This is something that has been an issue with some of our
8 committees in the past. As US citizens, you are fully
9 entitled to lobby your governments on issues that are
10 personal to you, but we ask that you not represent this
11 group. Jack is our chair, and he represents the group.
12 If there are any issues that have to be brought up to
13 congress, he'll work with EPA's office that's involved in
14 that to make sure that happens.

15 In the event that you do go up to congress, we
16 ask that you do it on your own dime and on your own time.
17 So, while the government has brought you here, you
18 shouldn't leave this meeting for a couple hours to run up
19 to Capitol Hill to talk to your member of congress. You
20 shouldn't put in a travel voucher for the taxicab that
21 takes you there and back. Any questions on that, I'd be
22 happy to field those.

1 This is the same prohibition also that EPA
2 employees, myself, and Dea are subject to as well. We
3 can't go up to congress and lobby them to do things that
4 we think they should be doing on behalf of the agency
5 either.

6 There's some limitations here. You're asked to
7 provide advice and recommendations directly to the EPA.
8 Sometimes some of our committees provide advice also to
9 congress or to the president. This is a dialogue
10 committee that their advice comes through the discussion
11 that takes place here and it goes directly to the agency
12 administrator.

13 With our approval, you can form subcommittees
14 and workgroups to accomplish the goals of the committee.
15 That's something you would have to work through Jack and
16 Dea to set up. Subcommittees must report their findings
17 directly through the parent committee for full
18 deliberation.

19 So, if there is a workgroup or a subcommittee
20 that's doing some part of your work here, they don't have
21 authority to present that material directly to the
22 administrator themselves. It has to be brought up to

1 this whole committee as a group before it can be passed
2 forward.

3 At EPA, we make our subcommittees go through
4 the same membership requirements that you do here for the
5 parent committee. That's not the case for other federal
6 departments and agencies. So, if you do set up a
7 subcommittee, we have to go through the full membership
8 process for that subcommittee.

9 Workgroups and subcommittees, generally what
10 they do is they'll do research into specific activities
11 that you're performing as a committee. If this committee
12 doesn't generate a written report for the committees that
13 do often, there will be a writing subcommittee or a
14 research workgroup that will look into those aspects of
15 it.

16 Workgroups are not subject to FACA. That's the
17 good thing about workgroups at EPA or elsewhere
18 throughout the agency. We don't have to go through
19 membership requirements. We don't have to go through
20 chartering requirements for them. We can set them up.
21 The only thing that you have to be careful of, and Jack
22 and Dea know this already, is that you can't invoke a

1 forum.

2 So, if you have a subcommittee that has more
3 than half -- at EPA, we consider a quorum to be 50
4 percent plus 1. So, if we have a subcommittee or
5 workgroup of more than half the committee, you invoke the
6 quorum and then it's a full meeting and we have to go
7 through all of our meeting requirements.

8 Additional resources, there's the Federal
9 Advisory Committee Act that you can look up. Our EPA
10 website is full of information. Like, the ODACMO website
11 is where most of this is kept. ODACMO stands for, as I
12 said earlier, Diversity Advisory Committee Management and
13 Outreach. That's the office that I work in. Really, the
14 best source, if you have any questions, is to go through
15 Jack or Dea. If they need additional resources, they'll
16 contact me or other appropriate partners in the agency.

17 Again, I'd like to thank you all for serving.
18 This is a great thing that you do, and the agency
19 appreciates it. I'm available for any questions now or
20 else I'll hang around a little bit, too, if you have any
21 later. Any questions now?

22 Cynthia?

1 CYNTHIA: What's the difference between a
2 subcommittee and a workgroup?

3 MR. McCLEARY: At EPA, a subcommittee has to go
4 through the full membership cycle. So, we have to
5 balance it and everything like that. A workgroup doesn't
6 have to do that.

7 CYNTHIA: I see that, but how do you determine
8 -- so, all of our small groups are workgroups?

9 MR. McCLEARY: Well, it depends. It depends
10 largely on the DFO and how the DFO wants to manage that.
11 Workgroups are usually for a limited purpose and a
12 limited duration. So, you have a specific purpose. We
13 need you to research this issue for the group to present
14 at the next meeting. A subcommittee can be ongoing. So,
15 if you wanted a subcommittee that dealt with a specific
16 portion of what you do and it's going to continue on into
17 the future, that's when you would invoke a subcommittee.

18 Other questions?

19 MR. HOUSENGER: Cheryl?

20 CHERYL: So, thank you for that. I'm really
21 interested in understanding some of these definitions, as
22 Cynthia was as well. I've served for five years now, so

1 I'm in my third term. I found this to be an excellent
2 forum for broad discussion and different viewpoints. But
3 I haven't found it to be a forum for a lot of consensus
4 or full recommendations. We've had recommendations out
5 of subcommittees that have sometimes been adopted. But
6 this idea of consensus -- so, one of your slides said you
7 should work towards consensus as much as possible.

8 At one point, Steve raised his hand and said
9 you don't vote. This committee doesn't vote. So, how
10 else do you reach consensus if we don't vote? What are
11 the expectations and processes? Along those lines, if
12 you're watching a whole lot of other FACA groups, are
13 there some best practices from those groups that maybe we
14 haven't used here?

15 MR. McCLEARY: Thank you to that question.
16 This is a dialogue committee. This is EPA's only
17 dialogue committee, so this is a little bit unique here.
18 So, working towards consensus probably isn't as important
19 in this group. What we're looking for from a dialogue
20 committee like this is your discussion and this open
21 exchange of ideas that occurs during the course of your
22 meeting. So, that slide is part of my regular

1 presentation, but this group is a little bit unique as
2 EPA's only dialogue committee.

3 Consensus is usually very important when you're
4 working on a written report because a written report is
5 providing advice to the administrator. We want to give
6 her some very concise recommendation. That's hard to do
7 if you don't reach consensus. But since you don't
8 produce a written report here, it's through dialogue and
9 consensus. As a result, it's not as important.

10 Dawn?

11 DAWN: Thank you. So, if a workgroup felt that
12 they may want to transition into a subcommittee to
13 continue or felt that they could have an ongoing extent
14 beyond three years, what would be the process and
15 limitations and benefits?

16 MR. McCLEARY: The process would be going
17 through Jack and Dea and saying that we think this
18 workgroup has a role far beyond this immediate cycle. We
19 should consider turning it into a subcommittee. The
20 benefit is that subcommittees are open to all the
21 transparency requirements and openness requirements that
22 the general committee is subject to.

1 The downside is it's a lot of work. You didn't
2 see it necessarily, but when putting this group together,
3 what Dea had to go through to get you all on board was
4 impressive. It's a lot of work to make sure it's
5 balanced, to make sure you have the top people on board.
6 So, that's the downside of it.

7 MR. HOUSENGER: Ray?

8 RAY: Does FACA, as a law and its associated
9 regulations, recognize a difference between an advisory
10 committee and a dialogue committee?

11 MR. McCLEARY: No, it's not mentioned in FACA.

12 RAY: What is the difference?

13 MR. McCLEARY: Well, a dialogue committee is
14 specifically for that, to dialogue for this exchange of
15 ideas that's discussed.

16 RAY: If it's not recognized in FACA, there's
17 not a difference. That's my contention. If you're going
18 to ask us for advice, we give advice, whether it's a
19 dialogue or an advisory committee, if we're operating
20 under FACA.

21 MR. McCLEARY: Can you say that last part
22 again?

1 RAY: If you're operating under FACA and it's
2 associated regulations, and there's no difference
3 recognized there, how can EPA create a difference between
4 an advisory committee and a dialogue committee?

5 MR. McCLEARY: Well, we don't make that
6 distinction. A dialogue committee is an advisory
7 committee.

8 RAY: You have made that distinction here.

9 MR. McCLEARY: Well, perhaps I misstated it,
10 then. But a dialogue committee is a Federal Advisory
11 Committee. You are a chartered Federal Advisory Committee
12 of the EPA. Your charter is filed with congress. You
13 are a Federal Advisory Committee. What we're asking you
14 to do is dialogue as opposed to writing a report.

15 RAY: If EPA is going to represent the actions
16 and activities of this committee as having done an issue
17 by the Federal Advisory Committee, having run an issue
18 past the pesticide program dialogue committee, unless
19 it's been asked for a report or a formal recommendation
20 of the committee, it cannot represent running it passed
21 the committee either as agreement by the committee or
22 lack of disagreement by the committee. If there's no

1 formal report, then just simply running it by the
2 committee doesn't imply any agreement or disagreement.

3 MR. McCLEARY: I would agree that there's no
4 implied agreement or disagreement. We're asking for your
5 dialogue.

6 RAY: Another question. You mentioned
7 specifically that subcommittees must pass their
8 recommendations through the full committee and cannot
9 pass those on directly to the agency.

10 MR. McCLEARY: That's correct, yes.

11 RAY: Is there any difference in how a
12 workgroup handles recommendations or results that it
13 comes up with?

14 MR. McCLEARY: No, it's exactly the same. They
15 would also have to pass any recommendations or advice
16 that comes from them through the parent committee.

17 MR. HOUSENGER: Steven?

18 RICHARD: Me?

19 MR. HOUSENGER: Yes.

20 RICHARD: It's Richard with the Ag Retail
21 Association. I just had a question, and this is maybe
22 for new members or current members. This goes back way

1 before my time or Jim Thrift from ARA. There was a spray
2 drift working group, if you all recall that, going back a
3 ways. They actually did issue a report. So, there was
4 consensus with that workgroup. I believe it's part of
5 the EPA archive.

6 So, if those reports are put together, there's
7 a lot of time and effort put on that, what happens with
8 those? Those are actually written reports that are put
9 together. What happens with those recommendations or
10 reports?

11 MR. McCLEARY: Would you like me to answer
12 that?

13 RICHARD: Sure.

14 MR. McCLEARY: Okay. Several things happen
15 with reports that are generated by Federal Advisory
16 Committees here at EPA. Copies are sent to the Library
17 of Congress. They require eight hard copies, even in
18 this day and age of electronic submission. They require
19 eight hard copies to be sent there. EPA's library also
20 maintains these reports. Usually, the program office
21 would have them printed and disseminated and sent out to
22 their channels. So, they're maintained, they're kept,

1 they're archived. Those are written reports of this
2 Federal Advisory Committee.

3 Now, I'll make a distinction that these are not
4 work products of the EPA. You are not EPA employees, for
5 the most part. Your reports are the work product of this
6 committee. So, federal archiving and records
7 requirements are usually not applied to those reports.

8 RICHARD: A follow up. So, it's not
9 necessarily like the PPDC is approving those reports;
10 those are just like part of the dialogue that you may
11 review? Is that what part of that is?

12 MR. McCLEARY: That's absolutely right. The
13 committee will approve it, but the program office will
14 not approve it at all. This is advice that you're
15 providing to EPA. EPA is not allowed to have undue
16 influence by saying you've got to retract this or you
17 have to add this or anything like that. If you're going
18 to generate a report, it would be your work product.

19 RICHARD: Did you just say the PPDC would need
20 to approve the work product?

21 MR. McCLEARY: That's right, yes. If it was a
22 report generated by a workgroup of the PPDC, it would

1 have to be presented to the full board of the PPDC for
2 approval before it could go any further.

3 RICHARD: So, there are some reports, then,
4 that are approved by the PPDC for review by EPA?

5 MR. McCLEARY: If you generated them, then,
6 correct, yes.

7 MR. HOUSENGER: We tend not to ask for them.
8 But if the workgroups want to generate a report, then
9 yes, it would be before the committee.

10 Dawn?

11 DAWN: If you don't mind, are those reports
12 citable in any particular format?

13 MR. McCLEARY: Yes. They do get cited on
14 occasion, especially the reports from our scientific
15 committees who will be approving levels of chemicals and
16 things like that. They often get cited in scientific
17 journals. News agencies will often cite to them. I
18 don't know that there's any specific format for doing
19 that, but they can say, you know, according to this
20 report by the PPDC, this is what they concluded. So,
21 yes, they are cited. You will see citations to Federal
22 Advisory Committee reports of EPA in many media.

1 MR. HOUSENGER: All right, if that's it, thank
2 you, Jim. Thanks for the warning on the foul language.
3 I'll refrain.

4 MS. MONELL: Thank you very much.

5 MR. HOUSENGER: Before we start with our next
6 presentation, I think included in your packets is the new
7 organizational chart. Since the last PPDC, we've named
8 two new directors. One is Dana Vogel, who is the Health
9 Effects Director. Do you want to stand up, Dana, so they
10 can see you behind me? The other is Steve Knizner,
11 who is the Antimicrobials Division Director.
12 So, I just wanted to introduce those to the committee.

13 MS. MONELL: While we're at it, I have another
14 piece of information for you. This concerns the web
15 address information. Either WWW or WWW2 will work for
16 your searching purposes. If you enter WWW, the browser
17 will show up as WWW2. The servers are being merged.
18 There will be no impact on your ability to search,
19 however. So, you can use either one, it will work fine.

20 MR. HOUSENGER: That's in theory. I use Google
21 to get my things.

22 So, our next workgroup presentation is going to

1 be made by Jennifer McLain, and she's reporting on the
2 21st Century Toxicology Effort.

3 MS. McLAIN: Good morning. So, I'm going to
4 talk about the toxicology for the 21st century new
5 integrated testing strategies workgroup. I'm the chair
6 of the workgroup. This workgroup has been around for
7 quite some time. It was established in 2008.

8 So, I'm not going to go through the whole
9 presentation you have in your packet. That's really so
10 you can understand the details of the accomplishments of
11 the workgroup over the years if you're interested in
12 those details.

13 Mainly, it also goes on the slide which is the
14 charter of the workgroup and give you some highlights of
15 those accomplishments so that you can understand what the
16 workgroup has done to meet this charter. Then, I'll talk
17 a little bit about the recommendation of the workgroup as
18 far as continuing on.

19 We had a discussion yesterday, and I think
20 there are some folks here that are a part of our
21 workgroup and also part of the PPDC committee. They
22 might want to share some perspectives on that afterwards.

1 So, we have a very engaged and interested group
2 of core members, probably about a dozen members who
3 regularly come to our meetings, our teleconferences, or
4 our face-to-face meetings. We have many more than that
5 that are officially signed up for the workgroup, but
6 there really has this dedicated core, and it's been great
7 working with them.

8 The charter of the workgroup is to focus on
9 communication and transition issues as EPA phases in new
10 molecular and computational tools. We identified key
11 transition activities being identifying other internal
12 and external applications of this new science and
13 providing process recommendations to transition to the
14 new testing paradigm.

15 An important perspective to note is that this
16 workgroup was set up right at the time of the National
17 Academy of Sciences report on 21st century toxicology.
18 EPA, in particular the pesticides program, was very
19 interested in how we're going to be using this new
20 science and how we can change the way we do things to
21 improve the quality of our risk assessments and make our
22 risk assessments and our testing program more efficient

1 and beneficial.

2 We set up this workgroup because it was a big
3 change that we were contemplating, and we wanted to make
4 sure that we were going through that change thoughtfully
5 with the consideration of a multitude of perspectives
6 that are represented in the workgroup.

7 So, as I said, I'm not going to go through each
8 slide, but some of the things that the workgroup have
9 done over the years, we started as a workgroup learning
10 the aspects of the science that we were contemplating
11 transitioning to. So, we had a lot of folks come in, EPA
12 scientists from both Office of Pesticide Programs and
13 Office of Research and Development, and sometimes from
14 other agencies and groups to come and talk to the group
15 about some aspect of emerging science.

16 The group itself put identified issues that
17 either their group had or others had that they had heard
18 in other contexts about primarily concerns with moving to
19 new science. What would this mean? Where were the
20 places of discomfort? Why were they there?

21 Using that, we hosted three different workshops
22 on various aspects of 21st century science and the

1 transition that the pesticide program was making into its
2 regulatory application. Two of those were broad on tools
3 and their application of pesticide programs. One of them
4 was specific to biomarker tools.

5 These perspectives that the workgroup has been
6 discussing and that were brought forward in even greater
7 detail in the workshops that we put together have been
8 very helpful as EPA has, over the course of these years,
9 been developing guidance and policies on how we're going
10 to be incorporating specific tools into our program.

11 We've taken those perspectives into
12 consideration as we've been putting together the
13 policies, developing the documents, and making sure that
14 we are touching upon those issues that we know are out
15 there in the stakeholder community so that our program is
16 fully explained.

17 We have two ongoing projects right now that the
18 workgroup is still looking at. One of them is primarily
19 now in OPP's hands. OPP is following up on a
20 recommendation that came from our workgroup to this PPDC
21 group, and then the PPDC group recommended to OPP, which
22 is the establishment of metrics by the program for

1 advancing alternative approaches. That recommendation
2 from the workgroup and the discussion in the workgroup I
3 think has given our program a lot of energy and moving
4 forward with that.

5 For example, we put out a guidance document for
6 public comment last year on the process for evaluating
7 alternative approaches. As someone mentioned earlier in
8 one of the discussions, we're looking now at the acute
9 testing and mapping out our goals for significantly
10 advancing alternative approaches with respect to the
11 acute testing.

12 The second project that's ongoing is on the
13 biomonitoring tools that I mentioned or the focus of one
14 of the workshops that the group did. This has been
15 ongoing discussion in subgroup within our workgroup.
16 Right now, the subgroup is developing a paper that is
17 going to be outlining the need for more research in this
18 area.

19 So, beyond those two pieces that we're working
20 on, where are we now in 2015? Obviously, as a program,
21 we feel there's never an end to communication. The
22 objective of this workgroup was quite broad to begin

1 with. We always want to be engaging stakeholders and
2 being transparent with changes and new ideas that our
3 program is thinking about.

4 We're definitely as a program not in the same
5 place now that we were in 2008. Science is definitely
6 not in the same place. The science has been rapidly
7 developing, and the acceptance of that science has been
8 rapidly changing over the years since this workgroup was
9 established. We've really transitioned to more of an
10 implementation phase than we were when the workgroup was
11 established.

12 I think we had pretty general agreement
13 yesterday that the workgroup has accomplished its charter
14 that it was initially set out to do. It would be a good
15 time to sunset the workgroup. There were a number of
16 different perspectives in the workgroup about whether
17 there is a need for a new group to focus on the
18 implementation of 21st century tools in the program.
19 That is to carry on the communications with the
20 stakeholders maybe to work on some specific aspect of the
21 implementation.

22 There was also some discussion about the fact

1 that a lot of the work that we are doing in
2 implementation we are doing in coordination with various
3 stakeholders. It's happening through other venues. So,
4 there's some perspectives that those other venues are
5 serving that purpose right now, and that perhaps we don't
6 need a workgroup under this PPDC to carry on that work or
7 to provide additional input.

8 As I mentioned, from a program perspective, the
9 communication is always paramount and will be regardless
10 of whether there is a workgroup. We will certainly be
11 coming to this PPDC group to be talking about where we're
12 going, what advancements we've made. For example, if
13 we're developing a new policy or guidance, we'll be
14 coming to this group at some point to talk about what
15 we've done, and why, and to hear your comments on those.

16 So, that's all I had for this summary. I know
17 that a few folks from the workgroup wanted to share their
18 ideas on the future. So, I think I'll hand it over to
19 anyone who wants to speak on that point.

20 PAT: I guess I'll jump right in here. Pat
21 Bishop with PITA. I think a lot of what Jennifer said,
22 you know, there was agreement on. I don't think people

1 were completely ready to give up the workgroup, maybe
2 just have it in a different forum or have a different
3 charge.

4 We think because the implementation of tox 21
5 methods is kind of really building now, that there still
6 may be a role for us. It may not be all of the same
7 people that were originally on the group. There are,
8 like Jennifer said, sort of a core group, but there's a
9 lot of people listed that get the notices that never seem
10 to participate. But I think there's people out there
11 that we can draw upon if we maybe get some more of the
12 right people in.

13 But I guess, from my perspective, we're
14 interested in helping EPA in any way that we can for
15 implementation of the alternative methods. Jack, I don't
16 know if you want to talk about this later, but we had a
17 stakeholder meeting a couple weeks ago to talk about some
18 of the acute tox methods and eventual adoption of them or
19 approval of them by EPA.

20 We talked about a few barriers that might come
21 up to that adoption. So, I think there's some areas
22 there that maybe we can help you with and figure out how

1 to try to get by some of these barriers or working on the
2 international scale with Europe and some other countries
3 that have already adopted some of these methods, how did
4 they do it. The issues get into classification and
5 labeling, things like that, which may be kind of sticking
6 points. There may be some way we can help you guys
7 with that.

8 But I think what a lot of people were saying is
9 we need to hear from you as an agency too as to where you
10 think we can help you the best, where can we provide
11 input or advice or whatever to try to get by some of
12 these issues.

13 I don't know if, Cheryl, you want to kick in
14 there, too.

15 CHERYL: So, I had to exit for another meeting,
16 but when I left the first meeting to go to the incidents
17 meeting, I was hearing that we definitely had not let go
18 of the workgroup, but wanted to refocus for sure. I just
19 want to make sure one more time, Jennifer, to clarify,
20 when you say the biomonitoring subgroup is working on a
21 publication, we just had a big discussion about what's a
22 PPDC workgroup product and what's not. That publication

1 can come from members, but it's not a PPDC workgroup
2 product.

3 JENNIFER: Right. Yes, Cheryl, that is
4 correct. I can't remember if you were in the room or not
5 when we had that specific conversation, but that question
6 was asked. It might have been you that asked it, I can't
7 remember.

8 CHERYL: I think that's very important.

9 JENNIFER: Yes, it is.

10 CHERYL: I think the workgroup broke off into
11 these different pieces and tackled a bunch of different
12 things. Then, that biomonitoring piece took a couple of
13 different twists and turns. You've got a lot of
14 information, and there's some people that really want to
15 put together a publication. But that publication can't
16 come out of the workgroup; it needs to come from those
17 authors.

18 JENNIFER: Right, right, yes. That was an
19 accurate description of the conversation we had
20 yesterday. Thanks for that clarification.

21 Aimee?

22 AMY: Hi. So, I have a couple questions

1 about this workgroup because I've been involved in
2 various stages of it. I guess I'm concerned. One of the
3 pieces that the migrant clinicians network has been very
4 concerned about since the inception of this workgroup is
5 that front line clinicians lack the clinical diagnostic
6 tools to be able to determine with a test whether or not
7 one of their patients is exposed to pesticides in helping
8 with their diagnosis.

9 So, I guess I feel like that was actually looking
10 back to the original objective of this workgroup. That was one of
11 the very reasons we proposed this, because we still feel
12 like there is this need. So, I know the science has
13 changed, and we've come a long a way, but somehow this
14 workgroup really got more into a lot of different things
15 which, in part, still address that.

16 But the reason I think that there was folks
17 working on a publication is that there's still this very
18 important need that when pesticides are put on the market
19 and people are exposed to them in their work or in their
20 day-to-day lives, that clinicians still do not have a
21 good way to understand those exposures.

22 So, it's sort of circling back, but I'm not

1 quite sure where the agency is going with this at this
2 point in time. From 2008 to 2015, clinicians still don't
3 have tools at their disposal to be able to help with the
4 diagnosis. I think the publications are important
5 because -- Jack, you can speak to that because I know
6 that you're a part of it. The publication is coming out
7 because there's still this need.

8 JENNIFER: Thanks, Amy. I think that's
9 exactly where this subgroup who is working on the paper
10 landed a way to get out the communication of the need for
11 research on biomonitoring tools more broadly and in the
12 science community.

13 MR. HOUSENGER: Sharon.

14 SHARON: Hi. I have not been involved with
15 this working group. Just learning a little bit since
16 this is my second PPDC meeting about the work. So, just
17 kind of a question. In risk assessment, there's usually
18 an evaluation of multiple lines of evidence at different
19 levels of biological organization.

20 So, my question is about the transition which
21 appears to be in place for some of the new traditional
22 studies to move to new kinds of studies. I'm just

1 wondering what effect that might have or if the
2 discussion has taken into account those multiple lines of
3 evidence for the robustness of risk assessment through
4 looking at interacting systems at the organismal level
5 and at the ecosystem level.

6 JENNIFER: That's a pretty big question, but I
7 guess I'll just basically say yes. The way OPP is doing
8 this implementation basically is on an action-by-action
9 basis. We're delving down deep into those questions as
10 we make specific changes.

11 MR. HOUSENGER: Are you concerned that we would
12 just use the non-animal tests and the results of that
13 without considering all the other information out there?

14 SHARON: Well, sort of. Again, not fully
15 understanding what the neutrals are, it's hard to know if
16 that's really totally my concern. I'm looking at the
17 concept of looking at different levels of biological
18 organization and understanding the effects of pesticides
19 at the molecular level, at a tissue level, at an
20 organismal level, and at an ecosystem level, and
21 wondering if the thrust of this workgroup, which is not
22 new, is going to be able to adequately account for those

1 different levels with these new tools.

2 JENNIFER: The workgroup itself has been
3 focused on identifying perspectives of concerns, such as
4 the one you're raising. Are you going to be using a full
5 set of information in your decision-making? So, EPA, when
6 developing policies or determining to allow new tests to
7 be used and the information that we're receiving that
8 we're using in our risk assessments, we can ensure that
9 we're taking those perspectives into consideration and
10 understanding.

11 For this example, there's a concern that we
12 wouldn't be using a full range of information as we
13 integrate this new test or as we use this new method,
14 and making sure that we're fully discussing that in our
15 policy document that we're laying out.

16 MR. HOUSENGER: Ray.

17 RAY: I recognize that the biomonitoring
18 question and the research question has been before the
19 workgroup for several years. If a subgroup prepares a
20 paper on the topic with the intent on providing advice to EPA on
21 how it's conducted, mentions this workgroup as the source
22 of its concern or efforts, if EPA has provided support

1 through the workgroup or any portion of that paper, it
2 should come back to PPDC for review before publication
3 and promulgation.

4 JENNIFER: Okay. We'll take that into
5 consideration.

6 MR. HOUSENGER: I guess you listened to Jim.
7 Amy?

8 AMY: (Not on mic)

9 MR. HOUSENGER: Right. One of the things I've
10 struggled with as we've talked about biomonitoring over
11 the years is what is the specific need, what do the
12 clinicians need, what are available to you now, are you
13 using those tools, how effective are they, are you
14 looking for something different. All those things is
15 number one.

16 Number two, we're going to talk about two rules
17 that are coming out, one that has already been passed
18 that will help address this issue, but still recognizing
19 that there is this need. I think the paper will
20 hopefully answer those questions a little better than
21 they've been answered in this group in the past. I'm
22 still struggling with what is it specifically that you're

1 asking for. Getting that out and having some research
2 done on it I think is a good job, but I think people need
3 to know what they're shooting for.

4 UNIDENTIFIED FEMALE: (Not on mic).

5 MR. HOUSENGER: I guess one of the things I
6 struggle with is if you have a test to say I've been
7 exposed to a certain pesticide and if I've been out in
8 the field, I might be exposed to a number of pesticides.
9 Are you looking for a test that tells me that you've got
10 enough exposure to cause an illness or that I've just
11 been exposed? How does that influence your treatment?

12 UNIDENTIFIED FEMALE: (Not on mic)

13 GOEFF: I would agree that there
14 are not a whole lot of tests available for clinicians to
15 determine if a person is exposed. So, if such tests were
16 available, you could compare the results of that test
17 with the baseline, what you would expect in the normal
18 population.

19 So, for example, the CDC, through the
20 NHANES study, they measure pesticide metabolites or
21 the parent compounds. So, if a clinician has a result on
22 a patient, they could compare the results on that patient

1 with the population norms. So, if the result of the
2 patient is elevated, that would be indication that the
3 pesticide exposed patient was exposed to the pesticide
4 acutely.

5 The issue is that a lot of these pesticides
6 don't produce unique health effects, so they produce
7 health effects that are common for other diseases. So,
8 if you want to distinguish between like a flu or
9 gastroenteritis versus a pesticide toxicity, it would be
10 helpful to have that information to prove that the
11 patient was overexposed to the pesticide.

12 I think that's especially important when you
13 have a worker's compensation case. You're trying to
14 prove to the worker's compensation insurance company that
15 this person was made ill by the pesticide. If you can
16 show that there's pesticide exposure information,
17 biological information to prove that case, then that's
18 going to make it more likely that the patient will get
19 the worker's comp benefits, which is important since a
20 lot of workers don't have health insurance and a lot of
21 times just can't afford the healthcare associated with
22 some of these exposures.

1 MR. HOUSENGER: Pat?

2 PAT: I just wanted to go back to Sharon's
3 question a little bit. We were talking about the
4 different levels of impact that are tested for. I saw
5 that David Dix is going to be on later. The endocrine
6 disruptor program is one of the areas where EPA has made
7 a lot of progress in using some of these alternative
8 methods, not only in vitro or molecular tests but
9 computational, toxicology, and predictive models for both
10 hazard effects and exposure. So, I'm hoping maybe he'll
11 cover some of this stuff.

12 The way this whole tox 21 stuff is working is
13 we're trying to develop what they call adverse outcome
14 pathways where you can figure out what happens from
15 exposure to effect at the molecular level, the cellular
16 level, tissue level, population level, organ level,
17 whatever.

18 So, there are ways to do this. I think that's
19 one of the challenges of the transition between those
20 kinds of methods and what we have now of testing
21 specifically animals, getting some sort of black box
22 result and trying to figure out what does that mean in

1 terms of the impact on an individual versus a population.

2 So, I'm hoping when David gives his talk, that
3 will become a little bit more apparent as to how we might
4 do this. The stuff we were talking about earlier with
5 the Q tox testing where you're just looking at a lethal
6 dose or an acute affect on an animal or if you put
7 something on your skin, what is it going to do, we have
8 ways to do that now, where we've done side by side
9 comparisons of in vitro and in vivo data and showing that
10 method works quite well for many classes of chemicals.

11 MR. HOUSENGER: We can get David to do that.

12 Cheryl, you're the last one, and you're between
13 us and lunch. So, it better be good.

14 CHERYL: I want to come back to Amy's call for
15 kits and tests. I've been part of this biomonitorng piece though
16 I'm not on this paper, but I have been part of the biomonitoring
17 subgroup at some point. I think some of this also comes
18 back to scope, though, because this whole biomonitoring
19 question took a number of twists and turns where we
20 talked about in order to get a test or a kit at the
21 clinician's office, you still have to go back through
22 what's an appropriate biomarker, what's the toxicokinetics

1 what's the (inaudible) profile, is there a
2 common metabolite, is it specific? So, when you made
3 this broad call for pesticides, it gets really difficult
4 and it's kind of a research area for any given pesticide
5 or class of pesticide.

6 So, the PPDC workgroup really struggled with a
7 couple of these aspects. How do you advance this? We
8 went through the exercise of looking at basically some
9 decision documents on the ADME that comes out of the
10 registration process. Does that get you further?

11 We talked about the fact that Europe has these
12 biomonitoring requirements for acutely toxic pesticides
13 in blood and urine and could clinicians make use of that.
14 It's not a kit, but there are methods out there. All of
15 this went on and we went through the process of criteria
16 for what you want to your point. There was not
17 agreement. Do you want a criteria for like an epi
18 biomarker long term, do you want it for an acute
19 poisoning? All of these things swirled within the
20 effort.

21 I think it kind of comes down to scope because
22 there's scope for OPP of where they can regulate and

1 what's in their purview to ask for. There's also scope
2 of what a workgroup of just a few people can do and
3 discuss and tackle. So, I think that's why, after going
4 through all of that, coming out with a paper from a
5 certain perspective is probably a really good outcome.
6 It's not reflective of the entire PPDC workgroup, but
7 it's a good outcome, call for research. How do you
8 address that further? I'm not sure.

9 MR. HOUSENGER: Did someone have something else
10 to say?

11 RICHARD: Yes, Richard Gragg, if I could. I
12 would just like to know first off, with the new
13 toxicology paradigm, is there some strategy or objective
14 to focus on specific pesticides as it relates to certain
15 populations or certain health outcomes? Also, what is
16 the time line that this transition and implementation is
17 going to occur in where there will be some results that
18 people can look at?

19 I'm not clear either on how this activity will
20 tie into clinical research or clinical practice. It
21 seems to me as it's outlined here, it's mostly basic
22 science research that will link into regulatory decision

1 making, but I don't see it clearly linking into clinical
2 practice.

3 JENNIFER: This is Jennifer. There are a
4 number of different aspects to your question, so let me
5 know if I don't capture them all. The time line has
6 really been ongoing since the inception of this
7 workgroup. It started basically before the workgroup was
8 even established.

9 So, this change in science that has been
10 happening globally and the workgroup's purpose was to
11 help EPA adopt new science in a thoughtful way and ensure
12 that as we integrate new science into our guidance and
13 policies and methods of doing risk assessment that we are
14 doing that with an understanding of the various
15 perspectives of our stakeholders as well as staying true
16 to the science.

17 The specific question about how is it appearing
18 in a clinician's office I think is specific to the
19 biomonitoring tools. So, as we've been discussing, the
20 group has talked a lot about biomonitoring tools, in
21 particular, the need for biomonitoring tools in a
22 clinician's hands. The paper that the subgroups members

1 are currently working on, the intent of that paper is to
2 outline that need case someone was talking about and
3 basically put out to the science community the need for
4 more research in this area to develop tools for
5 clinicians.

6 So, the hope would be that with that paper,
7 there would be interest to do that research. That
8 ultimately would result in the development of tools that
9 clinicians could use.

10 RICHARD: Is there a strategy or priority to
11 focus when and how on vulnerable populations in terms of
12 pesticide exposure and health outcomes with this in the
13 context of this new research paradigm or toxicology
14 paradigm?

15 JENNIFER: The basic tenets of our risk
16 assessment in terms of looking at vulnerable
17 subpopulations aren't changed by integrating new science,
18 new ways of getting information into those assessments.
19 So, we will still be looking at vulnerable populations in
20 our risk assessment.

21 RICHARD: Okay, thank you.

22 MR. HOUSENGER: All right, so it's lunch time.

1 We have until 1:15. There's a restaurant across the
2 street at the Renaissance. There's a little tiny place
3 right up the road here on the right. There's a place to
4 eat across from the Hyatt. If you want to walk, there's
5 places down the road. So, just be back at 1:15, and
6 we'll get started with worker protection standards.

7 Thank you.

8 (A luncheon recess was taken.)
9
10
11
12
13
14
15
16
17
18
19
20
21
22

AFTERNOON SESSION

MR. HOUSENGER: Let's get started with our next session. You can tell it's the afternoon. People aren't as obedient as they were this morning. So, the next session is on the worker protection standard. I know that this is a long time coming. It was 20 years in the making, assuming that we started right when we issued the other one, which it seems like for some, I'm sure. It's a big rule. It's a complicated rule. It's a rule that there was not all consensus by all parties, as I'm sure we'll hear as we go on with this. But it's the rule that we have. So, now we're looking for ideas of outreach and implementation and how we can effectively get this rule out and implemented so it starts protecting workers that haven't necessarily been protected to this extent in the past.

So, I'm going to turn it over to Kevin Keaney and Nancy Fitz.

MR. KEANEY: I guess you are going to enthusiastically turn it over us. The agricultural worker protection regulation covers farms, forests, nurseries, and greenhouses where they have workers and

1 pesticide handlers. It places an obligation on the
2 agricultural employer to be in compliance with the
3 regulation.

4 As I said, it covers a great number of people.
5 They're usually a challenge to reach and to train. There
6 are a lot of challenges that we face. It's nothing, if
7 not bureaucratic arrogance, to think that writing a
8 regulation in this building is going to make it real in
9 the field where it will matter. So, we look forward to
10 engaging you as a group and engaging you as individuals
11 to help us in communication, outreach communication, and
12 implementation activities.

13 We do have a fairly extensive network in the
14 state regulatory agencies and the state extension
15 services and a number of grants that will help us with
16 that. I think engaging with you, as I said, as a group
17 and individually will benefit us and benefit the
18 population.

19 MS. MONELL: We can't hear you.

20 MR. KEANEY: Anyway, engagement with us is
21 going to be productive and ensure that we try to get the
22 benefits to where it's appropriate and work with the

1 agricultural community to allow them to understand the
2 regulation and to be in compliance with the regulation.

3 Nancy is going to give you an overview, and
4 then we can discuss implementation strategies and
5 methods.

6 MS. MONELL: Just before we do that, can the
7 folks on the phone hear? Is anyone on the phone?

8 RICHARD: Richard Gragg.

9 MS. MONELL: Can you hear all right?

10 RICHARD: Yes, I can.

11 MS. MONELL: Great. Anyone else?

12 SUSAN: Marty, it's Susan. I can hear fine.

13 MS. MONELL: It's Susan who?

14 SUSAN: Susan Studlien, and I can hear fine.

15 MS. MONELL: Oh, good, Susan, thank you. Glad
16 you could join us.

17 UNIDENTIFIED MALE: This is Valentin Sanchez. Can
18 you guys hear me?

19 MS. MONELL: Yes, thank you.

20 MS. FITZ: I'm going to give a real quick
21 overview of the WPS and highlight some of the key
22 provisions in the final rule, and then talk about the

1 outline of our implementation and outreach program, and
2 then leave a lot of time for discussion. So, I'm going
3 to breeze through the slides. You've got the details.
4 They'll be posted on the website. We can answer
5 questions as they come up. So, that's the general plan
6 here.

7 Kevin actually covered a lot of the overview,
8 but just to make sure we're all on the same page, the
9 worker protection standard, the responsibilities lie on
10 the agricultural employers of crop-producing
11 establishments. It's farms, forests, nurseries, and
12 greenhouses, and commercial pesticide handling
13 establishment employers.

14 The protections are provided for farmworkers,
15 those who work in the field to harvest, cultivate,
16 irrigate, actually doing the hand labor, pesticide
17 handlers who are the applicators, mixers, and loaders of
18 the pesticides, and there are protections for other
19 persons during pesticide applications. So, the
20 pesticides have to be applied in a manner so as not to
21 contact workers or other persons. This is true for the
22 current rule, and it's true for the revision. There's

1 nothing changed about that.

2 During the comment period, we received a lot of
3 comments kind of questioning why we need WPS when all the
4 protections are on the label. In a nutshell, the WPS is
5 a way that some of those label protections are
6 implemented.

7 So, for example, the restricted entry interval
8 is the time that workers have to stay out of a treated
9 area for the residues to decline to a safer level, but
10 the workers don't actually have access to the labels.
11 They're not the ones with the labels, so WPS provides a
12 way for that information to get to the workers.
13 Similarly, the labels identify what personal protective
14 equipment has to be worn, but it doesn't say the employer
15 has to provide that.

16 So, that's the function of WPS. So, that's
17 sort of the relationship, the symbiotic relationship.
18 Then, there's also a number of things like training and
19 some of the requirements that apply to all pesticides.
20 It's just more efficient to have it in one place. That's
21 why we need both.

22 This slide lists the goals of the revised

1 worker protection standards. One of the key ones is to
2 improve occupational protections for workers and handlers
3 to provide comparable protections to those covered by
4 workers and other industries by OSHA.

5 The second one is even though we think the
6 current WPS has provided a lot of protections and
7 improvements and the number of incidents have decreased
8 from the estimates when the 92 rule was produced, there's
9 still too many in our opinion, and we think many of those
10 are preventable. So, we're still trying to reduce those
11 acute exposures that cause workers and handlers to become
12 ill and miss work.

13 The rule is reorganized and streamlined, so
14 it's easier. We think this is going to make it easier to
15 comply with. Just the way things are grouped and
16 phrased, we think that's going to help people understand
17 what's actually in the current rule as well as the new
18 requirements.

19 And then to address areas of concern that have
20 been raised through many years of discussions with
21 stakeholders, including a PPDC group, the National
22 Assessment, meetings with regulatory partners, and also

1 in comments. We received over 2,400 comments from all
2 different types of commentors. We looked at them
3 carefully. I know some people think we didn't address
4 all of their concerns, all their comments. We probably
5 didn't accept all of any single individual commentor's
6 concerns, but looked at them all, tried to find what made
7 sense. We did tweak a lot of things based on those
8 comments.

9 A couple of the key points that are in the
10 revised rules, we did keep and actually expanded the
11 exemption for farm owners and their immediate families,
12 family members, which there's about 500,000 farms that
13 fit under this that are exempt from many of the WPS
14 provisions. They still have to comply with some, so you
15 can't say WPS exempts family farms. That's not the case.
16 But farm owners and their immediate families do not have
17 to comply with many of the protections in WPS.

18 We also delayed compliance dates to give
19 Farmers, states and everybody a chance to get their heads
20 around what the new requirements are. I'll talk about
21 that in a little bit more detail, but most of the
22 requirements will kick in 14 months from when the rule is

1 published, which should be any day now. Then there are a
2 couple that kick in a year after that.

3 This is going to be the five minute version of
4 some of the key requirements. Again, the details are
5 there, but we want to focus on outreach and
6 implementation. I'm going to just hit the highlights
7 here.

8 So, pesticide safety training was an important
9 component of the final rule. Probably the biggest
10 changes there are changing it so workers and handlers
11 have to be trained every year instead of every five
12 years, just to reinforce the important information, how
13 to protect themselves.

14 We expanded the training content to cover take
15 home exposure and ways to reduce the exposure to farm
16 workers and handlers at home and their families. We got
17 rid of the grace period, so workers and handlers have to
18 be trained before they go into work in an area that has
19 been treated with pesticides or before handlers work with
20 pesticides. That's kind of the quick version of
21 training. We think it's important for people to know how
22 to protect themselves and what they're dealing with.

1 Notification is how workers find out about the
2 restricted entry intervals and when they can and cannot
3 enter areas that have been treated. Currently, unless
4 the label requires both, a notification can be given to
5 workers orally. One of the things we changed was if the
6 restricted entry interval is greater than 48 hours, the
7 field has to be posted. If it's 48 hours or less,
8 there's still that option to post or provide the
9 information orally.

10 Another thing we tightened up a little bit was
11 to make sure the people who are going into a treated area
12 before that restricted entry interval is up, which we
13 call early entry workers, make sure they have the proper
14 personal protective equipment and all the information
15 they need to protect themselves and to understand what
16 their tasks are and how long they're allowed to be in
17 that area.

18 For hazard communication, we did retain the
19 requirement to post pesticide application records at a
20 central location. We also added the requirement that the
21 safety data sheets for those pesticides also have to be
22 available at that central location so workers and

1 handlers have access to the information about what has
2 been applied and then what the hazards are associated
3 with those pesticides.

4 In addition to the requirement to keep those
5 displayed at a central location for 30 days after the
6 restricted entry interval has expired, which is what's
7 in the current rule, the revisions also require that ag
8 employers keep that information for an additional two
9 years, so the application records and the safety data
10 sheets.

11 Those are available from the display period for
12 that whole time in certain ways. First, the worker and
13 handler can request access to it or request copies of it
14 either orally or through a written request. Treating
15 medical personnel and people working under those
16 treating medical personnel can also request it orally or
17 written.

18 Then, lastly, the rule allows workers or
19 handlers to have a designated representative to provide a
20 written request to obtain copies of or access of that
21 information. The designated representative has to be
22 identified in writing by the worker or handler. There's

1 certain information that has to be provided, including
2 when that person worked there and the specific
3 information that's requested.

4 The final rule establishes a minimum age of 18
5 for handlers. Again, those are people who are mixing,
6 loading, and applying the pesticides, and for early entry
7 workers. So, people going in while the restricted entry
8 interval -- before it has expired. So, there's no
9 minimum age for workers who are going in to harvest or do
10 work after that restricted entry interval has passed.

11 As it's listed on the slide, members of the
12 owner's immediate family would not have to comply with
13 this minimum age requirement. We also expanded the
14 definition of immediate family to go beyond basically
15 parent-child relationships. It also covered
16 grandparents, grandchildren, in-laws, aunts, uncles,
17 nephews, nieces, and first cousins. So, we have an
18 expanded definition of immediate family.

19 Only a couple more and then we can get into the
20 meat of this. For respirators, the final rule requires
21 if respirators are required on labels, the handler
22 employer has to ensure that the handlers comply with the

1 fit test requirements, medical evaluations, and training
2 requirements that are in the OSHA regulations. Make sure
3 that the respirators actually fit and do the job that
4 they're supposed to be doing.

5 Lastly, there's a number of provisions in the
6 WPS that try to prevent exposure to people during
7 pesticide applications. The approach in the final rule
8 was to define what we call an application exclusion zone,
9 which is essentially a bubble around the application
10 equipment, whether it's an airplane, a tractor, or a
11 sprayer, whatever it is. What it comes down to is the
12 agricultural employer has to keep people from not being
13 near that application equipment. If somebody does happen
14 to be near that application equipment, the applicator has
15 to temporarily suspend application until that person
16 moves.

17 So, there are a lot of details. It's 100 feet
18 for some, and it's 25 feet for others. But what it comes
19 down to, the approach we propose was that the entry
20 restricted area would be all the way around the outside
21 of the treated area. This is actually just around the
22 application equipment because that's where the pesticide

1 is most likely to land. So, ag employers need to keep
2 people out of that area, and handlers have to stop and
3 temporarily suspend application if someone is in it.

4 So, I'll talk a little bit about the outreach
5 and implementation. The rule was announced on September
6 28th. I think your handout says August 28th. That's my
7 mistake. It just seems like it was that long ago. It
8 will be published at some point, we think this month.
9 So, the clock actually starts once it's actually
10 published in the Federal Register.

11 For the sake of argument, let's say it's going
12 to be October 25th. Then, there's a 60-day period. It's
13 essentially a holding period before the rule becomes
14 effective. So, that would take us to late December of
15 this year. Most of the new requirements, compliances
16 required with them, kick in a year after that. So, that
17 would be December 2016. Up until December 2016, the
18 current WPS requirements will be in place and will be
19 enforced.

20 There are three requirements that we needed a
21 little bit more extra time, and that's the display of
22 some of the pesticide safety information, training on the

1 new contents, because it's going to take us a while to
2 get the training materials available and get everybody up
3 to speed on that. And then, the requirement for handlers
4 to suspend application if somebody is in that application
5 exclusion zone, we needed to make sure that there was a
6 whole training cycle for handlers before that one kicked
7 in. So, that's the reason for those being extended a
8 little bit.

9 We know there's a long list of materials. We
10 started some. Some are available and others we need to
11 develop. We have fact sheets and a standard
12 presentation. There's a number of different comparison
13 tables. There's a short one, if you call five pages
14 short, on the website.

15 We have a longer version that includes the
16 current requirement, the proposed requirement, and the
17 final requirement. Even this only focuses on the key
18 requirements. So, we're working on one that is
19 completely comprehensive and covers everything.

20 We know there are areas where we're going to
21 have to provide more detail, like things on the
22 respirator requirements. That's a new area for a lot of

1 people, so that's something we need to provide
2 information so growers know how to comply. How do I do
3 this medical evaluation? How do I do a fit test? Who
4 can I contact? The information is out there. We just
5 need to provide it for them.

6 The application exclusion zone, that's a new
7 idea. Those types of areas we know we're going to have
8 to have separate individual fact sheets or presentations
9 and ways to get that information out. We do plan to
10 revise the How to Comply Manual. That was a big comment
11 from states and industry. It's probably not going to be
12 a 100 page paper document again. We're going to try to
13 figure out how to make it more useable. We're open for
14 ideas on that. Then, hopefully at the end here we'd love
15 to get your ideas about what educational materials you
16 see a need for as we move forward.

17 In addition to the educational materials,
18 there's a lot of work being done to get us set for
19 compliance and enforcement, including some of the
20 internal implementation guidance for inspectors,
21 questions and answers. If you've been involved with WPS
22 for a while, you know there's a long list of interpretive

1 questions and answers. We need to update that for the
2 new rule, as well as I'm sure there will be new questions
3 that we'll add to that list.

4 The last time, in 92, we had issued inspector
5 pocket guidance. That's probably going to be inspector
6 smartphone guidance now, but we need to figure out what
7 that is, what that looks like, and what people are going
8 to need to have access to while they're out in the field.

9 We mentioned the need to update the training
10 materials for both workers and handlers to make sure we
11 incorporate the new content. Some of that we'll be doing
12 ourselves. Outside groups can also develop that, but it
13 does have to go through an EPA approval process. That's
14 something else we'll be working on.

15 In terms of training, our focus at the
16 beginning here has been to try to focus on the regions,
17 EPA regions, and the states. We have a three-day
18 training course in two weeks for the regions. Then
19 there's a state PREP course the first week in December.

20 We're trying to develop a pretty large body of
21 people who have a good understanding of the rules so when
22 there are requests for presentations -- there's only a

1 handful of us. So, we can't be in all 50 states all the
2 time. So, we're trying to make sure that there's a lot
3 of people who understand the rule.

4 The other group that we're going to hit soon,
5 and Wayne, I guess this is a heads up for you, are the
6 pesticide safety educators, because we know we're going
7 into the big training season. You guys need to know
8 what's going on. Like I said, we're almost done with
9 that standard Power Point presentation with talking
10 points. So, if you kind of heard the overview, you
11 should be able to go ahead and give that presentation.

12 So, this is an area where we'd love to get your
13 input. We need help reaching growers, commercial handler
14 employers, and other people who actually have to comply.
15 So, we're reaching out through the channels we have,
16 again, states, regions. Hopefully, we'll get a lot of
17 ideas here.

18 We do think the best way to explain this rule
19 to somebody is face to face so they have somebody they
20 feel like they can call if they have questions. So, we
21 need a mechanism to find out about good meetings to
22 attend, opportunities to spread the word on this.

1 Hopefully, you guys can help on that with all of your
2 networks.

3 We also plan to do a number of webinars, both
4 overview and sort of specific topics in detail. Those
5 aren't quite as good as the face to face, but it will do
6 in a pinch. Again, we're open to ideas about how best to
7 do that. Should we do them every couple weeks, do one
8 and put it on the web in a recorded version? If you have
9 ideas on that, we'd love to hear them.

10 I just want to give an example of working with
11 the regulated community. We talked with the Ag Retailers
12 Association on Friday about combining/coordinating on a
13 tri-fold brochure that they would get to their members to
14 distribute to their customers, and also maybe having some
15 sort of ongoing conversation about what outreach
16 materials are useful and is there a way to sort of
17 consolidate meeting opportunities. So, just throwing
18 that out there as a starting point for some ideas.

19 So, these are some questions that I posed
20 throughout. So, what outreach materials are there? How
21 can you help us reach growers? Any ideas on how to run
22 the webinars? What opportunities do you see for us to

1 partner with you to help get the word out?

2 So, that's what I've got. Questions?

3 Comments?

4 VALENTIN: If I could speak.

5 MS. MONELL: Did someone on the phone try to
6 make a comment?

7 VALENTIN: Yes. This is Valentin Sanchez.

8 MS. MONELL: I'm sorry, it's very difficult to
9 hear you. Can you speak closer to your microphone?

10 VALENTIN: Yes, this is Valentin Sanchez with
11 the Oregon Law Center. Can you hear me now?

12 MS. MONELL: Yes, that's better.

13 VALENTIN: Okay, sounds good. First of all, I
14 want to thank EPA. I recently had a meeting with a group
15 of farmworkers who say thank you, thank you. In the span
16 of 20 years of the current WPS existence, we still have
17 some farmworkers who are still unfamiliar with WPS.
18 Also, enforcement is another big issue.

19 But one thing I wanted to mention is that it
20 may be a great idea, and this is just a thought I'm putting
21 on the table, to perhaps have a workgroup looking to WPS
22 implementation and outreach, because I don't think in 15

1 or 20 minutes we'll be able to talk extensively about how
2 it needs to be done.

3 There's another thing that I'd like you to have
4 in mind. We have a lot of minority farmers and also
5 farmworker contractors and most of the contractors
6 assuming they speak Spanish. So, those are
7 some of the things that we should in mind.

8 One question I have is, I just want to know
9 more about how much money has been allocated for outreach
10 and implementation.

11 MS. MONELL: Actually, a significant amount.
12 In addition to the PRIA set aside for worker protection
13 activities that are being used -- and Kevin and his folks
14 can give you more particulars. But, as you probably are
15 aware, though, those monies have been used to fund
16 specific activities around worker protection and now
17 obviously the focus will be adjusted to include
18 implementation of the new standard, or revised standard.

19 In addition to that, though, the agency, the AA-
20 ship is committed to the implementation of this rule
21 making. It's one of the more important rule makings that
22 this administration has undertaken. So, we have

1 allocated thus far almost \$3 million in appropriated
2 funds to help support the implementation activities, one
3 of which I should note is geared towards Spanish
4 translation of materials.

5 MR. KEANEY: I can put together a list of all
6 of the things that are being funded and what the intent
7 would be of them and send it through the network here.

8 MS. MONELL: That would be great.

9 MR. KEANEY: Did we hear you wanted to
10 establish a workgroup out of PPDC?

11 MS. MONELL: That's what Valentin was suggesting, I
12 think.

13 MR. HOUSENGER: Andy?

14 ANDY: Since this is a final rule, I won't
15 point out all of the things. I think what's more
16 important from EPA's standpoint with the training
17 materials, don't focus so much on what as how. In other
18 words, whoever normally writes guidance for EPA, don't
19 let them do it.

20 Write it in a way that is easily distributed
21 and transmitted to the people who are going to use it.
22 Know your audience when you write this because it is

1 going to be extremely -- it's a huge deviation from what
2 we have done in the past, and it's going to be a
3 transition for these people to understand that. Work
4 with the state lead agencies a lot. However many
5 webinars you have planned, double it. They are going to
6 need a lot of help.

7 I've talked to several lead agencies. Just
8 write it where it's very clear, it's very plain, everybody
9 understands exactly what they're supposed to do and what
10 their obligations are. We'll transition much more
11 smoothly. Write it, take it out in the street, pull some
12 guy off the street and let him read it. If he doesn't
13 understand it, you probably need to work on it some more.
14 I think that is one of the biggest problems that we have,
15 being able to translate things out of this office to our
16 membership. Thank you.

17 MR. HOUSENGER: Thanks. I'm surprised our
18 guidance isn't always clear.

19 Cynthia?

20 CYNTHIA: You mentioned translation of some of
21 the materials into Spanish, and it's great. I'm just
22 wondering what are the requirements for languages for

1 worker notifications. For example, when there's a
2 restricted entry interval, are there certain
3 requirements?

4 MS. FITZ: The notification has to
5 be provided in a manner that the worker can understand.
6 So, that generally means there's somebody there that can
7 translate for them. Similarly, the training has to be
8 provided in a manner that the workers and handlers can
9 understand. Currently, we have the worker training
10 information in probably 15 to 20 languages. That's not
11 going to happen in 12 months, but we'll get a couple out
12 and then keep working to add the relevant languages.

13 MR. HOUSENGER: Richard?

14 RICHARD: Thank you. As Nancy said, we look
15 forward to trying to work with you all on clear and plain
16 language to make it easier for our members to understand
17 and their farmer customers. That's going to be kind of
18 critical, as was mentioned. I mean, the rule is final.

19 We still have some angst with some of the cost
20 estimates and things, but it is what it is at this point.
21 We want to make sure our members are aware of it, the
22 farmer customers are aware of the regulations, and make

1 sure they're complying with those regulations. So,
2 again, having the industry involved and just folks that
3 aren't necessarily lawyers. I am a lawyer, but clear and
4 simple terms will be kind of critical.

5 I did want to get some clarification, and maybe
6 some of that was in the slides that Nancy had about
7 potential problem areas implementing the regulations and
8 then a question on the training schedule. One is maybe a
9 little bit better explanation about the designated
10 representative, exactly how that's going to work with the
11 regulations, and also the criteria qualifications for the
12 fit test of respirators. Those are two things that maybe
13 will be flushed out by EPA for explanations.

14 On the training side of things, I was just
15 asking if that training is for EPA officials for outreach
16 compliance or on enforcement side. Are those combined
17 trainings or how is that actually internally with the EPA
18 and the training sessions you're looking for externally
19 with industry? Since they're kind of in alignment and on
20 the same page, are those going to be similar training
21 sessions?

22 One is a little different because you're on

1 enforcement, but the basic premise of what you're trying
2 to comply with are the same. So, making sure there's
3 apples to apples understanding from the enforcement arm
4 and the industry side of things we think will be very
5 critical because that has not always occurred in other
6 regulations in the past.

7 MS. FITZ: We realize the designated
8 representative and respirators are areas where we're
9 going to have to -- those are on our list for needing
10 some clearer explanation and guidance.

11 In terms of the training, right now we're
12 focusing on trying to make sure everybody understands the
13 rule. For example, the regional training, there's a
14 program and an enforcement person from each region. The
15 first course with the states is, again, focusing on
16 content with some discussion about outreach education and
17 compliance and enforcement.

18 Then, in the late spring there will be a more
19 detailed inspector training, again focusing on covering
20 the content but also how are the inspections going to be
21 done, what are the tricky parts with some of these new
22 requirements, what are they going to look for for the

1 respirator requirements, things like that.

2 I agree with you that I think the same
3 information that we go over with the states and regions
4 should be gone over with industry to make sure everybody
5 is on the same page. With the container containment
6 rule, we shared the check lists with anybody who wanted
7 them. So, I think the best thing for people who have to
8 comply is to know what they have to do and what's going
9 to be looked for. So, we'll push for that.

10 RICHARD: I'll just say, that model,
11 because you helped drive that, the container containment
12 rules helped a lot with the implementation of it. So, if
13 you follow closely to that model, I think you'll be in
14 good steps.

15 MR. KEANEY: So, in effect, you're
16 saying Nancy is suffering now for her past performances.

17 MR. HOUSENGER: Louis?

18 LOUIS: Thank you. I think that's a wonderful
19 report. I like the direction and where it's going. I
20 had some questions on enforcement, which Richard has
21 actually covered. I think that's an important aspect of
22 everything you're setting in place, because if you don't

1 enforce it or it cannot be enforced, it's almost an
2 exercise in futility).

3 There's one more thing I was wondering about.
4 On one of your slides, you showed that training is going
5 to be now every year from every five years. I wonder
6 what instructed that, because I think it's really --
7 well, I'll let you tell me because every year for
8 training it looks like too much, in my opinion,
9 especially if there's no guarantee there's going to be
10 something new to learn every year. Why don't you tell us
11 what instructed you to do that. Then, is there a fee
12 associated with that training? That's the other thing
13 that I'd like to find out.

14 MR. KEANEY: Well, the training primarily is
15 basic safety principles. We know that there's a heavy
16 turnover in the work force. We also worked on the basic
17 premise that if you're hiring someone to work in areas
18 that might present hazards, they should know the nature
19 of the hazards and how to protect themselves. So, I
20 mean, all of those things drove us away from a multi-year
21 cycle to you hire someone, you bring him in, you put him
22 through some sort of your hired process. Part of that is

1 a fairly short insight into what you might be facing on
2 the job and how you can better protect yourself.

3 LOUIS: Is there any fee for that?

4 MR. KEANEY: Any what?

5 LOUIS: Any fee? Is there any charge for the
6 training?

7 MS. FITZ: So, this can be done on the farm, so
8 you can do it -- the people who can do the training are
9 certified applicators, people designated as trainers by
10 the state, EPA or the tribe, or people who have gone
11 through a train the trainer program. So, if you have a
12 certified applicator on your establishment, you used EPA
13 approved training material, which could be a video that's
14 developed, you can do that in house, essentially. So,
15 there's a cost in terms of the time spent, but it
16 shouldn't be \$50 per worker.

17 MR. KEANEY: One of our grants that I'll be
18 telling you about is the Association of Farmer Opportunity
19 Programs. It's a national network. They are
20 a network of safety trainers that are providing free
21 safety training to comply with this regulation.

22 MR. HOUSENGER: Wayne?

1 WAYNE: Thank you, Nancy and Kevin, for being
2 here, and congratulations for getting this close to the
3 finish line. One thing that I would suggest is if Kevin
4 can give you the afternoon free to video tape or perhaps
5 put this onto a webinar format, it would be great. The
6 information that could be submitted or sent out to
7 extension typically doesn't get read. But every agent
8 eats lunch in his office. So, this would be a great
9 lunch and learn kind of thing. So, I would suggest just
10 saying it the way you just said it and having it
11 available that we could send out.

12 MS. FITZ: If we're going to record it, that's
13 going to be Richard. He's knows it way better, but
14 that's a good idea.

15 MR. HOUSENGER: Eric?

16 ERIC: On the enforcement side of things, we all use
17 these things more and more, so I agree with the smartphone end of
18 things. But don't not print the pocket guides because if
19 you're out in the bright sunlight, you can't see these
20 things, if you have battery problems. There's a whole
21 host of things.

22 MS. FITZ: Good information and very consistent

1 with what we're hearing from other people. There's still
2 a need for paper, which actually makes me feel better.
3 I'm not that much of a dinosaur.

4 MR. HOUSENGER: Dawn?

5 DAWN: I think Wayne's reading my notes. I
6 just want to put that on the record. I obviously rely
7 heavily on your current network of CE providers.
8 Consider having a session at the IPM symposium in 2018.
9 There is a new initiative there to engage practitioners.
10 They may end up being more your training of the trainers
11 rather than your (inaudible).

12 Engage with the tribal pesticide program
13 committee as well as IHS. Video, video, video, video,
14 video, not just for your train the trainers and your
15 lunch and learn, which I love that idea, but also gets
16 around the whole literacy challenges. So, I would really
17 encourage you to invest in that. Special training
18 initiatives for territories and migrant worker teams.

19 I also had suggested webinars, mobile web pages
20 rather than apps, which are platform specific, and
21 definitely want a pocket guide.

22 MR. HOUSENGER: Gabriele?

1 GABRIELE: My comment about outreach is about a
2 much bigger concept of outreach. Looking at the press
3 release that came out announcing this rule -- and Gina
4 McCarthy was out in California yesterday and did another
5 press conference out in the field. We got a call at 7
6 p.m. East Coast time Tuesday could we send someone to be
7 a back drop.

8 I have to admit, and I'm going to be very blunt
9 here, I'm not politic-ish. I can't figure out how you
10 are letting your boss say what she's saying about worker
11 protection, because it makes it sound like OPP has been
12 doing nothing for the last 20 years. That is not fair to
13 all the work you guys have been doing, whether it's on
14 the education side, the enforcement side, in individual
15 pesticide registration and registration reviews, the
16 number of decisions you've made where you've either said,
17 look, we cannot make a safety finding or we need
18 additional protective equipment.

19 So, I just want to say from my perspective, we
20 have absolutely this whole outreach aspect. I think in
21 California we may have somewhat easier systems in place
22 to make that more viable. So, I'm less worried about it

1 for us in California. I also want to say the outreach in
2 terms of the media and the way your bosses are talking
3 about this I don't think is fair to what OPP's work has
4 been.

5 MR. HOUSENGER: I'm not going to touch that
6 one. I know when I took this job, I claimed a lot of
7 stuff, too. But thank you.

8 Ray?

9 RAY: Several questions, minor and major. In
10 the proposed rule, there is a lot of controversy about
11 what we claimed were low estimates of the cost to the
12 agricultural community. In the final rule, those
13 estimates have changed. How and when will the analysis
14 that change those estimates be made available so that
15 they can be independently verified?

16 I mean, there was a great deal of effort gone
17 into challenging the original estimates. I assume you've
18 gone through a very rigorous process in revising those.
19 Are you going to make available your background analyses?

20 MS. FITZ: The economic analysis and everything
21 will be available in the docket as soon as it's published
22 in the Federal Register. So, that's in the next few

1 weeks.

2 RAY: Okay. You mentioned changes to the
3 definition of immediate family for specific purposes
4 within the rule. Do those definitions now correspond to
5 other definitions of immediate family used in other
6 regulatory programs, even outside of EPA?

7 MS. FITZ: Actually, the definition of
8 immediate family in WPS is broader than other definitions
9 of immediate family in other regulations. It doesn't
10 match up exactly with how USDA defines family farm, but
11 family farm is a little different than owner of a farm in
12 the immediate family. So, I think the revised definition
13 is a little closer, but it's not exactly the same.

14 RAY: The training materials that have yet to
15 be developed, there's a lot of relevant expertise among
16 various stakeholder groups, including NASDA, state lead
17 agencies, our industry, the crop protection industry.
18 How will the agency involve those stakeholders in
19 developing the materials?

20 MR. KEANEY: We intend to form workgroups from
21 the variety of stakeholders to work with us on those.
22 It's not going to be done independent of those people

1 that already have good experience.

2 RAY: Is that going to be done through some
3 extension of PPDC?

4 MR. KEANEY: It could be done through extension
5 of PPDC, or one of our cooperative agreements could
6 manage that activity.

7 RAY: Okay, getting closer. You mentioned \$3
8 million for the training for budget. Over what period of
9 time is that? Is that one year or five years?

10 MS. MONELL: It's over a five-year period.
11 Most of these cooperative agreements are for five years.

12 RAY: That's still a relative pittance
13 regarding --

14 MS. MONELL: Well, it's a three-year up front
15 commitment for the first year of funding. And then,
16 depending upon funds availability -- as you know, our
17 appropriation has swung widely in the last couple of
18 years. So, it depends upon -- all cooperative agreements
19 and grants are funded for the first year at a set amount.
20 Thereafter, the hope is that it will be the same amount,
21 but it depends upon available funding.

22 RAY: There's been a group from the crop

1 protection industry which is putting a significant amount
2 into the training efforts. I assume you're coordinating
3 with that group on how this is accomplished?

4 MS. MONELL: On how what is accomplished? On
5 how the training is accomplished?

6 RAY: Yes, developing the training materials
7 and proceeding with the training.

8 MS. MONELL: Well, I think, as Kevin indicated,
9 the intention is to have stakeholder involvement in some
10 sort of a workgroup to help with the development of those
11 relevant materials.

12 RAY: And the last question, the final rule
13 hasn't been published yet. On the website, there's, I
14 guess, sort of a disclaimer about this isn't yet final
15 until it actually appears in the Federal Register.
16 There's a bit of confusion there about whether any
17 wording change might happen?

18 MS. FITZ: Not intentionally. I mean, it's a
19 300 page document and it has to go through some process.
20 So, the point of that is that that's what we sent forward
21 to be published. There might be some spaces and
22 numbering fixes and things like that, but that's the

1 content of the final rule. I think that's just a CYA.
2 It's not official until it's published in the Federal
3 Register.

4 RAY: Okay, thanks.

5 MR. HOUSENGER: Amy?

6 AMY: So, first of all, I just want to say
7 thank you to the EPA for getting this out and that the
8 process was long, but you did indeed engage stakeholders.
9 My first stakeholder meeting I went to was 14-1/2 years
10 ago, but who's counting. Anyway, we're really pleased
11 that it's out there and it's really an important step in
12 the right direction for the protection of farmworkers and
13 their families.

14 It feels like a lot of your initial focus right
15 now is getting the word out to the folks that are going
16 to be responsible for doing much of the protecting in
17 terms of who is going to provide the training, who is
18 going to provide the PPE, who is going to do the record
19 keeping. So, I think you're asking the right questions
20 in terms of how do we get it out there, who are the
21 stakeholders. So, I would encourage you to carry on in
22 that direction.

1 I am not seeing much up there in your
2 questioning about sort of the worker piece of this and
3 how the information is going -- what kind of guarantees
4 we're going to have in terms of the type of information,
5 the literacy level, the content, the different types of
6 populations from Spanish speakers to people who speak
7 indigenous languages, and how all of that would work.

8 I encourage you to seek a broad spectrum of
9 stakeholders in conversations about the materials that
10 will be needed for workers. I do think that goes to some
11 of what Valentin was saying and what's being proposed in
12 terms of the enormity of this particular standard.

13 It's not at all over. We are turning our
14 attention to implementation and enforcement. I encourage
15 you to really maintain some kind of workgroup that you
16 can bounce ideas off of and get input specific to this
17 regulation because of its importance.

18 MR. HOUSENGER: Virginia?

19 VIRGINIA: Thanks. I also wanted to
20 congratulate you on getting a final rule out. As someone
21 who has been engaged on getting this rule out for many
22 years, I'm looking forward to the next phase.

1 I wanted to echo some of what has already been
2 proposed. Valentin had mentioned reaching out to
3 minority farmers, farm labor contractors. That's very
4 important. Groups who interact with many of the workers
5 first hand should be providing the training.

6 It's important to remember some of the minority
7 communities among the farmworker population as well,
8 indigenous language speakers, Haitians, to name a few.
9 Working closely with community based organizations that
10 work with farmworkers would be key to making sure that
11 that information is disseminated in a manner that workers
12 will understand.

13 In addition to the training that you will be
14 developing under the cooperative agreement, I think it's
15 also important to have resources available to approve
16 training materials from other organizations,
17 institutions, perhaps to address some of these other
18 languages that are needed.

19 I wanted to also remind you to remember workers
20 who are coming to the United States on foreign work visas
21 who also should be receiving the training. They come
22 from a variety of different countries. Don't forget use

1 of technology to disseminate information. Many
2 farmworkers do have access to smartphone technology, text
3 messaging. That's very important.

4 Finally, I just wanted to agree that I think it
5 would be a good idea to establish a workgroup within the
6 PPDC to address the implementation, outreach, and
7 enforcement issues. Thank you.

8 MR. HOUSENGER: Steven?

9 STEVEN: I kind of have an out in left field
10 question. I need a very short history lesson on why this
11 is a federal thing instead of letting the individual
12 states write their own worker protection standards?

13 MR. KEANEY: Well, there is the Fair Labor
14 Standards Act, which has omitted coverage of farmworkers
15 and service industries. There is a need for consistency
16 establishing a particular bar of protection that is a
17 national need. It's good public policy, it's good health
18 policy. Ultimately, it's good agricultural policy to
19 protect workers and to protect pesticide handlers at a
20 national level. Of course, that was the standard, to
21 protect the workers.

22 STEVEN: Jack, I have a follow up question.

1 I'm not trying to make equal weight here, but I see
2 similarities between pollinator protection, workers
3 protections. So, would the reasons for a worker
4 protection standard nationwide not be valid for a
5 pollinator protection standard nationwide? Do you see
6 any validity to that argument?

7 MR. HOUSENGER: That we protect the bees as
8 much as we protect the people?

9 STEVEN: No, that we have a federal policy to
10 protect bees.

11 MR. HOUSENGER: Well, I think on pollinators,
12 we're moving in a direction to get a policy in place that
13 will deal with the situation. Whether we need something
14 like a worker protection standard for pollinators, I
15 would hope that we don't have to get there. I would hope
16 that some of the measures that we're putting in place
17 make that happen, recognizing that the pollinator
18 situation is caused by a number of stressors not just
19 pesticides.

20 Louis?

21 LOUIS: I have what's really a general sort of
22 question, and anybody in the group can answer it. I was

1 just wondering, what was in the imagination when you
2 started talking about farmworker or pesticide applicator
3 or producer, because that obviously guided you as you
4 went along?

5 The reason I ask this is because most of the
6 time when this process is taking place, the image that a
7 lot of folks have is the image of a commercial farm, a
8 commercial producer. So, the point I'm getting at is,
9 did the image of a small producer, a small grower, factor
10 into these decisions?

11 This is important because as I go around
12 visiting farmers, I find a lot of small growers who are
13 in complete violation of worker protections, of NPBs (phonetic)
14 for themselves. So, this is a group that needs attention.
15 Maybe it's a little different in the northwest where I
16 think there's a lot more close interaction with small
17 growers, but that's a group of producers that need to be
18 put on the table. They need to be brought into the
19 picture when you're developing these processes.

20 So, what was that image that went through your
21 minds as you were going through this?

22 MR. KEANEY: Well, the image we had was the

1 full range of stakeholders, the full range of
2 agricultural employment that exists. We did consider
3 small farms. We did realize that the larger operations
4 are much more capable in having safety trainers and
5 safety programs.

6 Frankly, I think over the span from the 92
7 regulation to now, we've probably been not as aggressive
8 in trying to reach down to those farms that you're
9 speaking about and those farmers. It's something we'd
10 certainly like to correct. It's not something that's a
11 one-time exercise, obviously. We'll go through this
12 process that brings things into full implementation and
13 compliance in the field, but there's an ongoing need for
14 pretty aggressive communication through the whole range
15 of agricultural employers.

16 I agree with you that the small farms are
17 likely to be left out of the basic meetings and venues in
18 which this information can be shared.

19 MR. HOUSENGER: Okay, Nichelle, you're the last
20 one.

21 NICHELLE: I just have one quick comment I
22 didn't hear raised in the discussion today. That is to

1 one of the questions in the slide that's asking for what
2 other outreach materials are needed. Just my suggestion,
3 some type of educational material for the farmer to
4 educate them on minimizing tracking pesticide residues
5 from the field into the home. I think that would be very
6 useful because, as you see, inside the home is also a
7 considerable source of pesticide exposure, not only for
8 them but for their families as well.

9 MR. HOUSENGER: Okay.

10 RICHARD: This is Richard Gragg. I have one
11 question or statement. I didn't hear anything in the
12 presentation as far as -- I saw the zones, protection
13 zones, but I didn't hear anything mentioned about
14 pesticide drift.

15 MS. FITZ: The application exclusion zones,
16 there are a number of requirements already in the WPS,
17 particularly the statement on labels and the requirement
18 for handlers to apply the pesticides in a manner that
19 will not contact any worker or other person either
20 directly or through drift. So, that's actually already
21 covered.

22 RICHARD: Okay.

1 MS. FITZ: So, the requirement for handlers or
2 the applicators to suspend the application if somebody is
3 near the application equipment is sort of built to
4 strengthen that and give them something very specific
5 that they can do to accomplish the do not contact
6 requirement.

7 RICHARD: Okay, and just one other thing as it
8 relates to our previous conversation in toxicology. It
9 seems to me that this stakeholder group could be a good
10 group for testing in terms of exposure effects which
11 would help with the toxicology testing paradigm but also
12 in evaluating the strategy and effectiveness of the
13 worker training and outreach.

14 MS. MONELL: Is this Richard Gragg speaking?

15 RICHARD: Yes.

16 MS. MONELL: Thank you.

17 MR. HOUSENGER: So, I've neglected the members
18 on the phone. Are there any other comments from members
19 on the phone?

20 JEANNIE: Yes, this is Jeannie from the
21 Farmworker Association of Florida. Can you hear me?

22 MR. HOUSENGER: Barely.

1 JEANNIE: Oh, okay. This is Jeannie from the
2 Farmworker Association of Florida in Apopca. I just want
3 to say a couple of things. In Florida, we have both
4 large producers and small producers.

5 MR. HOUSENGER: Excuse me, Jeannie who?

6 JEANNIE: Jeannie from the Farmworker
7 Association of Florida.

8 MS. MONELL: Are you a PPDC member, Jeannie?

9 JEANNIE: No.

10 MS. MONELL: Well, then, you will have an
11 opportunity to make comments during the public comment
12 period. This particular time is restricted to PPDC
13 members only. So, those are part of the official rules.

14 JEANNIE: Okay, thank you.

15 MR. HOUSENGER: Okay. It's time for part two,
16 which is certification and training. Kevin is remaining.
17 Michelle Arling is replacing Nancy.

18 MR. KEANEY: There's the certification
19 regulation for pesticide applicators of restricted use
20 that's out for public comment. The comment period ends
21 the 23rd of next month. This is a regulation that is the
22 same vintage as EPA.

1 This regulation came into effect when EPA, USDA
2 retook the pesticide program to oversee it. It deals
3 with establishing competency standards for the
4 applicators of restricted use pesticides, more toxic
5 pesticides. It establishes competency standards and then
6 certification of these applicators who are required to
7 have that in order to purchase and use restricted use
8 pesticides.

9 So, it's something of a companion with the
10 worker regulation, because under this regulation,
11 certified applicators can supervise others to apply
12 pesticides. Very often, in the agricultural setting,
13 those being supervised are the handlers that are covered
14 by the agricultural worker protection. There's a certain
15 degree of overlap in the labor segment relative to this
16 regulation.

17 So, as I said, it's out for comment. We'd give
18 you an overview and again engage in discussions of
19 implementation and some guidance as to how productively
20 to comment. Michelle Arling and my staff will do that.

21 MS. ARLING: Let me know if you can't hear me
22 because I have a gentler voice than Nancy, I think.

1 So, I'm going to do a brief overview of the
2 current certification rule and then go over the proposed
3 changes and then the guidance we're giving for
4 commenting.

5 So, the certification rule, as Kevin mentioned,
6 has been in place since the 1970s. It establishes
7 requirements for determining competency of applicators of
8 restricted use pesticides, and it also sets standards for
9 states, tribes, and federal agencies to administer their
10 own certification programs for applicators in their
11 jurisdiction.

12 It covers private applicators who are those
13 applying RUPs on their own land in agricultural
14 production, commercial applicators who are applying RUPs
15 for hire, and then those using restricted use pesticides
16 under the supervision of a certified applicator who
17 don't themselves have to be certified.

18 There's about a million certified applicators
19 currently across the US and an unknown number of
20 uncertified applicators. I just talked a little bit
21 about applicator classification. Again, here are the
22 numbers and a better description of the types of

1 applications they conduct.

2 The program is administered by states, tribes,
3 and territories. FIFRA, which is our enabling statute,
4 authorizes states, tribes, and territories to certify
5 applicators under a certification plan that has to be
6 submitted to and approved by EPA. These certification
7 plans have to meet or exceed the federal standards.

8 Since we haven't revised our regulation since the 70s, a
9 lot of states have gone forward to strengthen their
10 requirements for certification well beyond our federal
11 standards.

12 Every state, as well as three territories, four
13 tribes, and four federal agencies, have certification
14 plans in place for applicators in their jurisdiction.
15 Because of a number of factors, a lot of states have
16 programs that are stronger than ours, but all the state
17 programs aren't comparable. So, it's not like they're
18 all stronger in the same areas or the same ways.

19 Some examples of state variance include
20 additional categories of certification and subcategories,
21 certification periods, and what's required to recertify,
22 and then requirements for those using pesticides under

1 the supervision of a certified applicator.

2 So, with all of this in mind, we are moving
3 forward with proposing changes to the rule. Two big
4 reasons for this are, as Nancy mentioned, there are
5 avoidable incidents that continue to occur, and they
6 occur in the applicator community as well as to
7 agricultural workers. Then there's the negative
8 environmental impact of RUPs that aren't applied properly
9 and can cause very severe harm.

10 So, these three primary goals we talk about in
11 the proposal for these revisions. The first is to reduce
12 adverse effects from avoidable pesticide exposure, to
13 ensure that applicators are meeting the level of
14 competency that we're assuming when we register a
15 pesticide as an RUP, and then to encourage reciprocity
16 between states to reduce the burden on applicators and
17 state certification programs. As I mentioned, each state
18 can administer its own certification program, but
19 applicators may be certified in more than one state and
20 be subject to more than one state's requirements.

21 So, the first area of change is private
22 applicator initial certification. This is an area where

1 states are much more stringent. So, our current federal
2 rule has a requirement for private applicators to attend
3 the training, pass a written exam, or demonstrate
4 competency through some mechanism that the state
5 determines as adequate. It also has a mechanism to allow
6 nonreaders to be certified.

7 The current standard federal rules cover five
8 points, recognizing common pests to be controlled,
9 reading and understanding the labeling, applying
10 pesticides in accordance to the labeling, recognizing
11 local environmental concerns to avoid contamination, and
12 recognizing pesticide poisonings and symptoms and
13 procedures in case of an accident. That's all that you
14 need to know under the federal rule to be certified to use
15 an RUP.

16 So, we're proposing to strengthen those
17 requirements to be more detailed and to incorporate more
18 agricultural pest management information and to provide
19 more information on regulations relevant to
20 these applicators, such as the worker protection
21 standard.

22 We're also proposing to strengthen the ways

1 that private applicators can be certified to require
2 either that they have to pass a written exam or take a
3 training that covers these detailed competency standards.
4 The last thing we were talking about is eliminating the
5 mechanism that allows nonreaders to be certified. So,
6 we'd like to require that those who are using RUPs can
7 read the labeling of the products that they're using.

8 The next area that we're talking about is
9 adding something we're calling application method
10 specific categories. So, there's no standard in the
11 current rule that we're updating. This would be a new
12 area of the rule.

13 For high risk application methods, such as
14 aerial application, soil fumigation, and non-soil
15 fumigation, we're proposing that applicators be certified
16 specifically to use these application methods to ensure
17 that these applications are performed properly because
18 they have a higher risk of harming applicator by-
19 standards in the environment.

20 The next area that we're talking about changing
21 is the administration of certification exams and training
22 for initial and recertification. The current rule has

1 limited information about this. It just requires that
2 commercial applicator certification be based on a written
3 exam.

4 In 2006, EPA issued a policy requiring that
5 certification exams be closed book and proctored, but
6 that hasn't been incorporated in the current regulation.
7 So, we're proposing to require that exams for
8 certification or recertification, if offered, are written
9 and closed book and proctored, and to require that
10 candidates present identification for initial and
11 recertification courses to ensure that the person who is
12 registered and will obtain the license is the person that
13 they say they are.

14 We've gotten a lot of questions about what
15 closed book means. It doesn't mean you can't use any
16 resources; use only resources provided by the test
17 administrator. So, if they wanted to provide a pest
18 identification guide, that would be acceptable. But
19 people taking the exam couldn't bring in their own study
20 materials or notepaper or things that they could leave
21 with a copy of the exam.

22 A big area where reporting changes is related

1 to recertification, the current rule has a very limited
2 section on recertification, and it's under the state plan
3 administration portion of the rule. It just requires
4 that states have a process in place to assure continued
5 competency of applicators. There's no time frame,
6 there's no requirements for what would qualify as
7 recertification.

8 So, looking across state programs and looking
9 across other types of recertification programs, we
10 developed a proposal to establish a three-year
11 certification period to allow recertification either by
12 taking an exam or by earning continuing education credits
13 and when laying out the kinds and the amount of continuing education
14 that each type of applicator would have to earn.

15 So, commercial applicators would need to earn
16 six hours of training for core, which is the basic
17 pesticide safety principles that apply across all
18 certification categories, and six hours of training for
19 each category in which they're certified.

20 Private applicators would have to recertify by
21 taking an exam or by taking six hours of training for
22 their general private applicator certification and three

1 hours of training for each additional category of
2 certification they have.

3 The last bit of our proposal really is trying
4 to make sure that people are getting continuing education
5 throughout the certification period. The proposal would
6 require applicators to earn at least half of their
7 required hours within 18 months of the expiration date of
8 their certification.

9 The next area of change is related to minimum
10 age. The current rule has no minimum age requirement for
11 people using RUPs. We're proposing to require that those
12 using RUPs as private applicators, commercial
13 applicators, and noncertified applicators working under
14 the supervision of a certified applicator be at least 18
15 years old. This is an area where some states have taken
16 action and established varying minimum ages from 16 to 18
17 for various categories of applicators.

18 We are also proposing changes to two areas
19 related to noncertified applicators using RUPs under the
20 supervision of certified applicators. For the
21 noncertified applicators themselves, the rule has very
22 basic information and just requires that the RUP is

1 applied by a competent person acting under the
2 instruction and control of a certified applicator. I
3 think that actually comes right out of FIFRA. So,
4 there's no required demonstration of competency, and
5 there's no explanation of the kind of information that a
6 noncertified applicator should be provided with in order
7 to use an RUP safely.

8 So, we're proposing to make sure that people
9 using RUPs can do so safely by outlining annual training,
10 outlining training requirements in the rule that would be
11 provided annually. That covers pesticide safety,
12 application equipment, safe application techniques,
13 personal protective equipment, pesticide labeling, and
14 avoiding pesticide take-home exposure.

15 Then, recognizing that a lot of people using
16 RUPs under the supervision in agriculture could also be
17 handlers under the worker protection standard, we propose
18 to allow qualification of the handler under the WPS to
19 also satisfy the training requirement in the
20 certification rule.

21 We're also proposing to allow passing of the
22 core exam, which is just basic pesticide safety

1 information and application information, to satisfy the
2 training requirement. We're looking to offer flexibility
3 in meeting it, but want to make sure that people using
4 RUPs are equipped to do so safely in a way that protects
5 themselves and others.

6 We're also proposing changes for those people
7 who are supervising noncertified applicators. These are
8 certified applicators. Currently, there aren't really
9 any additional requirements to supervise a noncertified
10 applicator. So, we're just doing a little bit of
11 tightening by requiring that these supervisors be
12 certified in the category of the application they're
13 supervising. So, if you are doing a right of way
14 application, you have to be supervised by somebody who is
15 certified to do a right of way application. You couldn't
16 be supervised by somebody doing an aquatic application.

17 We're also proposing to make the supervising
18 applicator responsible for insuring that those under his
19 supervision have met the necessary training requirements.
20 For commercial applicators, to maintain records of that
21 training or however the qualification was obtained. This
22 record keeping requirement is only for commercial

1 applicators because FIFRA prevents EPA from requiring
2 private applicators to maintain records.

3 Then, finally, to ensure adequate communication
4 between the supervisor and supervisee, we're proposing
5 that the supervisor ensure that there's a mechanism for
6 communication, not just instructions to call this number
7 with a quarter to use the nearby payphone, but to make
8 sure there's equipment available so the supervisee can
9 contact the supervisor immediately if necessary.

10 In this section, we're also requesting comments
11 on a lot of other limitations that were suggested to us
12 by stakeholders, such as the distance between the
13 supervisor and the noncertified applicant and the number
14 of people that can be under the supervision at one time.

15 Other areas where we're proposing changes that
16 I won't get into in as much detail are updates to the
17 state plan requirements to match the revised regulations.
18 So, once the rule is finalized, states would have to
19 update their state certification plans to ensure they
20 meet or exceed the new requirements.

21 We're proposing revisions to the options for
22 tribal certification to reflect EPA's Indian policy and

1 to allow tribes the flexibility to administer
2 certification programs in a way that works for them.

3 Then, codifying a policy for federal agency
4 certification plans and removing the option for a single
5 federal government-wide certification plan for all
6 federal employees using RUPs.

7 So, the next part is where we are looking for
8 some feedback. It's definitely an area where we're
9 encouraging public comment from all the stakeholders.
10 This is the implementation on what we're proposing for
11 implementing the rule.

12 So, we plan to provide resources for
13 implementation. We currently have a database called the
14 certification plan and reporting database that states can
15 use to keep track of their certification plans, to submit
16 them and update them, and to report on the number of
17 people certified annually. We will update that when the
18 final rule is updated.

19 EPA has worked with states and other
20 stakeholders to develop certification exams and manuals
21 for applicators in different categories, and we plan to
22 continue doing that as necessary after the final rule is

1 issued, and to work with all stakeholders to develop
2 other resources as requested.

3 The time frame we're proposing for implementing
4 these rules once the final rule is issued and effective
5 is to have two years after the final rule publishes for
6 states to update their certification programs. They
7 would make any necessary changes to their recertification
8 period or what categories they require or anything else
9 required under the rule and to submit that to EPA for
10 approval. EPA would have two years.

11 So, after four years of the rule's publication
12 date, we would require that certification be done
13 according to the new plans as long as they've been
14 approved by EPA. But we did include a provision in the
15 proposal that if EPA hadn't approved a plan within that
16 four year period, the existing plan would stay in effect
17 until such time as a final plan can be approved. We do
18 want to make sure that the timing for implementation
19 works for states and applicators and other affected
20 groups.

21 So, this is just a general rundown of the costs
22 included in the proposed rule. The annual cost is about

1 \$47 million. We calculated per applicator cost by state for
2 private applicators, commercial applicators, and state
3 and government applicators, as well as the cost to state
4 government agencies. This is another area where if there
5 are costs we didn't incorporate or we weren't aware of,
6 we're hoping for public comment on how we could better
7 capture the cost of the regulation.

8 Here's just a little bit of what we think the
9 benefits from reducing the incidents are. We think it
10 will reduce the effects of RUP exposure to certified and
11 noncertified applicators and also to other people who
12 happen to be around RUP applications. We also think that
13 the quantified benefits would be \$80 million, and then there
14 would be unquantified benefits because we didn't
15 calculate environmental impacts.

16 So, for public comment, as Kevin mentioned, we
17 issued the rule in August. It published in the Federal
18 Register in late August of this year. There was a 90-day
19 comment period. The comment period is currently
20 scheduled to close on November 23rd. So, we encourage
21 you to read the proposal and put in any kind of comment
22 you want. I'll talk more about the kinds of comments

1 that would be most helpful in a minute.

2 Actually, this slide is out of date since we
3 sent it in. We have received two formal comments to
4 extend the comment period, so we're considering those now. Of
5 course, we'll publicize any extension to the comment
6 period.

7 So, here's some information on how to submit
8 comments. The docket number you need to use, and you do
9 it electronically through regulations.gov. We also have
10 a document we like to reference to provide a resource for
11 developing effective comments.

12 So, we're encouraging all public comments. We
13 really appreciate effective public comments. So, as
14 Nancy said, we got 2,400 comments on the WPS, and we took
15 them all into consideration, and it impacted a lot of
16 what we ended up with in the final rule. So, we take
17 into consideration everything you say.

18 Things that help us more are things that tell
19 us what works or doesn't work and why. If there's an
20 alternative that would be better, explain what the
21 alternative is and why it would be better for your state
22 or your applicator group or the organization that you

1 represent. So, hearing that you don't like a three-year
2 recertification period is good for us to know, but
3 telling us that a five-year recertification is easier for
4 a state to administer is more useful information for us
5 to develop and justify the final requirements in the
6 rule.

7 In doing this proposal, we're trying to raise
8 the bar nationally. We're not trying to hamper states or
9 applicators or organizations that are already doing above
10 and beyond or are already doing the spirit of what we're
11 trying to achieve.

12 So, that's all I had in terms of a
13 presentation. So, if there are any questions or
14 comments?

15 MR. HOUSENGER: Andy?

16 ANDY: Thank you. I appreciate you referencing
17 the extension of the comment period. I do think that is
18 going to be necessary for us.

19 MS. MONELL: Could you get a little closer to
20 the microphone?

21 ANDY: I'm sorry. I do appreciate you
22 mentioning the extension of the comment period, and I

1 look forward to that. I hope that you will take that
2 under serious consideration.

3 I was also curious if there were any lawyers in
4 the room and if they could tell me how many CLEs they are
5 required to have in a year.

6 UNIDENTIFIED MALE: I'm a lawyer. It's usually
7 12 hours worth of CLEs annually, unless you get a waiver
8 by not practicing law or living out of state.

9 ANDY: I think the requirement of six hours or
10 three hours for each category that an applicator is
11 certified in is excessive. You can only tell them read
12 the label, don't drink it, and wear your PPE so many
13 times. I just don't know that there's that much that
14 somebody could learn. I have some applicators that are
15 certified in 10 categories. We're talking 60 hours of
16 CEUs for them. They mentioned that that may be
17 excessive.

18 I look forward to an extension because it is
19 pretty in depth. We're going through this with our
20 extension agency. I'm curious as to why the importance
21 of a written exam versus an online exam.

22 MS. ARLING: So, a written exam could be given

1 online. A requirement for it to be written just means
2 it can't be oral. But delivering it electronically would
3 be acceptable.

4 ANDY: I would clarify that in the proposed
5 rule and say written or online. Some people take it
6 literally to mean written.

7 MS. MONELL: These are excellent comments. Be
8 sure that you place them in the docket as well.

9 ANDY: Yes, ma'am.

10 MS. MONELL: Okay, thanks.

11 MR. HOUSENGER: I wasn't sure if there was a
12 lawyer joke in there about them needing more hours.

13 MS. MONELL: Be careful.

14 MR. HOUSENGER: Okay. Let's see, Robyn?

15 ROBYN: Hi thank you. I just have a couple
16 questions. On your slide about the costs, was that new
17 costs or increased costs over what is currently required
18 from the existing protection plan or whatever?

19 MS. ARLING: The cost for state and for
20 applicator are based on what states currently require and
21 what it would cost to come into compliance with what we
22 proposed.

1 ROBYN: Okay. What was your justification for
2 minimum age of 18 for required age?

3 MS. ARLING: So I can give you a snapshot and
4 then I encourage you to read the proposal for more
5 information. We looked at --

6 ROBYN: Because that was also the same
7 thing we heard as minimum age for the worker
8 protection. Yet, I would think you would want to be a
9 little bit more protective of the applicators versus the
10 workers. It's a bigger requirement being applicators, in
11 my opinion. I'm sorry, I'm a nurse.

12 MS. ARLING: So, we looked at the development
13 of judgment and maturity in adolescents. We looked at a
14 lot of scholarly literature on brain development and
15 decision-making skills. While all of those might point
16 to a higher minimum age, what we felt comfortable going
17 forward with was a minimum age of 18.

18 ROBYN: And then, lastly, I'm just curious how
19 many -- under the existing applicator certifications on
20 your slide about private applicator's initial
21 certification, the current rule, how many nonreaders were
22 certified?

1 MS. ARLING: Really a few. In talking with
2 states about that, a lot of states have outlawed it
3 entirely. Then, states that still had it on the books,
4 we talked to many of them and it hasn't been used in 20
5 or 15 years or they might have one or two over the last
6 10 years. We didn't hear of any rush for nonreaders to
7 be certified.

8 MR. HOUSENGER: Louis?

9 LOUIS: Thanks. This may just be a nuance or
10 semantics, but on slide number 7, nonreaders, I have a
11 problem with that. What do you mean by a nonreader? My
12 understanding is that you are actually saying somebody
13 who is a non-English reader? What is a nonreader?

14 MS. ARLING: The current rule talks about
15 people who can't read the label.

16 LOUIS: Yes, absolutely, in English or any
17 language?

18 MS. ARLING: In the language that labeling is
19 available in.

20 LOUIS: Okay, it needs to be clarified. I
21 think it's somewhat vague and I'm coming from the
22 university, but when we pick on stuff like that -- and

1 this is a document that's going to go a lot of places. I
2 think it's important to be more specific than what it
3 reads. Again, it might just be semantics or a nuance.
4 It's not a big deal.

5 But the more important point I'd like to raise
6 is that in the previous presentation, I had a question
7 about how they got from five to recommend one year of
8 certification. Now, in this one, you have three years
9 and both this and the previous WPS presentation, there are
10 a lot of things in common. There's a lot of overlap.
11 That was the reason I was asking.

12 I thought that gap from five to one was
13 a little too much. Actually, you strike a good balance.
14 I like it. Three years makes me feel a little more
15 comfortable. I just throw these out because the same
16 things, the same argument that was made for WPS you could
17 actually make it for this as well, you know, hiring new
18 folks and sort of need to be retrained. You can say the
19 same exact thing about this. So, do you think three
20 years is best or are you considering one year like they
21 did?

22 MS. ARLING: We're accepting public comments on

1 the range of recertification period. So, I hope you
2 provide that.

3 MR. HOUSENGER: Gabriele?

4 GABRIELE: Two questions. One is just making
5 sure I'm understanding the proposed time frame for
6 implementation correctly. The four year one, because it
7 was phrased in terms of when the states need to do it, if
8 you're an applicator, does that mean, then, four years
9 after the rule is final, that's the date that you need to
10 be certified under the new standards? I'm just trying to
11 understand for the applicators what's the time frame for
12 them.

13 MS. ARLING: That's what the proposal is. So,
14 four years after the final rule is effective, new state
15 plans would be in effect that have new requirements. I
16 don't think it means that at the four year mark you have
17 to rush and take all new tests.

18 GABRIELE: That's the part that I think I need
19 to clarify, because it's one thing for the states to have
20 everything in place and educating in the right way. It's
21 another thing for the applicators to know by when do they
22 need to have met all the new requirements.

1 Then, the other question, this is really more
2 for the high risk compounds. I mean, a number of those
3 are in the middle of registration review. So, my
4 question is, really, how is this proposal tying in with
5 some of the work going on, whether it's any of the
6 fumigants or some of the other compounds? There's
7 overlap there and I don't know how the timing of this
8 rule and working through it and the comments will tie in
9 with the time frames that you're working on registration
10 review. I'm seeing questioning eyes.

11 MS. ARLING: So, I can talk from soil
12 fumigation perspective. When we did the decisions for
13 the soil fumigants, there was either (inaudible) by the
14 labeling that would be registrant provided or states
15 could adopt a soil fumigation certification category that
16 would allow applicators to get certified in that category
17 and apply any of the soil fumigants covered by the
18 decision. So, we took that requirement, what was laid
19 out in the registration decision, and incorporated that
20 into the rule.

21 GABRIELE: But then the flip side of it is like
22 for post-harvest fumigations, you're still in the middle

1 of registration review and you may have exposure concerns
2 in those. How does something like this tie in with that
3 process? You talked about it going from the
4 reregistration into the standard, and I'm also asking
5 about the other way around.

6 MR. HOUSENGER: So, we'll look at individual
7 chemicals on a case by case basis and put specific
8 restrictions, protective equipment, warnings on those as
9 needed. But this is a separate effort from that that
10 will just complement it.

11 GABRIELE: But I guess I could envision -- I'm
12 not sure, I don't know the details. I could envision
13 that something that's in this rule might mitigate
14 something that you're worried about in the risk
15 assessment process. So, that's what I'm trying to
16 understand.

17 MR. HOUSENGER: John?

18 JOHN: Just a few questions from a state
19 standpoint. Of the roughly one million noncertified
20 applicators, do we know how many states do not allow or
21 essentially allow application under the supervision, how
22 many states that is?

1 MS. ARLING: So, when we talk about
2 noncertified applicators, we estimated that there's about
3 a million, but we don't actually know the number. We
4 know that four states don't allow use of RUPs under the
5 supervision of a commercial applicator, and I think three
6 states don't allow it under private applicators. But
7 otherwise, it's permitted in other states.

8 JOHN: So, would a survey by AAPCO be
9 helpful to inform any kind of decisions? Numbers of
10 noncertified applicators or --

11 MS. ARLING: Sure. Any information we can get
12 about the number of people that would be affected would
13 help us better estimate the impact.

14 JOHN: Then, here's the money question, because
15 obviously this is going to be very expensive. Typically,
16 states have cooperative agreements, as you well know.
17 States are given money to do training for folks like
18 we're talking about.

19 But the big issue, we know that extension is
20 really hurting. I'm not here advocating for extension.
21 I'm just saying that the dollars that might be needed are
22 pretty significant, at least they appear to be. So, what

1 is the dollar impact? Marty, you talked about \$3 million
2 for WPS. It's got to be \$6 million for this, right?

3 MS. MONELL: We have not yet identified a
4 number. I will say that the cooperative agreements that
5 the states receive every year under our STAG
6 appropriation, that the total amount has remained pretty
7 flat. But we have some discretion along with OECA in it
8 through the NPM guidance in assisting with the focus of
9 how that money is spent. I know that worker protection
10 is going to be updated as a priority in 16's guidance as
11 well as 17. I'm sure that the C & T implementation
12 activities will likewise be there.

13 In terms of the extension services, if you
14 recall, we used to have an interagency agreement with
15 USDA thru which money was given to the extension services
16 to reimburse them for the training in this area. That
17 effort has since been disbanded by USDA just because of
18 the processing overhead costs.

19 But we have still, through PRIA set aside and
20 our own appropriated funds, maintained a program whereby
21 by and large it is the extension services that receive
22 the funding to do this training, notwithstanding we don't

1 go through USDA any longer.

2 So, we have existing mechanisms for funding,
3 and we certainly plan to increase the importance of this
4 effort through the NPM guidance. Then, any funding that
5 we have available through the vehicles that Kevin is
6 talking about, or similar, will be made available.

7 MR. KEANEY: We are entering into a five year
8 grant with a recipient that's going to be distributing
9 these monies. The PRIA monies were \$500,000 and we're
10 adding \$500,000 to that, so it's a five year for a
11 million a year to extension.

12 JOHN: So, it's about a \$1 million outlay then?

13 MS. MONELL: Well, that's just for the specific
14 training.

15 MR. KEANEY: Right. We have other grants that
16 would help extension with training materials or
17 training --

18 JOHN: Also, from the SLA point, we get two
19 pots of money. We get the OECA and the OPP. Do you see
20 a switch in terms of percentages?

21 MS. MONELL: I'm assuming the OECA percentage
22 is higher.

1 JOHN: Really? It is, you're right.

2 MS. MONELL: Well, the activities that they
3 fund are in the compliance and enforcement arena, which
4 are done through the states for our programs. So, it
5 would naturally follow that that would receive the larger
6 portion of monies.

7 JOHN: You don't see that changing, then?

8 MS. MONELL: Not right now, no.

9 JOHN: Okay, good, thanks.

10 MR. HOUSENGER: Wayne?

11 WAYNE: Hi, Michelle. Thank you for your
12 presentation. I imagine you're getting tired of giving
13 this over and over again.

14 I was just looking at a couple of issues. I
15 saw on slide 12 you talk about noncertified applicators
16 and the proposal there would be -- well, there's three
17 options that are bulleted. The first one sounds a lot
18 like the WPS training that we talked about. Is that
19 something that you had conceptualized here, that being
20 the annual training on safety application, personal
21 protection, and pesticide labeling? Would it be very
22 much along the lines, if not exact, to what WPS would

1 look like?

2 MS. ARLING: So, the requirement and the
3 proposal for training have a lot of elements similar to
4 the WPS training, but it doesn't include things like REIs
5 or other WPS specific requirements.

6 WAYNE: So, it would be similar with the
7 exception of --

8 MS. ARLING: It's substantially similar, yes.

9 WAYNE: Okay. Then, also, I would agree with
10 Andy that it's obviously going to be a huge challenge for
11 us in extension, not a burden, to provide the extra hours
12 of training. We already are hurting, as John was
13 indicating, with expertise and personnel to do that.

14 But I'm just wondering with the funds that
15 would be administered through EPA, would there be a
16 process similar to WPS where things are preapproved? In
17 other words, there might be more training manuals or
18 training material. In that case, would they be vetted or
19 approved by EPA and then made available or distributed
20 widely?

21 MS. ARLING: We are hoping to do something
22 similar as we've done under our cooperative agreement

1 with the National Association of State Departments of
2 Agriculture and Research Foundation where we developed
3 the soil fumigation manual and exam and made it available
4 to states and extension, and did the same for aerial
5 applications and the core manual. So, as we get
6 information on what's needed, we're happy to help
7 with developing national resources.

8 WAYNE: Those are well done and very much
9 appreciated. I was just curious, from the standpoint of
10 looking at it in a different direction, within North
11 Carolina, as in other states, commercial applicators are
12 certified in various categories. Turf and ornamentals
13 come to mind. There aren't many restricted use
14 pesticides in use in turf and ornamentals, outside of
15 golf courses and sod farms.

16 But is it possible that states could establish
17 a separate certification and training plan that would
18 deviate from this, but it would just apply toward those
19 groups that are not using restricted use pesticides? In
20 other words, could they develop a three year
21 certification period that is less than the number of
22 hours required here for RUP users? It's an interesting

1 wrinkle, isn't it?

2 MS. ARLING: I don't know if I understand your
3 question.

4 WAYNE: So, this is a proposed change for
5 recertification of restricted use pesticide applicators.
6 But for many categories, there are no -- well, a number
7 of categories there's a very few restricted use pesticide
8 users. Turf and ornamentals is a good example of that.
9 Many of the products that our folks use are general use
10 pesticides, but they are certified because they're
11 applying pesticides to a property of another. So, in the
12 business, they are certified.

13 Could it be that our state or other states
14 could actually develop a different certification plan
15 that is not as stringent as this plan for groups that do
16 not use restricted use pesticides?

17 MS. ARLING: I think it would be great to get
18 that as a public comment.

19 WAYNE: Okay.

20 MR. HOUSENGER: And Richard?

21 RICHARD: Maybe I should know this, but I was
22 just curious about more information on that part of the

1 noncertified applicators for at least as it relates to
2 commercial applicators. Where is this the most prevalent
3 where they're using noncertified applicators? Is it
4 certain areas of the country, certain industries? Where
5 is the prevalence for that? We're having a discussion
6 actually about maybe a clarification of where it says
7 insure that immediate communication is possible. What do
8 you mean by immediate communication? Texting, cell
9 phone, or I guess a clarification for that as well.

10 MS. ARLING: So, we, as I mentioned, don't have
11 a lot of data on noncertified applicators. So, our
12 economic analysis does have some estimates of where
13 noncertified applicators are state by state. But they're
14 really rough estimates. So, if there's more information
15 that you can provide or any organization can provide,
16 we'd welcome that. But we're not aware of specific areas
17 where it's more or less prevalent.

18 RICHARD: At least for commercial applicators,
19 as I remember, I think most of them are licensed and
20 certified. So, I was just curious of the data, if it's
21 mainly outside of ag or what. So, any information you all
22 have additionally would be beneficial.

1 MS. ARLING: And then, for immediate
2 communication, it's basically any way you can get in
3 touch with somebody immediately. So, texting would be
4 fine. Making sure that both parties have cell phones
5 that are turned on would be fine. Having two way radios
6 in areas where cell phone communication isn't always
7 possible would also be okay.

8 MR. HOUSENGER: Okay, we're going a little
9 late, so the names that are up are the last ones I'm
10 taking. Then I'm going to the phone.

11 Mark?

12 MARK: Thanks, Jack. Mine, you'll be happy to
13 know, is not a question, but it's a comment and a
14 recommendation. As an older but still enthusiastic
15 entomologist that watches the farm reports, what has gone on
16 with both the air rule and the water rules (WOTUS) and the
17 resistance that you are going to get on this kind of
18 thing, your work on the cost benefit analysis is
19 powerful.

20 I don't know what you are allowed to do about
21 that from a communications and PR aspect, but I would use
22 the hell out of it in anticipation of what's going to

1 happen. I'm very supportive. I think you've done great
2 work, but you need to have this case out there. I think
3 you've done a good job but have somebody who is good at
4 PR working on it.

5 MR. HOUSENGER: Sharon?

6 SHARON: Just a follow up with what Wayne was
7 saying. I just want to clarify. This proposal is
8 actually broader than just restricted use pesticides now,
9 but the additional application methods are part of the
10 proposal, is that correct? So, it would include
11 nonrestricted use pesticides if they're applied by these
12 three application methods?

13 MS. ARLING: No. They're limited to restricted
14 use pesticides at the federal level.

15 MR. HOUSENGER: On the phone, the members of
16 the PPDC, any comments/questions?

17 VALENTIN: Yes, just one comment and one small
18 question. First of all, I want to just say that you guys
19 are heading towards the right directions to protecting
20 some of the most vulnerable farmworker population
21 because most incidents here in Oregon, I think, could
22 have been prevented.

1 The question I have is, I just want to know if
2 it's possible to try to obtain demographic information
3 about the applicators that are certified?

4 MR. HOUSENGER: Are you saying where the most
5 restricted use pesticides are applied?

6 VALENTIN: No. I was just saying that you guys
7 are heading towards the right direction in protecting
8 farmworkers just because some of the incidents here in
9 Oregon could have been prevented. My question is in
10 regards to slide 3 about the private applicators and
11 commercial applicators. I just want to know if there's a
12 way in which we could try to obtain demographic
13 information about the applicators?

14 MS. ARLING: We can tell you the number of
15 certified applicators by state in each category, but
16 that's all the demographic information we have right now.

17 VALENTIN: Okay, thank you.

18 MR. HOUSENGER: It's 3:08, depending on what
19 clock you look at. Let's come back in 15 minutes, so
20 20 after, let's say.

21 (A brief recess was taken.)

22 MS. MONELL: If everyone would please take

1 their seat, we're ready to resume. By anyone's clock,
2 it's time. For those on the phone, we're about to
3 restart the session.

4 MR. HOUSENGER: Our next session is on
5 endangered species. Anita Pease of the EFED here -- I'm
6 not going to go into that acronym -- and Gina Shultz of
7 Fish and Wildlife Service are going to run through the
8 presentation. Then we'll have a discussion.

9 MS. PEASE: Thanks, everyone. So, I'm from the
10 Environmental Fate and Effects Division. I'm the
11 associate director. I'm happy to be here with Gina
12 Shultz, who is the deputy assistant director of the
13 Ecological Services Program at the Fish and Wildlife
14 Service. We're going to be copresenting today to the new
15 PPDC members, so welcome.

16 So, I will be covering the first bullet. I'll
17 be talking about the status of our ESA related activities
18 and providing updates to our biological evaluation
19 schedule for our first nationwide consultations that
20 we've been working on with the services. Then, Gina will
21 pick up the next two items on stakeholder engagement and
22 the next steps on the step 3 biological opinions.

1 So, just by way of introduction, I'm sure most
2 of you have seen this slide, but this really outlines the
3 three step process that was recommended by the National
4 Academy of Science in their 2013 report. This is the
5 process that we are following, the interagency group is
6 following to conduct the pesticide consultations. I'll
7 just walk you through this very quickly.

8 Basically, in step one, we determine whether
9 the use of the pesticide, according to the product label,
10 will result in either no effect or may effect to listed
11 species as well as designated critical habitat. If we
12 determine there's no effect, we basically don't consult
13 with services. We're done at that point in time and we
14 would move forward with the action.

15 If we determine there's a may effect call, we
16 would move into step two. At that point, we would
17 determine whether the pesticide is likely to adversely
18 affect, which we call LAA, or not likely to adversely
19 affect, NLAA, the species in the designated critical
20 habitat.

21 If we determine the pesticide is not likely to
22 adversely affect, we would seek concurrence on that

1 determination with the services in what we call informal
2 consultation. If we determine likely to adversely affect,
3 we then move on to step 3, which is the jeopardy opinion,
4 the adverse mod opinion. That's the biological opinion
5 of the services.

6 All three steps incorporate the existing
7 ecological risk assessment framework. This includes a
8 problem formulation, an exposure characterization, an
9 effects characterization, and then the integration of
10 those two pieces and the risk characterization.

11 The first two steps are largely EPA's
12 responsibility, so that's the biological evaluation, or
13 BE. Sometimes we refer to this as our effects
14 determination. Then the third step, the biological
15 opinion, is the responsibility of the Services. So,
16 that's basically the three step process.

17 So, in terms of progress on our ESA related
18 activities, it's been about two and a half years. Time
19 flies when you're having fun -- since the report came
20 out. The NAS report came out in April of 2013. Since
21 that point in time, we've had three interagency
22 workshops, we've had technical staff in the Services, as

1 well as management, participating in workshops where
2 we've gotten together for a week long period to work out
3 interim methods to address the NAS report
4 recommendations. We've also been refining those interim
5 methods over time.

6 Our next workshop we're planning is for January
7 of 2016. In that workshop, we hope to start tackling the
8 step three biological opinion methods, as well as
9 discussing lessons learned on some of the work we've been
10 doing thus far in steps one and two, and looking for ways
11 to streamline and come up with a more efficient process
12 for steps one and two.

13 In addition to that, we've had four stakeholder
14 workshops. I did check the web links on these. I heard
15 the discussion this morning about the change to WW2, so
16 if you click on those links, they will take you to the
17 presentations for those workshops. In those workshops,
18 we heard feedback from stakeholders on the interim
19 methods that we had developed. We also provided status
20 reports on the status of our efforts as we move through
21 this process.

22 Gina is going to talk a little bit more when

1 she gets to her slides on the next stakeholder workshop
2 that we have planned for January of 2016.

3 In addition to the interagency and stakeholder
4 workshops, we've also been pretty active at various
5 technical/professional meetings. We've had a number of
6 our technical staff present on the updates to these
7 methods at SETAC, (phonetic) at the American Chemical Society
8 meetings, as well as the CropLife RISE meeting in the spring.
9 We have two sessions, I believe, planned for the upcoming
10 SETAC meeting in Salt Lake City, and that's in November.

11 Finally, we've obviously had some settlement
12 agreements that have focused this work. Most recently,
13 what we refer to as the grand bargain, was a settlement
14 agreement that all three agencies came to on existing ESA
15 litigation. It really allowed us to align our resources
16 to work on the first ever nationwide consultations for
17 five pesticides. Those include chlorpyrifos, diazinon,
18 and malathion, and then carbaryl and methomyl. That
19 grand bargain set schedules for final biological opinions
20 to be delivered for the first three organophosphates --
21 that's chlorpyrifos, diazinon, and malathion -- by 2017
22 and then carbaryl and methomyl by 2018.

1 In addition to that, EPA has also, this past
2 summer, come to a recent agreement with the Center for
3 Biological Diversity on an existing ESA litigation
4 related to the San Francisco Bay. So, for that
5 particular litigation, EPA was on the hook for providing
6 effects determinations for 75 different chemicals,
7 pesticides, for 11 species in the San Francisco Bay area.
8 We completed 59 of those determinations. We have 16 left
9 to do.

10 So, the result of this new settlement agreement
11 basically allows us to swap out those remaining 16
12 pesticides and do the next four nationwide consultations
13 for four different chemicals. So, it sets the schedule
14 beyond the first five for the next four. Those chemicals
15 include atrazine, glyphosate, propazine, and simazine
16 We've agreed to provide biological evaluations, or BEs,
17 for those four chemicals by 2020.

18 So, in terms of the status of the ongoing work,
19 really we've been mostly focused on the three OPs, right
20 now in completing the steps one and two analysis for
21 those first three chemicals, chlorpyrifos, diazinon, and
22 malathion. These will be the first ever nationwide

1 pesticide consultations for listed species.

2 The work the teams have been doing has been
3 very collaborative. There have been weekly meetings. We
4 even have a staff person from National Marine Fisheries
5 sitting up in EFED daily interacting with our staff. So,
6 a lot of coordination on this work.

7 The work on these BEs is really consistent
8 with the NAS report recommendations and the interim
9 approaches that we've developed. Right now, in terms of
10 the draft biological evaluations, we're going to be
11 releasing them in two phases, which I'll discuss in the
12 next slide. We're still on track for the final
13 biological opinions for these three chemicals in December
14 of 2017.

15 So, in terms of the revised schedule, basically
16 the interagency teams have experienced a delay in
17 completing the draft BEs for chlorpyrifos, diazinon, and
18 malathion. In previous communications, we've said that
19 these draft BEs would be out late summer/early fall of
20 2015. Right now, that's not going to happen. We're not
21 going to be releasing those documents right now.

22 What we're going to do is release them in two

1 phases, the first of which will be a couple months from
2 now, in December 2015. So, we'll be providing the draft
3 problem formulations, the exposure characterizations, the
4 effects characterizations, and all the related appendices
5 for the three chemicals.

6 So, you'll be getting three different sections
7 and a lot of information. Basically, what you'll be
8 getting is all the analysis plans for the three
9 chemicals, as well as all of the underlying data that
10 we'll be using to make the effects determinations.

11 The next piece of it will come in April, in the
12 spring of 2016. We'll be coming out with the rest of the
13 document, which will include the effects determinations,
14 the no effect, LAA. NLAA calls for 1,850 species, as
15 well as 800 designated critical habitats. So, calls for
16 all those species. That will also include the weight of
17 evidence analysis for all those species.

18 So, although we're a little disappointed we
19 couldn't get them out earlier, this really is a lot of
20 work. It did take longer than we had originally
21 anticipated. The teams have really completed an enormous
22 substantial amount of work in the time since they've been

1 working together. So, I want to highlight some of the
2 tasks that they've completed, things that they're working
3 on, and what we need to do to get to the finish line.

4 There's been a lot of back and forth. A lot of
5 these sections have gone through multiple rounds of
6 comments between the agencies. We've really taken the
7 time to make sure that we have agreement before we move
8 forward.

9 It's difficult, as I'm sure most of you know,
10 to work not only within your staff, but then when you
11 expand it to different agencies with different regulatory
12 statutes, it makes it even more difficult. But the
13 people working on this project have been extremely
14 professional, and they've really come up with a good
15 approach. I think this will serve us well moving
16 forward.

17 So, in terms of the accomplishments, they have
18 come to agreement on methodologies for a weight of
19 evidence approach that will be used to be making the
20 effects determinations.

21 The interagency teams have completed the
22 reviews of all the registrant submitted studies,

1 as well as information in the open literature for all the
2 fate and toxicity data that you'll see in the documents
3 that will come out in December. Even that was a large,
4 large undertaking, especially with the open literature
5 data, to review and come to agreement on those data
6 reviews, and also select the thresholds that will be used
7 to make the effects determinations.

8 Along with that, you'll also be getting data
9 arrays, which I'll describe a little bit more as I
10 describe the tools. All this information will be
11 displayed graphically in the documentation that will be
12 provided in December.

13 Another large, large effort is obtaining
14 species range maps. So, we, in collaboration and with
15 the help of the industry task force FESTF, which is the
16 Federal Endangered Species Task Force, we were able to reach
17 out to the species experts within the services, the Fish
18 and Wildlife Services field offices. We've obtained
19 species range maps for almost all the species that are
20 currently listed.

21 So, we have all the species for the 48
22 contiguous states. I think we have almost all the

1 Hawaiian species and those in the Pacific Islands as
2 well. So, that's something that we never had before that
3 we actually have geographic shape files for all those
4 species in house now to help make these effects
5 determinations.

6 We also have been gathering all the biological
7 information for each of these species. So, this is a
8 life history data on body weight, growth, diet, habitats,
9 things that are inputs into our models. We've compiled
10 all that information in endangered species knowledge
11 base. The teams have been working on that. It's also an
12 extremely large effort and a lot of work. We've
13 identified all the model inputs based on that life
14 history information that you'll see in these December
15 drafts going out.

16 Finally, there's been a lot of work on the tool
17 development. It became pretty obvious when we started
18 doing these effects determinations that you just really
19 can't brute force this analysis for almost 2,000 species.
20 It's just really not possible. So, we recognize the need
21 to have to automate the tools that we have.

22 So, basically, a lot of work has gone into tool

1 development as we're developing the methods to make these
2 effects determinations. We have a number of newer tools
3 that are upgrades to existing tools for aquatic exposure,
4 including the surface water concentration calculator,
5 batch runs, and also post processors, and downstream
6 dilution.

7 Basically, all this automation makes it really
8 possible to automate thousands of aquatic modeling runs
9 that would have otherwise had to have been done for each
10 use pattern. So, this is a huge tool upgrade, and it
11 will help us moving forward in all of our work.

12 In addition to that, we have a new tool called
13 the TED tool. This has gone through a couple renames,
14 but we like TED. It makes us think of a little fuzzy
15 teddy bear, so we like that. This is the terrestrial
16 effects determination tool. Basically, what this is is
17 an aggregation of existing models that we have in house.
18 So, this aggregates TREX, Terra Plant, THERPS.

19 It also includes ag drifts, so it calculates
20 buffer distances, off field transport. It also
21 incorporates a new tool we're developing called BREX,
22 which will estimate exposure to bees and other

1 terrestrial invertebrates, as well as an earthworm
2 (inaudible) model. So, this tool allows us to make
3 effects determinations and provide all the exposure and
4 effects data to allow us to make effects determinations
5 for mammals, birds, reptiles, amphibians, terrestrial
6 invertebrates, and terrestrial plants. So, this is a
7 huge upgrade to our current models.

8 In addition to that, we also have TIM and
9 Mcnest. TIM is the terrestrial investigation model.
10 These are complementary models that allow probabilistic
11 assessment of risk to birds. So, these tools will also
12 be incorporated into our analysis.

13 Finally, we have a couple of new tools to help
14 us characterize the effects. So, one of these is called
15 a data array builder. So, basically, what this does is
16 take all the registrants submitted and open literature
17 data and it displays it graphically in a way that you can
18 filter things not only by endpoints but also by taxonomic
19 groups. So, a very effective way of looking at a lot of
20 information in a concise way.

21 The last tool we've been working on, and it's
22 currently built, is called the species sensitivity

1 distribution, or SSD toolbox. This is a tool we built
2 in collaboration with our Office of Research and
3 Development, ORD. This allows us to portray species
4 sensitivity distributions for acute mortality data so
5 that we can derive a hazard of HD5, which is basically
6 our threshold for acute mortality. So, this has also
7 been a huge upgrade. This is completely automated to
8 allow that data analysis.

9 So, with that, I'm going to turn it over to
10 Gina.

11 MS. SHULTZ: Thank you, Anita. So, I'll
12 elaborate a little bit more on the stakeholder
13 engagement. Several years ago, the four agencies, EPA,
14 USDA, National Marine Fisheries Services, and Fish and Wildlife
15 Service made a commitment to enhance stakeholder input in
16 the pesticide registration and ESA consultation process.

17 A component of that has been workshops. As
18 Anita mentioned, we've held four workshops to date. The
19 agencies, as well as many stakeholders, believe that
20 these workshops have not allowed for the type of
21 information exchange and dialogue that we had hoped for.
22 So, we plan to modify the format to improve the

1 effectiveness of these workshops.

2 One thing we are thinking about is perhaps
3 having some smaller group discussions or breakout
4 sessions on given topics. To ensure that we have a
5 better process for the stakeholder workshop, we also will
6 engage the stakeholders in advance of the January 25th
7 workshop to seek input on how we can better structure the
8 workshops.

9 As Anita mentioned, we will have released in
10 December a great deal of information. So, we're thinking
11 that one thing might be to, as we said, have some
12 specific smaller discussions/breakout sessions around
13 some of those key points. Again, we're going to seek
14 input on that. That will be noticed, the workshops, and
15 the agenda will be noticed as the prior ones were.

16 So, transitioning from step 2, which Anita
17 talked about, that's the process where EPA is going to
18 make a determination of likely to adversely affect or not
19 likely to adversely affect. Actually, a third
20 possibility, some of the things that made it into step 2,
21 it's possible that after doing further analysis, there
22 could be a no effect determination. In that case, as

1 with the step 1, if EPA makes a no effect, that
2 terminates consultation on that species or critical
3 habitat.

4 The not likely to adversely affect call, as
5 Anita said, that would require concurrence by the
6 service. Then consultation will be concluded for that
7 species or critical habitat. For those that end up being
8 likely to adversely affect, those would be moved into
9 what we call the step 3 analysis or biological opinion.

10 So, for those likely to adversely affect
11 determinations, the service will conduct jeopardy
12 analysis for the listed species and adverse modification
13 analysis for critical habitat. The jeopardy analysis
14 considers the types of effects to individuals of a listed
15 species that's described in the biological evaluation
16 that EPA is preparing for step 2. But it expands the
17 analysis to populations, and ultimately, the species
18 determines if it's a jeopardy or not.

19 It considers the effects in the context of the
20 environmental baseline status of the species and any
21 interrelated and interdependent activities, if there are
22 any, and then also the cumulative effects of future

1 nonfederal actions.

2 The jeopardy analysis will result in either a
3 no jeopardy conclusion -- and if there's incidental take
4 of a listed species, reasonable and prudent measures to
5 offset that take could be included, or a jeopardy
6 conclusion along with reasonable and prudent
7 alternatives, if there are any, that are developed in
8 consultation with EPA and the registrants.

9 The adverse modification analysis considers the
10 effects of the primary constituent elements and essential
11 biological futures of the critical habitat from the
12 pesticides. It expands the analysis to the whole
13 critical habitat designation as a whole. The result of
14 the adverse mod analysis would be either no adverse mod
15 conclusion or an adverse mod conclusion along with some
16 RPAs if there are reasonable and prudent alternatives that are
17 developed in consultation with EPA and the registrants.

18 In step 3, the service will review the analysis
19 and other information provided in the biological
20 evaluations and gather additional information related to
21 the species and critical habitat and their status in the
22 action area. This is actually something that we have in

1 progress now. We know the species that are in step 2, so
2 we're already doing that part of it.

3 It will also include the environmental baseline
4 and activities related to anticipated cumulative effects
5 in the action area. We'll conduct a population level
6 analysis using any tools and methods available or
7 appropriate. Through step 3, we will continue to work
8 with the interagency team to address information gaps and
9 any uncertainties that arise in step 3.

10 We plan to use the interagency workshops that
11 Anita mentioned to work through, as was done with step 2,
12 the interagency teams, the staff from all the agencies,
13 and work closely together to agree on the methods used in
14 step 2. We will use that same process in step 3 to
15 ensure that the step 3 process is also transparent and
16 there are no surprises in the biological opinion. We
17 plan to kick this off at our January workshop that Anita
18 mentioned.

19 MR. HOUSENGER: I guess you're done.

20 Aimee?

21 AIMEE: This is a question about step 1.

22 Recognizing that it's in EPA process to determine no

1 effect or may effect, but also knowing kind of the
2 history of the difference between FIFRA and ESA and some
3 of the original no effects that came out, there was
4 concern from the Services that maybe they weren't using
5 ESA screen on those, going back a decade. I'm just
6 curious, today, looking at what we have, how much
7 engagement did the Services have in looking at the
8 process EPA used to evaluate for no effects/may effects?

9 MS. PEASE: Historically, I think those
10 determinations, those no effect calls we made decades
11 ago, I mean, there was very little collaboration at that
12 point in time. I think if you look at those same use
13 patterns and the same pesticides and the same species
14 now, we probably would have come to a different
15 determination, because the step 1 analysis that we're
16 working on now is based on a co-occurrence of use with
17 range maps, with where species are in space and time.

18 So, depending on the use patterns, some of
19 these pesticides are used all over the country. We
20 probably would have come to a may effect. Now, we might
21 have come to a not likely to adversely effect based on
22 further analysis, but yes, they probably would have been

1 different.

2 MR. HOUSENGER: Sharon?

3 SHARON: I have a couple of questions about
4 process and a question about tools. So, my first
5 question on processes, with the December release and the
6 April release, is this information only or is it going to
7 be posted for comment at the docket?

8 MS. PEASE: So, good question. What we're
9 thinking right now is that the release of the documents
10 in December would be just for your knowledge only, not
11 for public comment at that point in time. We'd be
12 releasing all these documents to be viewable. The
13 official public comment period would start in April. We
14 hope that by providing these documents early on, three
15 months or however many months it is, in advance of the
16 actual effects determinations, it will give people time
17 to really digest the information. It's going to be very
18 large documents, so we wanted to give people advance
19 notice. Hopefully, that will mitigate the need for an
20 extended comment period, by providing them in phases this
21 way.

22 SHARON: Okay. I have a couple others. So,

1 with regard to the concurrence process, which normally
2 follows the likely to adversely affect, since there's
3 been such close collaboration between the Services and
4 the EPA, I'm kind of wondering if that is sort of a done
5 deal, so to speak. I mean, since the agencies are
6 working so closely together, is it a reasonable assumption
7 that concurrence is essentially just going to be a very
8 quick process afterwards?

9 MS. PEASE: Yes, I think you're right. I think
10 since we've been working so closely together, I think
11 that we're concurring along the way. We're talking to
12 each other daily.

13 SHARON: Will the final biological opinions also
14 include the incidental take authorization with RPMs?

15 MS. SHULTZ: Yes. If there's incidental take
16 anticipated, then it will include the incidental take
17 statement with reasonable and prudent measures to
18 minimize the take.

19 SHARON: Then, for the tools, since you're developing and have
20 merged together a number of different existing tools, and these are
21 complex tools, what's the status of posting of those at the website?

22 MS. PEASE: So, we're hoping to post those
23 tolls in December at their current state. Right now,

1 we're hoping to hang all this material on our website
2 rather than putting it in a docket, just because of size
3 limitations. So, we're probably going to use our
4 existing ESPP web page to put all these documents on a
5 separate website or a separate web page within that site.

6 There would be a separate page for provisional
7 tools or provisional models as they exist now. Some of
8 these, like I said, we're kind of building the plane
9 while we're flying it a little bit. So, the full QA/QC
10 documentation of some of these tools is still ongoing.
11 So, when they get complete, they'll go on our models web
12 page. As they're being built and we're using them,
13 they'll be on this provisional models site. That's our
14 intention right now.

15 MR. HOUSENGER: Gabriele.

16 GABRIELE: Just two questions. The workshop in
17 January, is that going to be held here? I missed where
18 it was.

19 MS. SHULTZ: Sorry. It will be at the U.S.
20 Fish and Wildlife Services office in Falls Church,
21 Virginia.

22 GABRIELE: Okay. Following up on the question,

1 I just want to say I'm not someone who has been following
2 ESA in detail, but this tool development is pretty
3 amazing in terms of the complexity of what you're being
4 asked to do in developing these tools.

5 The one thing I would ask that you do as part
6 of maybe the December setup, and I'm sure you have all
7 the time in the world to do this, but I semi made the
8 mistake of attending one of your more detailed
9 environmental risk assessment meetings here in April. I
10 found myself very quickly off the deep end of the pool.

11 But one thing I took out of it is each little
12 component of the tool has a certain amount of
13 uncertainties in it. You're now combining all these
14 different models together into a single model,
15 essentially, if I'm understanding it. So, I think it's
16 really critical to make clear where the assumptions are,
17 I think more from the human health risk assessment
18 perspective where you have your no effects level versus
19 your effects level. There's already a safety margin
20 built in there. Then, you have your 10x and then
21 potentially additional safety factors. Is there
22 something that helps someone understand all these

1 factors?

2 I will say what I did take out of that meeting
3 was there is a lot of safety margins built in to each of
4 these submodels. Then, there's also uncertainties on the
5 other side. So, I really think it's going to be critical
6 to understand that part of it in a way that someone like
7 me or maybe even less than a Ph.D. can understand who doesn't
8 have a tox background.

9 MR. HOUSENGER: Cheryl?

10 CHERYL: So, I was thinking a lot along the
11 lines of what Gabriele just said. We know that when we
12 string model after model after model and we string them
13 all together, we're also stringing together precaution
14 after precaution after precaution. Sometimes that
15 quickly builds up to be something that maybe we didn't
16 want. Maybe it pushes out reality. So, what effort is
17 there to validate the models? What effort is there being
18 made to use existing exposure information and monitoring
19 information as you go through and string these together?

20 That's question one. I have one more.

21 MS. PEASE: Okay. I can translate that first
22 one. So, let me just reiterate. These models that we're
23 stringing together, it's not like we're adding a lot of

1 uncertainties, compounding uncertainties on top of
2 uncertainties. They're just taking tools that are
3 separate right now and putting them all in one
4 spreadsheet. You put the inputs in once, and you get the
5 output. So, it's essentially doing the same thing that
6 all these separate models did but doing it all in one
7 model. So, there's no compounding of uncertainties in
8 relation to these models.

9 In terms of what you were talking about for
10 using monitoring data and ground truthing, we are trying
11 to do that with our surface water concentration
12 calculator. Right now, we are having trouble modeling
13 some of these aquatic bins with flowing water bodies.
14 So, we are trying to look at existing data sets.

15 Atrazine comes to mind as a robust monitoring
16 data set. Looking at that and ground truthing the
17 information we're getting out of the surface water
18 calculator against monitoring data to see if we're in the
19 general ballpark. It has been a struggle to try and come
20 up with those particular exposure values.

21 CHERYL: The better you can articulate the
22 assumptions and validate the models, the better it's

1 going to be.

2 The other question I have, you're spending a
3 lot of time in tool development, and correct me if I'm
4 wrong, but I believe that ESA consultations are not
5 unique to pesticides; they just presented some late
6 challenges. So, at what point do some of the tools that
7 you're developing for these pesticides translate outside
8 into other types of consultations that are required under
9 ESA?

10 MS. PEASE: I'm sure there's some utility for
11 these tools elsewhere. I mean, right now they're focused
12 on our existing tools to calculate pesticide exposure and
13 effects for pesticides. It doesn't mean that they can't
14 be used elsewhere. I know some of the models we're
15 looking at to calculate surface water concentrations go
16 beyond these models like SWAT and Basins and there's some
17 other (inaudible) tools that are out there. So, there is
18 utility beyond just pesticide consultation. But right
19 now, the focus is on that.

20 MR. HOUSENGER: Al?

21 AL: Thank you. I did want to tell you I
22 appreciated a little bit of lead time on the next

1 stakeholder workshop so we have a chance to get prepared.

2 So, thanks for giving us some time lines there.

3 I did want to respond to your comment about not
4 stringing together uncertainties. I would suggest that
5 you look a lot at the various uncertainties and the
6 various conservatism that's built into a lot of the
7 surface water modeling, because that is worthwhile to
8 think about in terms of what you eventually decide in
9 your effects determination, effects meaning this may
10 effect or no effect or likely to adversely effect, not
11 likely to adversely effect. You also have in here a
12 reference to looking at the weight of evidence of effects
13 that could apply in a couple of places in the entire
14 process.

15 So, I think one of the things that I was
16 wondering was whether there had been a lot of
17 developments in that weight of evidence agreement since
18 what we heard in the ACS meeting, I'm not sure what we'll
19 here at the SETAC meeting, where a lot of the focus was
20 on the toxicological effects, the actual basic data. Can
21 we draw a conclusion on those versus what's the potential
22 effect, no effect, may effect, on the individuals or the

1 species ultimately? So, is that developed or --

2 MS. PEASE: The weight of evidence approach? I
3 mean, the matrix still remains the same. It's still the
4 same lines of evidence. I think we'll be able to provide
5 more detail on that at the next stakeholder workshop as
6 we start to really work through the examples that we're
7 doing in the next phase of the work. Right now we are
8 trying to get all the data in place for the December
9 release. I think at that point in time we can give you
10 an update on the weight of evidence analysis.

11 AL: Okay. If I could ask one more and then we
12 can move on. Gina, you went by this rather quickly, but I
13 thought you made the comment that when you got to step 2,
14 you were sometimes finding that you could make a no
15 effect determination.

16 Is that something that you're finding is
17 common, because there is a difference between looking at
18 a range map and then looking at, I think as you were
19 pointing out in step 3, where those species are within
20 that range and what the primary elements are that you
21 would need to be looking at. So, there is a difference
22 in concept of space between those two steps, as I

1 understand what you're doing now.

2 MS. PEASE: So, I think you did mention in step
3 2 were making no effect calls. But that actually is step
4 1. So, we are making some no effect calls in step 1 for
5 some of these chemicals. That is something that would
6 happen at step 1, not in step 2. It's kind of semantics.

7 MS. SHULTZ: I probably confused things by
8 saying that it's possible -- I was talking process. It's
9 EPA that makes the calls not Fish and Wildlife Service.
10 I was just trying to say processwise, it's possible in a
11 step 2 analysis that an agency could, after further
12 analysis, find that there is a no effect in theory.
13 Sorry for the confusion.

14 MR. HOUSENGER: Cynthia?

15 CYNTHIA: So, I'm very interested in your
16 surface water concentration calculator and what exactly
17 it entails and whether it's publicly available or when it
18 will be. The reason I ask is because the American Bird
19 Conservancy is currently engaged in a mapping exercise
20 looking at acute and reproductive risk to birds by
21 watershed across the United States. We are finding that
22 doing these surface water concentration calculations is

1 very, very challenging. So, I'd love to hear more about
2 how you're going about it.

3 MS. PEASE: Okay, I'm probably not the right
4 person to ask about all the details of that, but I do
5 know that what I've heard from our staff is that that
6 particular model will be final by December. So, it will
7 be available in December on our website. Really, it's
8 just an upgrade to our existing prison exams model. So,
9 it incorporates some new scenarios specific for
10 endangered species assessments. It also incorporates the
11 ability to drive exposure estimates not only in static
12 water bodies but also flowing water bodies.

13 These post processing tools provide not only
14 point estimates of exposure but also magnitude and
15 duration over a period of time. So, you can get any
16 different probability distribution of output that you
17 would like from these particular models.

18 CYNTHIA: Fantastic. Can you tell me who would
19 be the best contact at EPA?

20 MS. PEASE: Probably Dirk Young (phonetic),
21 but I can give you that information offline.

22 MR. HOUSENGER: Aimee?

1 AIMEE: First, I just quickly want to thank you
2 guys for taking the time -- every time I've looked at the
3 biological opinions and throughout the different
4 processes, how very transparent you are, how you note all
5 of the uncertainties and make it clear to us as people
6 from the outside what you're questioning still. I really
7 appreciate that, and I really appreciate the caution that
8 you take that endangered species warrants. So, just
9 thank you for that, recognizing it's challenging, but --

10 My one question is a little bit separate from
11 this. I'm curious how much during this back and forth
12 there had been discussions around what label changes can
13 we make? Are there changes that we can shift in a way so
14 that we don't have to undergo a full process? Is that
15 something that's still ongoing, because that seemed like
16 a really valuable step?

17 MS. PEASE: Yes, that's ongoing. It's a good
18 comment, and it's something that we're looking at more
19 closely. I mean, we would all save ourselves a lot of
20 time and resources if we could clean up some of the
21 labels to make sure they are clear. So, we're trying to
22 do that with these chemicals. I think we have done it

1 for a couple of these. We've had some label clean up
2 that's helped a lot. Any mitigation that we can get up
3 in front of the BE or in front of the biop will help us
4 in the long run. So, we are pursuing that.

5 MR. HOUSENGER: Al, do you have another
6 comment?

7 AL: Yes, I do. I was looking at the last page
8 and thinking about it. I was thinking a little bit more
9 about this difference between the range that you're using
10 in step 1 and step 2 and your comment here on the status
11 in the action area, which is in progress. But are you
12 finding that there would be a difference in the outcome
13 of the assessment if you were to look at their status in
14 that action area in an earlier step?

15 MS. SHULTZ: So, that is an important
16 consideration in the step 3 and the jeopardy analysis.
17 The status of the species currently along with the
18 anticipated affect of the registration of the pesticide
19 is what's going to be factored into what does that mean
20 for the species as a whole in determining jeopardy or
21 not.

22 AL: But it's not been thought of in terms of

1 looking at a likely to adversely affect or not likely
2 adversely affect?

3 MS. SHULTZ: No, because that question in the
4 step 2 is at the individual level, so it's not looking at
5 what does it mean for the species as a whole or a
6 population of the species. Will it adversely affect
7 individuals or an individual? So, the status of the
8 species as a whole then -- so, if the answer is yes,
9 there's an individual, then we look at what's going on
10 with the species in the affected area to determine
11 whether jeopardy or not. It's just a different trigger.

12 MS. PEASE: Just something to add on to that.
13 One thing we'll be doing as part of the April release is
14 for species where there is an overlap of the pesticide
15 use with their range map, we are going to be providing
16 the extent of that overlap. So, some species may be a
17 very small overlap with where the species range, overlaps
18 with where pesticides are used or could be exposed.
19 Whereas, others may be a complete overlap. We'll be
20 providing a percent overlap for each use, pattern for
21 each species, as part of the analysis. I don't know if
22 that helps to answer your question.

1 AL: Yes, it does, but it brings up others.

2 MS. PEASE: I'm sorry I said it then.

3 AL: We can follow that up perhaps in January,
4 but if your percentage is small so that the probability
5 of an interaction is low, why wouldn't you be trying to
6 think of that at an earlier stage? Is this likely or not
7 likely?

8 MS. PEASE: Well, I think that's something that will
9 inform the jeopardy opinion. We could consider it in
10 step 2 also.

11 MS. SHULTZ: That would go into the question
12 of, so, if it's not likely to adversely affect, is the
13 affect insignificant or discountable. That's where it
14 might play into determining if it's insignificant or
15 maybe discountable. EPA makes it not likely to adversely
16 affect.

17 MR. HOUSENGER: Number 3?

18 UNIDENTIFIED FEMALE: I spent a lot of years
19 thinking about this. Last quick question, and if you
20 need to direct me to the NAS report or somewhere else,
21 you can feel free. I'm curious, in step 1, when you're
22 doing that overlay, all of a sudden I realized which use

1 maps are you looking at. There's a lot of ways of
2 determining use.

3 MS. PEASE: Yes. So, if you were at past PPDC
4 meetings, you missed the talk about how we described the
5 pesticide footprint. So, we're using crop land data
6 layers for 11 different categories. I can talk to you
7 more about this offline. We have presentations,
8 actually, on our website, whole presentations of how
9 we're determining pesticide footprints.

10 MR. HOUSENGER: Okay, anybody on the phone who
11 is a member of the PPDC? You have any
12 questions/comments?

13 RICHARD: One question, if I may.

14 MR. HOUSENGER: And you are?

15 RICHARD: Richard Gragg, Florida A&M
16 University. Did you mention in your talk and in these
17 methods, are you all looking at mixtures?

18 MS. PEASE: Good question. Yes, we are looking
19 at mixtures. So, in steps 1 and 2, we have a qualitative
20 analysis of mixtures that will be included, I think, as
21 part of the release in December. That analysis will be
22 included.

1 RICHARD: Okay. And that could also go over to
2 the actual -- if you get to step 3, it can go over to
3 your biop in your evaluation as well, right?

4 MS. PEASE: Yes, that's correct.

5 RICHARD: Okay, thank you.

6 MR. HOUSENGER: All right, thank you very much.

7 Next up, organophosphates. Dana Vogel is going
8 to walk us through the presentation, and Anna Lowit is
9 providing moral support.

10 MS. VOGEL: She's here for really technical
11 questions.

12 MR. HOUSENGER: If it gets too deep, we go to
13 Anna.

14 MS. VOGEL: Good afternoon, I'm Dana Vogel.
15 I'm the director of the Health Effects Division. I'm
16 going to give you a quick update. I don't have too many
17 slides on the human health risk assessment approach we
18 are using for the organophosphates.

19 So, just a brief outline of what we're going to
20 go through. We're going to talk a little bit about the
21 strategy we use to do the hazard assessment. Part of
22 that will be -- and we'll get a little bit more in depth

1 on the safety factors and how we determine those. I'll
2 go over a little bit of the exposure summary, risk
3 summary, talk a little bit about PBPK because that was
4 part of at least one of our major OP assessments and how
5 we'd like to move forward with PBPK, and then tell you
6 what's coming up in FY 16 and 17 for the OPs.

7 So, for our hazard assessment for the OPs, as
8 we have done in the past, we're relying upon
9 cholinesterase inhibition. We evaluated
10 cholinesterase data for both the parent and the oxon (phonetic). We
11 updated and generated benchmark dose for both red blood
12 cell and brain cholinesterase across different routes of
13 exposure, whether that's oral, dermal, or inhalation.

14 So, what we did for the single chemical
15 assessments for the OPs, and it could be different for
16 different OPs, is we're going to rely upon most sensitive
17 compartment, whether that be RBC or brain.

18 We also did life stage comparison for
19 gestational and postnatal comparative cholinesterase
20 assay studies. So, that really helps us get to if
21 there's any sensitivities or differences between adults
22 and young, pregnant females, and/or in utero.

1 So, the endpoints we selected for the OP
2 assessments, we did an acute assessment, which is a
3 single day assessment. We have a specific point of
4 departure for females. We also did chronic, but it's not
5 really a chronic as we normally do.

6 It's a steady state assessment and point of
7 departure that we chose, because what we saw by looking
8 across the data that we have is that inhibition reaches a
9 plateau after two to three weeks. So, the points of
10 departure for cholinesterase that we're using are based
11 on that two to three week period.

12 So, it's a steady state point of departure.
13 So, keeping that in mind and knowing that about the OPs
14 and the time to affect and what we're concerned about
15 from the tox side, we matched that with the exposure
16 that we expect for the organophosphates.

17 So, safety factors. As you may be aware, right
18 now we have out for comment our OP 10X position paper. I
19 think that went out early September. What we did is it's
20 based on laboratory animal data that we have, mechanistic
21 studies, and epi data, human epi data as well.

22 We did a scientific literature review of all

1 the data that we had and kind of pulled it all together
2 looking at all the data and what it shows us in totality
3 to figure out the appropriate safety factor for the OP.

4 So, if we're discussing right now the FQPA
5 factor, when we looked at all of that data and we pulled
6 it all together, there are some uncertainties regarding
7 potential neurodevelopmental outcomes as we see in some
8 of the epidemiological studies that are available. Most
9 of the epi studies that we have on the OPs is hard to
10 distinguish between different OPs because they're
11 measuring a common biomarker of the DAP.

12 So, what the position paper says that we have
13 out for comment is it's for at least for the ones we have
14 out and potentially for all the OPs right now as a draft
15 position. We're applying a 10X FQPA factor to the OPs for
16 the potential uncertainty around the neurodevelopmental
17 facts that we see in the epidemiological data.

18 So, using and expanding our use of PBPK models.
19 As science advances, we're following science and
20 decisions, NAS report. We're trying to use the best
21 available science to inform our risk assessments.
22 Specifically in this case, we're going to be talking

1 about the hazard assessment and then how that impacts the
2 overall risk assessment.

3 So, what we've done for one OP and what we're
4 encouraging the use of for other OPs is the recent
5 advances and how we extrapolate from in vitro to in vivo
6 and using comp tox models to get a better handle on data
7 derived inter and intra species factors instead of
8 relying upon the standard default assumptions that we
9 currently use, the ten and the ten.

10 We're trying to keep pace with it as much as we
11 can with emerging science. We do have out for comment,
12 as is listed right here, a framework for developing PBPK
13 models and using these new technologies in our risk
14 assessments. One thing I might mention is as you
15 probably are aware, in December of 2014, we put out the
16 chlorpyrifos risk assessment, and it does rely upon PBPK.
17 So, that's one example of where we've used it already.

18 One other thing I wanted to mention on this,
19 when we use PBPK models, it helps us get a better
20 understanding of the inter and intra species factor.
21 They could go up or they could go down. So, it's not
22 always going down. It could go up or down, depending

1 upon the science that you have.

2 For the OPs exposure, for dietary exposure, we
3 use the DEEM model. What we did was similar to what
4 we've done in different cumulative assessments. It
5 provides like more of a longitudinal, more of a 365 day
6 exposure estimate. This enabled us to better fit the
7 exposure, that steady state point of departure that we're
8 concerned about, that hazard with the appropriate
9 exposure. So, by using DEEM in this way and
10 incorporating the drinking water directly into our
11 dietary assessment, it's a better fit for doing the food
12 and drinking water assessment.

13 We also did occupational and residential
14 assessments, relying upon just our standard methodologies
15 and SOPs. We did our spray drift assessment and also
16 applied the volatilization screen. Spray drift, as you
17 know, was out for comment. We're hoping to make some
18 progress on that policy, making it final in the not so
19 distant future. Then, volatilization as well, was out
20 for comment for a while.

21 For the preliminary draft risk assessments,
22 these are the chemicals that have recently gone out.

1 They're preliminary in their draft. They're out for
2 public comment. These are the OPs. If you looked at any
3 of them, you will see that there are risks of concern
4 identified for a lot of those, if not all of them, for
5 different pathways.

6 What's coming up is we're working on now is
7 addressing the comment that we get back on the 10X FQPA
8 OP decision paper that we put out for comment. We're
9 also accepting comments on those draft risk assessments,
10 so we'll be taking those and incorporating those as soon
11 as we can.

12 Then, you see the PRAs that are scheduled to
13 come out for public comment in FY 16. Those, I will
14 mention, are scheduled, and that's what we expect to
15 happen right now. But, of course, things can always
16 change. That's TCVP, acephate, malathion, coumaphos,
17 chlorethoxyfos, bensulide, phosmet, phostebupirin, and
18 diazinon. Then, for FY 17, the schedule right now is
19 DDVP, naled and trichlorfon. They're grouped together
20 because they're similar.

21 I think that's it.

22 MR. HOUSENGER: Cheryl?

1 CHERYL: I know that this whole thing is
2 couched in terms of OPs. It's posted as OPs, but
3 there's a big huge change in policy here where you're
4 taking 10X from FQPA and putting it over on the worker
5 side. So, is this only viewed as OPs or is this a whole
6 change in policy for all worker assessments to come? I
7 have several questions.

8 MS. VOGEL: Okay. So, I just want to make sure
9 I answer your question right. So, it's your concern that
10 we're applying a factor to workers that we don't normally
11 apply.

12 CHERYL: My question is, is that the future
13 policy?

14 MS. VOGEL: Well, right now what we would do if
15 we have uncertainty for workers, we might not call it an
16 FQPA factor, but we would still apply uncertainty
17 factors. So, for instance, if there was a piece of data
18 missing, if there was a developmental neurotox study that we
19 thought -- that's a bad example. But if we did, we might
20 call that in as an FQPA factor, but we would also apply
21 an uncertainty factor to workers because of pregnant
22 female workers. We would call it a database uncertainty

1 factor.

2 CHERYL: That's a shift in policy.

3 MR. HOUSENGER: That was a shift a long time
4 ago.

5 MS. VOGEL: We've been doing that for a while.
6 It's not considered an FQPA factor, but it's a database
7 uncertainty factor that applies to workers because you
8 want to protect pregnant --

9 CHERYL: Okay, then, I stand clarified. The
10 bigger thing is I think this took several registrants by
11 surprise because we're taking 10X uncertainty from
12 basically epi data based on chlorpyrifos and diazinon out
13 of a Columbia study. We're translating it to an
14 entire group of OPs. At the same time, we're saying we
15 don't know exactly what the mode of action of these
16 effects are that we've seen in the Columbia study, but
17 we're going to still translate it to the group where we
18 classify them through this mode of action. So, we're
19 translating, but we're not clear, and we're going to put
20 the 10X on everything. It seems a little off kilter. At
21 the same time, you had a reduction in one of the factors
22 through the PBPK modeling for chlorpyrifos, but you

1 didn't apply that to all the OPs.

2 MS. VOGEL: We don't have PBPK models for all
3 of the others.

4 CHERYL: Right. So, we're going to take the
5 adverse effects from the Columbia study that hasn't been
6 completely vetted, and we're going to transfer those to
7 all the OPs. But the specific information that we have
8 as the PBPK modeling, we're not going to translate that.
9 So, again, it's a little bit -- registrants are kind of
10 scratching their heads a little bit about this.

11 MS. VOGEL: I mean, I'll give you my
12 perspective. I'm not sure if it will fully answer your
13 question, but if we're talking about the epi 10X, what we
14 did is we didn't just look at the Columbia study.
15 There's a variety of epidemiological data available.
16 It's the three cohorts and there's a lot of other
17 uncertainty. It's probably some of the best
18 epidemiological data that I think is kind of considered
19 the gold standard as far as epi data is.

20 We also looked at where we have animal data and
21 it doesn't match up perfectly. We don't know the mode of
22 action or the AOP. We don't know what the critical

1 windows are. However, we are seeing neurotoxicity in the
2 animal studies as well.

3 So, when we look at all these different lines
4 of evidence and we line them all up, it's hard to say
5 when you see the data and the information that comes out
6 of those three cohorts and how they all line up, that
7 there is an uncertainty surrounding neurodevelopmental
8 effects. So, we are trying to look at multiple lines of
9 evidence. We're not just solely -- it may be the main
10 thing that we're looking at, but we're looking at how all
11 the data kind of fits together.

12 As far as use of the PBPK model goes, I think we're
13 willing to discuss with registrants how a PBPK model
14 could be used for other OPs. There is something very
15 specific about the chlorpyrifos PBPK model, but it may be
16 a starting point for other OPs.

17 MS. LOWIT: I'll just add a little bit. Beyond
18 the Columbia study, there are two other children's
19 cohorts that are partially funded by NIH and, to some
20 degree, by EPA, but also private funding. There's the
21 cohort run out of Berkeley, often called Chumakis
22 (phonetic), and there's also another pollen cohort run

1 out of Mount Sinai.

2 We know Sinai and the Chumakis cohorts are
3 focused on the dialkyl phosphates, which are
4 more generic markers for all of OPs, not just
5 chlorpyrifos and diazinon. In fact, Chumakis has
6 actually found associations with the DAPs that are not
7 associated with chlorpyrifos, so not the ethyl
8 metabolites. It's actually the methyl metabolites.

9 So, if you look closely at the way we've
10 reviewed these over the last -- around 2008, we have kept
11 the three cohorts together because we think they belong
12 together. Columbia alone does not stand alone. The
13 three cohorts were started around the same time, so they
14 cover the same time period, but yet they're three
15 different sets of investigators, three different physical
16 locations, three different sets of individuals, different
17 sets of exposure pathways. They're using a similar set
18 of outcome metrics in the children, so there's a lot of
19 commonalities to those cohorts. So, they stand together
20 as a group. So, Columbia does not hold up by itself.
21 It's the three cohorts together.

22 Also, in our new paper, we did an update to our

1 2012 literature review. That 2012 literature review is
2 reviewed by the SAP with a lot of positive feedback.
3 We've updated that with new papers since 2012, which
4 brings in another new cohort from Mexico, but also some
5 other studies we haven't considered. The newer studies
6 are not as strong as the three perspective cohorts. They
7 do provide additional evidence. This is not just a
8 chlorpyrifos issue. When you look at it from the DAPs
9 point of view, there's a common pattern of outcomes.

10 With respect to the PBPK modeling, the
11 physiologically based pharmacokinetic model, which is
12 basically a big word to say. You can take a lot of
13 mathematic equations that characterize the physiology and
14 metabolism in the human body and do an outstanding job of
15 predicting what happens from the point of exposure to the
16 point of excretion across different life stages. So,
17 these are very powerful models built on years of
18 understanding of human physiology across the ages from
19 birth until the elderly.

20 In the last few years, there's been a rapid
21 development in ability to collect the information that
22 underlies those models. So, there's a belief that you

1 can take the chlorpyrifos PBPK model and its core and
2 with a fairly rapid amount of in vitro data and some
3 targeted in vivo testing, turn that chlorpyrifos model
4 into other OPs, because the foundation of the code is
5 built. It's publicly available. It's already been peer
6 reviewed. So, we'd like to have dialogues with
7 stakeholders who are interested in proving the science
8 that underlies our extrapolation and those risk
9 assessments.

10 MR. HOUSENGER: Al?

11 AL: For some time, there's been a lot of
12 question about the drinking water assessment that you've
13 now incorporated. I'm not sure exactly how you've done
14 that directly as you commented. But I wonder whether
15 you've been looking at different -- if you could talk
16 about how you did that and how you've been looking at
17 ways to get a more realistic picture of what the exposure
18 in drinking water might be in whatever the time frame is
19 that you are concerned about.

20 MS. VOGEL: All right, so, our drinking water
21 assessments are done in coordination with our
22 Environmental Fate and Effects Division. They use their

1 drinking water models. They model surface and ground
2 water. We take the outputs and we put it into our
3 dietary assessment model. In this case, because we're
4 worried about the two to three week window, we did
5 rolling averages, 21 day rolling averages, and put those
6 averages into DEEM, which is a very complex probabilistic
7 model that I definitely cannot explain to you. That's
8 how we did the assessments.

9 Now, we start when we do our dietary
10 assessments. When we do the drinking water assessments,
11 there's different levels of refinement. So, I think what
12 we're trying to as we refine more and more is get down
13 closer to the watershed level as opposed to more a
14 national level. So, we start with a national assessment
15 and we slowly go down to a more refinement with getting
16 down to the watershed level. I'm not sure that fully
17 answers your question, but it may be the best I can do.

18 AL: Well, partly what I was getting at was
19 actually the comment that I made to Anita that in looking
20 at a watershed level with those kinds of methods, you are
21 adding on some conservatism as you go through it. I just
22 wondered if you had been looking at other ways to model

1 that exposure that might have given you something that
2 fit maybe what we would expect to see if went out and
3 actually looked, did some monitoring data.

4 MS. VOGEL: I know also for chlorpyrifos as
5 well and what we try to do to some extent to where the
6 exposure patterns match up is see where/how the
7 monitoring compares to the modeling.

8 MR. HOUSENGER: Robyn?

9 ROBYN: Thank you. Just two quick questions.
10 I take it that the neurodevelopmental was the most
11 sensitive endpoint compared to reproductive or other
12 endpoints?

13 MS. VOGEL: The assessment is based on the
14 cholinesterase inhibition, the neurotoxicity effect.
15 What we're getting from the epidemiological data, we're
16 not using it for points of departure. We're using it for
17 the safety factor at this point because of the
18 uncertainty with the neurodevelopmental. Is your
19 question, from those studies, was that the most sensitive
20 thing they saw in the epi studies?

21 ROBYN: I guess I misunderstood the safety
22 factor. You said based on the relationship with the

1 neurodevelopmental effect because of its cholinesterase
2 inhibitor. On the slide above that, you're still looking
3 at single chemical assessments.

4 MS. LOWIT: That's where we are right now.

5 MR. HOUSENGER: Ray?

6 RAY: I'm not a toxicologist, and I share that
7 blissful state with a number of folks around the table.
8 I understand it's difficult to make these concepts
9 understandable to those who aren't toxicologists, but
10 that's your job in front of a federal advisory committee.

11 We understand that EPA has requested the raw
12 data for these epi studies that are the basis for the 10X
13 decisions. What's the status of that request?

14 MS. VOGEL: We've received some additional
15 information from Columbia. We don't have all of the raw
16 data, but we do have additional information that we
17 requested to do some additional analysis. If you want to
18 add anything to that --

19 MS. LOWIT: Only a little bit. It's true we
20 have, on a couple of occasions, gone directly to Columbia
21 and talked to them about our desire to have the
22 individual data. So far, they have not provided that,

1 but they have recently provided some additional summary
2 information that allows us to characterize the
3 distribution in a way that the publications do not.

4 We've also had some offline conversations with
5 Dana Barr (phonetic), who used to be at CDC. We ran a
6 lot of those data. We've had some conversation with her
7 about what she may be able to provide on top of the other
8 cohorts, Mount Sinai and Chumakis in particular. So far,
9 that's really just a conversation that we're having.

10 RAY: Are those data forthcoming?

11 MS. VOGEL: I don't know the answer to that.

12 RAY: But you made your conclusions without
13 having those data?

14 MS. VOGEL: One other thing I did want to add
15 was that we had some scientists when Vicki Dellarco
16 (phonetic) was here and a couple people go up to Columbia
17 and sit with Columbia investigators and query the data
18 there in person to answer the questions that we have.
19 They were somewhat satisfied after that with how that
20 meeting went. You're right, we don't have all the raw
21 data. I mean, that's for sure.

22 RAY: Well, being somewhat satisfied doesn't

1 sound like it's a satisfactory level of proof and level
2 of demonstration to the folks around this table as a
3 basis for the decision.

4 MS. VOGEL: So, I mean, we did go up there.
5 They did analysis that we wanted done in front of us
6 while we were there. Subsequent to that --

7 RAY: Can we see that analysis?

8 MS. VOGEL: I don't know that we have anything.
9 Do we have anything written down from that? I'm not
10 sure. I'd have to go back and check.

11 RAY: This is a really big deal.

12 MS. VOGEL: I would say, since then, when we
13 had additional questions, we went back to them for
14 another data request that we've recently gotten and are
15 looking at that data now. We're working, like Anna said,
16 with Dana Barr to see what additional information we can
17 get.

18 RAY: Are you going to make those data
19 available?

20 MS. LOWIT: I think we'll have to when we go
21 out with chlorpyrifos.

22 RAY: But you made your decisions without

1 making those data available.

2 MS. VOGEL: Well, it's a draft risk assessment.

3 MS. LOWIT: Everything at the time in December
4 2014, everything we had at that moment in time went out
5 in the docket. As we have more information, we'll
6 provide it publicly.

7 RAY: You've explained that you've done your
8 risk assessment based on cholinesterase inhibition. You
9 know an awful lot about cholinesterase inhibition, a huge
10 amount of research done on the OPs in the almost 20 years
11 since FPQA required that work. It seems like the story
12 is pretty well worked out for cholinesterase inhibition,
13 but is the epi data pointing to a different endpoint?

14 MS. VOGEL: I'll let you follow up on me again.
15 We've taken issue of a couple different SAPs. I think
16 the concern is is there a potential for
17 neurodevelopmental effects to occur below where we're
18 regulating for cholinesterase inhibition. They're
19 somewhat disconnected, but we need to make sure we're
20 being protective of those effects. So, with some of the
21 analysis we've done with the PBPK model, we're trying to
22 figure out what was seen in the epi data, is that a

1 result of the cholinesterase inhibition or is there some
2 other additional uncertainty, i.e., the
3 neurodevelopmental, the potential for ADHD, autism, all
4 different kinds of attentional issues to result from
5 exposure to OPs, chlorpyrifos, and others.

6 RAY: Wasn't most of the neurodevelopmental
7 testing concluded about at least 10 years ago?

8 MS. LOWIT: We'll do random development on
9 neurotoxicity studies for approximately 20 OPs, plus or
10 minus. I don't know the exact number. If we maybe
11 take a step back, the statute requires an extra 10X
12 factor is in place unless there is sufficient data to
13 change the factor. So, if that's the starting point, one
14 of the action items that the SAP recommended to the
15 agency at the 2012 SAP was to conduct what is often
16 called a dose reconstruction analysis. It's a big word
17 for using the PBPK model as a tool, taking an exposure
18 scenario, something like would be done (inaudible).

19 Using that exposure information, including it
20 into the PBPK model, and asking yourselves the question,
21 is there expectation of the exposures for -- in Columbia
22 specifically around the 1999-1998 time period, is there

1 reasonable expectation you would have seen cholinesterase
2 inhibition in the women living in the apartments at that
3 time? We follow through on that recommendation in our
4 2014 risk assessment.

5 That analysis shows that the residential uses
6 of chlorpyrifos that would have been available in the
7 late 90s, we really would not expect cholinesterase
8 inhibition in the women in that cohort. So, given that
9 piece of powerful information on top of a growing body of
10 information on the mechanistic understanding on a
11 biological activity of various OPs on in vitro, along
12 with animal studies and the three epidemiology cohorts,
13 that there begins -- if we think about weight of
14 evidence, you were asking about this question earlier,
15 how you take information across different levels of
16 biological information and bring them together, there
17 begins to be a picture that FQPA safety factor that's
18 statutorily there becomes -- we're unable to remove that
19 factor because we have uncertainty in the dose response in
20 the human around the neurodevelopmental.

21 RAY: But in multiple occasions, you have
22 removed that factor. You've come to the conclusion --

1 MR. HOUSENGER: We've removed that factor in
2 the absence of data causing some uncertainty like we have
3 with the OPs, right.

4 RAY: Well, you've removed the factor for the
5 OP. You've lowered that factor for the OP.

6 MR. HOUSENGER: Yes, that was before we
7 analyzed these data, went to the SAP with this. The SAP
8 basically said retain the 10.

9 RAY: There's a bit of confusion regarding this
10 September 2nd publication of the position paper. I've
11 asked a couple of my colleagues, and we don't know what
12 that is.

13 MS. VOGEL: So, I think that we're talking
14 about the 10X paper, the OP/10X paper. So, that is the
15 paper that explains our assessment, why we're proposing
16 to put an additional safety factor on all of the OPs for
17 the epi, looking at how it all compares to all the
18 different lines of evidence.

19 MR. KEIGWIN: Ray, that paper is included
20 in each of the dockets for the seven OPs that went out
21 for comment a little bit later in September. I think the
22 date of the assessment might be September 2nd, but the

1 docket is actually opened around, I want to say,
2 September -- the week of September 20th. So, Dana was
3 referring to the dockets that opened in that time frame.

4 RAY: That clarifies it, thanks.

5 MR. HOUSENGER: Nichelle?

6 NICHELLE: So, this is a lot of hard work, and
7 I want to thank the agency for doing it for this class of
8 pesticides. I also want to thank and encourage the
9 agency to apply the 10X safety factor approach, this
10 class of pesticides, that we know to be highly
11 neurotoxic. That's established in the scientific
12 literature, so I don't think that's a lot of debate on
13 that. Again, I'm urging the agency to retain that 10X
14 safety factor.

15 I also have a question. This is the human
16 health assessment for organophosphates, but is there any
17 work similar for other classes of pesticides in the
18 pipeline out of this work?

19 MS. VOGEL: Right now, these came up. We'll
20 following the registration review schedule. As we go
21 through, there will be other class of chemicals to go
22 through. Does that answer your question? Are you

1 asking, are we going to apply an additional factor to
2 other classes of chemicals?

3 NICHELLE: So, you're doing this work as a
4 class of pesticides. You're doing all of them at the
5 same time.

6 MS. VOGEL: So, they're coming up first in
7 registration review, the OPs.

8 NICHELLE: Oh, it's just the schedule.

9 MS. VOGEL: So, that's why we're coming to
10 these first.

11 NICHELLE: Okay.

12 MR. HOUSENGER: Gabriele?

13 GABRIELE: Just reflecting on the conversation
14 as I'm hearing it, I have to say this is one of the
15 harder things. This is at 4 p.m. one of the most
16 complicated risk assessments you've come out. You're
17 talking about in 20 minutes. This needs a lot more
18 conversation would be my assessment.

19 I realize you guys are understaffed and
20 overworked and anything like this is more work, but I
21 come back to my training wheels and learning about
22 pesticides with the whole FPQA implementation where EPA

1 had to sit down and explain how they did their risk
2 assessments. That made a humongous difference in the
3 quality of the risk assessments and how people understood
4 them and understood how they could participate in the
5 process.

6 The chlorpyrifos one, you may have made these
7 decisions three or four years ago. People may not have
8 understood you made decisions. But it's clear that in
9 that assessment were a lot of different decisions that are
10 suddenly cumulatively showing up.

11 I really encourage you to find a way to sit
12 down and go through this with a little bit more time than
13 20 minutes at the end of a long day, because I don't know
14 what you mean with a steady state due to equilibrium for
15 enzyme inhibition. I just don't have a feel for it. I
16 don't feel like you should be taking five minutes to
17 explain that right now. Yet, those are important
18 components into how you made your decision.

19 Using the epidemiological studies, you may have
20 taken it to the SAP, but my question is, how do we
21 determine which epi studies are worth using. What are
22 the criteria for an epi study to be usable in the EPA

1 world? I think it's a really good one because you have a
2 lot of epi studies out there, and it's really hard to
3 assess the quality of them and what are the factors and
4 so forth.

5 So, again, it's not saying it's necessarily all
6 wrong or all right, but here there's a lot going on.
7 When you have some of the experts in the room going, I
8 didn't understand you, that makes me worried. So, just
9 food for thought or a reflection on what I'm hearing
10 here.

11 MR. HOUSENGER: Right. I think there's
12 actually a number of venues that you can get involved in
13 this, including the SAP and others. It is, but I think
14 the question is, is it you that wants to hear this, is it
15 the whole group. We can make this into an expanded
16 presentation for the next time. I mean, there's always
17 the next time. We've got another one of these in May.

18 But it's difficult to figure out, especially
19 with the input from this group, what to put on the agenda
20 and how much time to allow for it. As you see, there's a
21 lot of things that we're working on. What's interesting
22 to you may not be interesting to someone else. What's

1 interesting to someone else may not be interesting to
2 you. So, it's a balance. But when we discuss topics, we
3 can get into it. But it's not easy to explain either.
4 I've been in this program for 40 years. It's getting to
5 the point where I need to get out before I don't
6 understand it any more.

7 UNIDENTIFIED FEMALE: (Not near mic)

8 MR. HOUSENGER: We can go back and do technical
9 briefings again if that's what people want. It is a lot
10 of work. Our resources continue to go down and our work
11 continues to go up. We used to spend a lot of time in
12 preparation for those, traveling for those, getting the
13 rooms for those. I'm not willing to do it if there's
14 only going to be five people attend it. But we can
15 discuss that at the end of the meeting, too.

16 UNIDENTIFIED MALE: What you're talking about,
17 and I'm not sure that I want to, it sounds like Ray
18 thinks that you've changed the rules in the middle of the
19 game.

20 MR. HOUSENGER: I would argue that we haven't.
21 We haven't had epi studies before that we thought were
22 good enough to use. But when we do have them and they

1 create uncertainties, I think our law is clear that we'll
2 retain the 10X until we can prove that it's not needed.
3 That's what's kind of happened here.

4 Did the same effect happen to workers who are
5 exposed? Definitely. If you're a worker, you don't know
6 the difference if you're a nonworker or a worker if
7 you're exposed to chlorpyrifos. If it's an effect that
8 you're going to see, you're going to see it regardless.
9 So, we think that it's prudent to apply that factor
10 regardless.

11 UNIDENTIFIED FEMALE: Just one comment. If
12 anyone is interested in hearing more about some of these
13 studies, I would suggest perhaps maybe running it through
14 one of the communities of practice webinars that EPA
15 holds every month or so on some of the work. You know
16 what I'm talking about?

17 MS. VOGEL: I know Anna does, but it's
18 typically some kind of research that's going on. You can
19 dial in. There's slides that you can see. Somebody goes
20 through for about an hour and talks about the work
21 they're doing and the results and stuff like that. I
22 find them to be very informative.

1 MR. HOUSENGER: There is a lot of information
2 on our website as well.

3 Cheryl?

4 CHERYL: I do get the precautionary need. I'm
5 really glad that we have precaution built into the
6 system. I'm not against that, but I think since I'm
7 supposed to have the mic for the registrant community, I
8 just need to make one more point here.

9 What Ray was getting at is if you're going to
10 make regulatory decisions and you still don't have the
11 raw data in your hand, there are some in the registrant
12 community that are going, okay, we've got peer review
13 publications that don't agree with the weight of evidence
14 that was articulated by EPA. We don't have the data in
15 hand, we can't validate it, and yet, you're going to make
16 regulatory decisions on it. It feels disconnected from
17 the way that you would treat registrants. You would
18 demand to be able to audit the data.

19 So, it's uncomfortable from the registrant
20 community to hear that you're going to weight these epi
21 studies so hard when all of this data has gone in under
22 the regulatory process with data call ins, with guideline

1 studies. Then, we can't even get to see the data
2 that's the trump card for the rest of the regulatory
3 process.

4 MR. HOUSENGER: I understand. It's hard to
5 measure the IQ of a rat, though. So, some of these
6 effects you're not going to see in our animal studies.
7 It does shed some uncertainties on the literature that's
8 out there. That's what's preventing us from removing the
9 10X.

10 Let's go to the phones before someone else puts
11 up their card. Oh, we've got another card. Wait, hold
12 on. We've gone one more here and then we'll go to the
13 phones.

14 AMY: I understand the complexity is
15 something that all of us in this room may or may not
16 understand. I do want to commend the agency for taking a
17 look at these robust studies that frankly had been rare
18 when we were looking at the types of pesticides being
19 used and thinking about what the effects might be on
20 workers and taking it to this level.

21 I echo what was said earlier in terms of can
22 this be applied to other pesticides that are out there.

1 It just happens that we have these cohort studies that
2 are showing these uncertainties. I think it's really
3 important that you're taking these steps.

4 MR. HOUSENGER: I'm not sure how many other
5 studies are out there like this that would be in the same
6 situation where we would apply a 10 or couldn't remove
7 the 10, in other words.

8 All right, on the phone, the members?

9 RICHARD: Yes, Richard Gragg, thank you. My
10 question, first question, has to do with how this
11 organophosphate will fit into the 21st century
12 toxicology scheme. Is it a priority based on the results
13 and decisions you're making now to integrate that into
14 the scheme?

15 MS. LOWIT: The analysis that we've done
16 for the OPs is part of the support to retain the 10X for
17 the class of OPs. We have, as part of the 2012 FIFRA
18 SAP, done a thorough review of the literature around in
19 vitro studies and adverse outcome pathways leading to
20 brain development in children. We have continued to
21 monitor that literature, but the adverse outcome pathway
22 is just many years away. It's just a reality of where we

1 are.

2 But I think at the higher level I think the
3 analysis shows how we're thinking about putting different
4 lines of evidence together. We do have a draft framework
5 that was reviewed by the SAP in 2010 or 2011, I think,
6 where we put together an analysis framework based on the
7 concepts of problem formulation and the Bradford Hill
8 (phonetic) criteria to think about how we would put
9 together lines of evidence from the point of exposure,
10 including QSAR and SAR (phonetic) and read across up
11 through molecular initiating events, things happening at
12 the tissue, to the organism level but also
13 ultimately to the population level either measured
14 through biomonitoring studies but also epidemiology
15 studies.

16 So, the OP situation, I think, provides a
17 context for how we've applied that framework in the
18 context of how the NAS is supporting the agency of
19 needing a check mark kind of thinking about (inaudible)
20 effects from animal studies to using all the available
21 information across multiple lines of evidence.

22 RICHARD: Okay. So, with that information, are

1 you planning also to look at information as regard to
2 mixtures in inclusive organophosphates?

3 MS. LOWIT: So, we have already, as part of
4 registration review, developed what we call a cumulative
5 risk assessment for the OPs, which is really a mixtures risk
6 assessment of OPs using the cholinesterase endpoint.
7 That was last updated, I think, in 2006 or 2007 as part
8 of reg review.

9 There are existing mixture studies in both
10 juvenile rats and adults, looking at mixtures of OPs that
11 support that cumulative risk assessment. But I think
12 it's also important to remember that the epidemiology
13 studies, that's the women and the cohorts, were
14 themselves exposed to all the chemicals that are just in
15 their everyday environment.

16 So, epidemiology studies are sort of inherently
17 thinking about mixtures. That's one of the reasons that
18 epi studies are so difficult to interpret, because there
19 is -- well, exposure situation in epi say it can be very
20 complex.

21 RICHARD: Okay, I'll stop there.

22 MR. HOUSENGER: Okay, one final comment before

1 we do public comments. If you haven't read our risk
2 assessments, that, I think, is the first step to do,
3 because I know that a lot of people say, well, I don't
4 understand it. Have you read it? No, we haven't. But I
5 would go through, and it's not a great document to get
6 through.

7 It's heavy reading, but I think if you
8 start there and read them, that's the best way to
9 understand what we're doing. I think a lot of the
10 things that we discussed today are explained fairly well
11 in that risk assessment, especially the 10X paper for the
12 OPs.

13 Public comments? Let's hear what the public
14 has to say. Jeannie, Florida, farmworkers, are you with
15 us?

16 MS. MONELL: She was on the phone. Jeannie, if
17 you're still with us, you represented some Florida
18 farmworker organization. Apparently, she gave up.

19 MR. HOUSENGER: Anyone else? Going.

20 (No response.)

21 MR. HOUSENGER: All right, we start at 9:00
22 tomorrow. Jim Jones will be here. Everybody get a good

1 night's sleep. Thank you very much for today.

2 (The meeting was adjourned.)

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

1 CERTIFICATE OF TRANSCRIPTIONIST

2

3 I, Marilyn H. McNulty, do hereby certify that

4 the foregoing transcription was reduced to typewriting

5 via audiotapes provided to me; that I am neither counsel

6 for, related to, nor employed by any of the parties to

7 the action in which these proceedings were transcribed;

8 that I am not a relative or employee of any attorney or

9 counsel employed by the parties hereto, nor financially

10 or otherwise interested in the outcome of the action.

11

12

13

14 MARILYNN H. McNULTY

15 Transcriptionist

16

17

18

19

20

21

22